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Front: Edward Wei , Meds 201 2. 
In honour of UWOMJ's inaugural geneti cs issue, 1 thought it would be interesting to juxtapose the old and the 
new -- the x-ray and th e microarray. Each represents an attempt to peer inside the inner workings of the human 
machine and di vine its mysteries. Of course, whil e the Roentgenesque head can be ea ily identifi ed as such, the 
radiograph gives us little information about the hea lth and fun ction of what li e beneath . The microarray, on 
the other hand, resembles nothing human at a ll, yet provides more informati on than we can rea lly handle all at 
once. The chall enge for medica l genetics in the future will be tbe integration of these multiple modalities -- the 
shaping and moulding of mountains of data into findings we can see, feel, and hear. 
Back: Juli e Huang, Meds 201 2. 
Michelangelo's Tbe Creati on of Man, found on the ceiling of the Si tine Chapel depict the hand of Adam 
reaching out to the hand o f God. The cover re ferences thi s iconic work, and brings into question the ways in 
which science and medicine use geneti cs as determinants of human creation. 
Page I 2 
79 
EDITORIAL STAFF 
EDITORIAL BOARD AND SUPPORT 
Editors-in-Chief Amber Menezes and Wendy Ng, Meds 2009 
Managerial Stream 
Managing Editor 
Senior Associate Editor 
Junior Associate Editor 
Contracts and Awards Stream 
Executive A sociate Editor 
Senior Associate Editor 
Junior Associate Editor 
IT Director 
Layout Editor 
DEPARTMENTAL EDITORS 
Clinical Procedures 
Sr: Paul Lau, Meds 2011 
Jr: Edward Weiss, Med 2012 
Health Promotion 
Sr: Laura Hinz, Meds 2011 
Jr: Jennifer N. Bondy, Meds 2012 
Medicine and Technology 
Sr: Penci lla Lang, Meds 20 11 
Jr: Jenny Shu, Meds 2012 
Thinking on your Feet 
Sr: Aiman Alak, Meds 20 11 
Jr: Kalpa Shah, Meds 20 12 
UWOMJ ADVISORY BOARD 
Dr. Lois Champion 
Dr. David Colby 
Dr. Kellie Leitch 
Dr. Jeffrey Nisker 
Dr. Douglas Quan 
PRINTER 
Wendy Ng, Meds 2009 
Tiffany Kwok, Meds 20 10 
Laura Hinz, Med 20 11 
Renata Villela, Meds 2009 
Jean Chen, Med 2010 
Pasquale Montaleone, Meds 20 11 
Tshvinder Chattha, Meds 20 11 
Wang Xi, Meds 20 11 
Diagnostic Review 
Sr: Jason E ue, Meds 20 11 
Jr: Rachel Bevan, Med 20 12 
History of Medicine 
Sr: Michael Livingston , Med 20 11 
Jr: Kate MacKeracher, Meds 20 12 
Medicine and the Law 
Sr: Abdullah Alabousi , Med 20 11 
Jr: Colin Meyer-MacAulay, Meds 
2012 
Zebra Files 
Sr: Jenna Ash kana e, Meds 20 11 
Ashley Brown, Meds 20 ll 
Jr: Anna Burianova, Meds 20 12 
Dr. Faisal Rehman 
Dr. Michael Rieder 
Dr. Jim Silcox 
Dr. Wayne Weston 
Dr. Ron Wexler 
InPrint Design: University Students' Council, University of Western Ontario 
UWOMJ, Vol 78, Issue 3 
Ethics 
Sr: Chri stina Morgan, Meds 20 11 
Jr: Hassan Mir, Meds 20 12 
Interdisciplinary Collaboration 
Sr: Abhijat Kitchlu, Meds 20 11 
Jr: Allanah Li , Meds 20 12 
Profiles 
Sr: Emma Love, Meds 20 11 
Jr: Juli e Hughes, Meds 20 12 
Page 1 3 
The mapping of human genes has been an 
important step in the development of medicines 
and other aspects of health care, emphasized by 
the worldwide interest in the Human Genome 
Proj ect that began in 1990 in the United States at 
the National Institutes of Health . It is with thi s 
deep respect for the profound importance of 
genetics that we are proud to present our newest 
issue of the Uni versity of Western Ontario 
Medical Journal. Case reports, reviews, and in-
depth di scuss ions cover a variety of topi cs on thi s 
fasc inating theme. Maj or implications for the 
future, present and past underli e each of these 
arti c les. 
The future is a focal point of both 
speculation and hope when it comes to the 
detection of blood vessel anomalies and 
microvascular di sease, as described in an 
enlightening article within the Clinical Procedures 
departmental section here in. Prenatal geneti c 
diagnosis helps us predict the future of an unborn 
child, as highlighted in a feature arti cle in thi s 
issue. Meanwhile, on a broader scale, the endless 
possibilities behind the cutting edge technology in 
personali zed cancer management are also 
explored in the Medicine and Technology 
departmenta l section. A feature arti cle di scusse 
how our seemingly innocuous current 
environmental exposures can even affect our 
future generations! 
And yet, despite all its predicti ve power, 
geneti c di seases continue to burden oc iety in the 
present time. What are the impli cati ons of long 
QT syndrome on quali ty of life? What role does 
geneti cs pl ay for pati ents diagnosed with 
rheumato id arthriti s? How should we sc reen for 
hemochromatos is? Our authors address these 
issues. Far more uncommon conditions, such as 
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EDITORIAL 
fibrodysplasia oss ificans progressa, can be 
detected early with genetic screening today, as 
described in the Zebra Files. Our Interdisciplinary 
Collaboration authors weigh in on the necessity of 
support when it comes to Huntington ' s Disease. 
But the folli es of genetics are al so addressed -
what does it mean to label one another as ill or 
healthy, particularl y when it comes to 
alcoho li sm? This dil emma is eloquently outlined 
in our Health Promotion departmental article. 
[t is a lso essential to look back in time. 
Our contributors do not forget to take an in depth 
look at the past. As our History of Medicine 
departmenta l arti c le demonstrates, genetic 
research has affected indigenous peoples, and 
ethical considerations have ari sen from hi torical 
cha llenges, leading to stricter implementation of 
inforn1ed consent principles today. 
Genetics connects all of humanity, from 
past to present to future, and underscores the 
similariti es and di fferences between us all. 
Understanding our past allows us to plan for the 
future. The recent period of volatility for the 
University of We tern Ontario Medical Journal is 
highlighted in thi s i ue, with a reflection piece 
that addresses the maj or changes that have 
occurred within the journal 's structure, 
operations, and content, ultimate ly producing the 
impre ive collecti on of quality articles that you 
see now. 
We hope that you find thi s issue re levant 
in looking toward the future, keeping up with the 
present, and under tanding the past when it comes 
to genetics and its wide-ranging impacts. Enjoy! 
-Wendy Ng and Amber M enezes 
Editors-in-chief 
A Bump in the Road for the UWOMJ 
In 2005, the University of Western 
Ontario Medical Journal had not printed an actual 
issue in two years, despite its long, successful 
history as Canada's second oldest medical student 
journal. At that point, the only printed issue that 
had been distributed in recent memory was the 
Obstetrics and Gynecology issue. Meanwhile, the 
Pediatrics issue had been laid out in full - with 
cover art, student articles and advertisements 
included - but there were no funds for printing, 
nor a printing service set up. However, there were 
still bills to be paid for the layout of the 
Pediatrics issue. At the same time, some articles 
had already been collected for the History of 
Medicine issue, but there was no realistic plan in 
place for the issue to go forward. 
My four years as the managing editor of 
the UWOMJ have been exteremely rewarding. 
When 1 both started medical school and joined the 
UWOMJ in 2005 , the position of "Managing 
Editor" was newly created and loosely defined -
my original job description was merely to 
implement a peer or faculty review process for 
student articles - but I learned quickly there was 
so much more to be done, and l vastly expanded 
my role. 
The company that had taken care of 
UWOMJ's layout, printing and distribution in 
previous years reportedly went bankrupt and fled 
North America. My phone calls and emails were 
not returned. The UWOMJ was caught 
unprepared in a confusing state of affairs. Many 
students were frequently asking me when their 
articles would be printed and questioning when 
the next issues would be coming out. Multiple 
advisors recommended to me that I should simply 
put a stop to printing the journal at all, and that I 
resort to online copies only. But this was not an 
acceptable answer to me - it was of utmost 
importance that the UWOMJ remain in print. 
UWOMJ, Vol 78, lssue 3 
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It was with this realization that I began to 
seek out alternatives for both advertising and 
printing. Individually soliciting advertisements 
for the journal was not at all an easy task - I came 
to this discovery through trial and error. I 
contacted CU Advertising, and with the help of 
my colleague Renata Villela, we signed our first 
contract with them for the Oncology issue. At the 
same time, I looked for a new printing company. I 
visited several, collecting proofs and comparing 
prices, before I finally decided to work with 
Imprint. I was confident that their staff would 
ensure that the journal was printed to our high 
standards. 
The Oncology issue was the first edition of 
the UWOMJ to accept only articles reviewed and 
approved by faculty at UWO. Recruiting 
contributors was a challenge in itself, and I 
designed an original new layout for the issue. I 
contacted dozens of faculty in 2005, asking them 
to join our faculty review board. Articles that did 
not meet rigorous review standards were rejected. 
I designed and sent out a peer review form to 
reviewers and requested countless revisions from 
authors. I acted as a mediator between all authors 
and reviewers to maintain absolute anonymity in 
the process. 
Finally, 1 needed a new process for 
distribution of the journal. I put together a long 
I ist of mailing addresses, and we had our first 
''mailing label sticker party" in the UWOMJ 
office. Amber and I carried the journals down to 
the mailroom, and the bulk of our very first new 
journals were on their way! 
However, a sustainable structure for the 
UWOMJ was sorely needed. Renata offered to 
take care of the contracts, while I worked on the 
journal itself. This was how the two divisions of 
the Editorial Board of the journal were born: 
Renata took charge of the Contracts and Awards 
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Division, while I headed up the Managerial 
stream. The backlogged Pediatrics and History of 
Medicine issues were published online. 
When Amber Menezes helped collect 
articles for the subsequent Family Medicine issue, 
authors were responsible for ensuring that their 
articles were indeed reviewed and approved by 
UWO physician faculty members before 
submission. This process has proven sustainable 
and has maintained the high quality of articles 
appearing in the UWOMJ. 
The first online summer supplement of the 
UWOMJ was put together by Stephen Chihrin in 
2005. This has become an annual tradition. 
Tiffany Kwok continued to produce the summer 
supplement and put together the Cardiovascular 
issue, our first alternatively funded issue. She also 
ensured that the UWOMJ office was clean and in 
a functional state for our editoria l staff - a 
massive task, given the mess that it was in before! 
Renata instituted some amazing new 
changes for the UWOMJ. Recently, she has 
spearheaded the process for the UWOMJ to be 
catalogued by PubMed. Notab ly, she suggested 
that we recognize our writers' and artists' talents 
and hard work with departmental and feature 
article awards, as well as cover art awards. We 
had our first Awards meeting in the early summer 
of 2008. Dr. Fai sal Rehman, who has been our 
most active facu lty supporter from our rocky start, 
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provided much-appreciated food and 
encouragement for this first meeting, and 
generously funded the awards. 
We are incredibly lucky to have a 
remarkable editorial team taking on the 
immensely rewarding and challenging experience 
of running the UWOMJ. Laura Hinz organized 
our first Awards Ceremony, where plaques were 
presented to very deserving winning contributors. 
She also initiated the creation of the new 
Interdisciplinary Collaboration department of the 
medical journal, reflecting the growing 
multidisciplinary nature of health care today. 
It has been unmistakably clear that the 
transition into sustainable operations has 
progressed pectacularly. We are fortunate to 
have an extraordinary group working on ensuring 
that the UWOMJ continues its high-quality 
publishing and distribution, whi le consistently 
exceeding our readership's expectations. The 
graduating students of the UWO Medicine C lass 
of 2009 have seen our medical journal recover 
dramatically over the past few years from its 
lowest point in 2005 . I eagerly look forward to 
following the journal as a UWO alumnus, with 
such a capable new editoria l team at the lead! 
WendyNg 
Managing Editor-in-chief 
Join the hospital that's 
building for the future. 
H umber River Regional Hospital is quickly earning a reputation for excellence in the delivery of acute medical care . We offer a full range of medical services, and are 
working actively to make our hospital a better place- for our patients and our physicians. 
NEW HOSPITAL APPROVED 
Our redevelopment plan , officially approved by the Ontario government, will see us move to a 
new showcase acute care facility in 2014. By joining Humber River now, you can be a part of 
program and facility planning for Ontario's newest hospital project. Help us build our new 
hospital ; one we plan to make the technologically advanced centrepiece of our New Model of 
Care. Preliminary site work is underway, and planning has already begun. 
We offer placements for clinical clerks, residents and clinical fellows. Humber River Regional 
Hospital is affiliated with University of Toronto and a number of HRRH physicians hold 
teaching appointments at the University. 
EXCITING CAREER OPPORTUNITIES 
Fundamental to the success of our hospital are the remarkable individuals who comprise our 
medical team. Their expertise, commitment and caring are integral to fulfilling our vision as 
the hospital of choice ... committed to patient and family needs. 
To meet the growing community demand for our services, we are looking for 
physicians who demonstrate excellence in clinical care to join our medical 
team. If you are interested contact us by email: mlatter@hrrh.on.ca 
CLINICAL PROCEDURES 
Nailfold Capillaroscopy and Hereditary Disease: Current Applications 
and Future Prospects 
Edward Weiss (Meds 2012) a nd Paul Lau (Meds 2011) 
Faculty Reviewer: Dr. janet Pope 
Nail fo ld capillaroscopy is a proven non-invasive method of examining the peripheral microvasculature. 
Primaril y u ed to a e s rheumato logica l di sease, it is being increasingly recognized as a versatile tool that 
can detect blood vesse l abnormalities in a wide range of conditions, including a number of hereditary 
di seases. As a complement to geneti c testing and other clinica l examinations, capill aroscopy can often yield 
important diagnostic clues, and has the potentia l to aid research in hereditary conditions as disparate as 
te langiectas ia, glaucoma, and schizophrenia. 
Introduction 
At an estimated length of between 50,000 
and I 00,000 miles, the vascular system of the 
human body holds the distinction of being longer 
than the road networks of many small countries. 
As a conduit fo r metabolites, hom1ones, 
e lectrolytes, and drugs , it excels in its function 
and is exquisitely sensiti ve to constant changes in 
supply and demand. Its very pervas iveness can, 
however, act as a doubl e-edged sword -
pathologies that affect one area of the vasculature, 
such as atherosclerosis or Marfan 's syndrome, are 
likely to affect other areas as we ll. 
As a diagnostic too l, the tight integration 
of the vasculature with all other body organs and 
systems can often be used to the c linic ian and 
pati ent ' s advantage , since s igns observed at one 
point in the vessel network can indi cate pathology 
at a di stant site. The presence of caput medusa 
around the umbilicus, fo r exampl e, is useful in 
diagnosing portal hypertension and inferi or vena 
cava obstruction. Often, however, abnormalities 
in the vascul ar system are more subtle and require 
suitable clini ca l skill to ascertain them. 
Na il fo ld capillaroscopy (NC) is the in vivo 
microscopi c examinati on of the capillari es found 
in the skin just prox imal to the nail. The 
capillari es in thi s area run para lle l to the surface 
of the skin , and can be eas ily visuali zed with 
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appropriate lighting and magnification. Using 
only a magni fy ing g lass, the 19th century Italian 
phys ician Gi ovanni Ra or1 was able to describe 
abnormal capillaroscopi c findings and re lated 
them to conjuncti val inflammation.' In the 
twentieth century, the practi ce of NC was refined 
and now it is used most prominently to detect 
markers of rheumatological di sease, such as 
systemi c sclerosis. However, there are indi cations 
that NC may a lso be helpful in the diagnosis and 
progno is of variou hereditary conditions that 
invo lve the microva culature. In thi s article, we 
hope to illustrate a genera l approach to NC as a 
tool in assess ing rheumato logica l pathologies as 
we ll as its potenti a l utility in the context of 
geneti c di sease. 
Procedure 
Traditi onally, NC has been performed 
with a light micro cope. The pati ent is seated and 
acclimati zed to the ambient temperature of the 
examining room. lmmer ion oil or c lear gel i 
applied to the nailfold area to enhance 
transparency of the skin and make the capillaries 
more visibl e, and the light source is positioned at 
a 45 degree angle to the nailfold . A green LED or 
green-filtered light is often used to further 
enhance vis ibili ty, as light in the blue-green part 
of the spectrum is preferentia lly absorbed by 
hemoglobin. A wide view of the terminal 
capillari es can be obta ined with a 1 Ox-60x 
magnification, and more detailed views can easily 
be achieved with higher magnification (250x-
1 000x). 2 Photomicrographs can be taken at the 
time of examination for further study or archival 
purposes. 
The capillaries can also be examined with 
hand-held instruments, such as an 
ophthalmoscope or a dermatoscope, although 
these often make it more difficult to spot areas of 
diminished vascularity. 3 More recently, 
specialized videocapillaroscopic systems have 
been developed to facilitate the analysis of 
capillary abnormalities, although the expen e of 
these systems may be prohibitive for some 
clinicians. 
The more common findings in patients 
with microvascular abnormalities include the 
presence of large or giant capillaries, 
disorganization of the vascular array, tortuous 
vessels, microhemorrhage, loss of capillaries, and 
ramified, or "bushy," capillaries.4 
Rheumatological Findings 
Classically, nailfold capillaroscopy has 
been utilized to differentiate patients presenting 
with isolated Raynaud's phenomenon (RP) from 
those who may have underlying connective tissue 
disorders causing secondary RP. The nailfold 
capillaries of healthy patients and isolated RP 
patients appear as parallel hairpin loops with 
visible afferent, transitional and efferent portions 
(Figure 1). In contrast, secondary RP patients may 
possess deviatory capillary patterns directing the 
clinician to investigate for certain connective 
tissue or autoimmune rheumatic diseases. 5 
The scleroderma pattern has been 
extensively characterized and represents a 
multitude of nailfold capillary changes seen in 
patients with systemic scleroderma.6 Three 
variations of the scleroderma pattern have led to 
the categorization into early, active and late 
phases (Figure 2). Specific findings that have 
been described include giant capillaries proposed 
to be a result of an autoregulatory response to 
tissue hypoxia, capillary microhemorrhages due 
to early vascular damage, avascular fields due to 
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increasing hypoxia and architectural di sruption of 
capillaries. 
Similar to systemic sclerosis, variations of 
the sclerodem1a pattern are also seen in patients 
with other connective tissue diseases such as 
dermatomyositis , systemic lupus erythramatosus, 
antiphospholipid syndrome, Sjogren' syndrome 
and occasionally rheumatoid arthritis.7 
Figure I. Normal nailfold capillaries. (Courte y of 
Dr. Joerg Piper) 
N ailfold Capillaroscopy in Hereditary 
Hemorrhagic Telangiectasia 
An autosomal dominant disorder 
characterized by easily bleeding telangiectases on 
the skin and mucosal surfaces, hereditary 
hemorrhagic teleangiectasia (HHT; OMIM 
187300) can lead to arteriovenous malformations 
in many organs and paradoxical septic emboli .8 
Therefore, early diagnosis is important for better 
prognosis. Currently, three typical teleangiectases 
are required to make the diagnosis of HHT, with 
genetic testing only positive for a small subset of 
families. If not diagnosed, arteriovenous 
malformations and septic emboli may be missed. 
One study demonstrated that over 80 percent of 
patients with HHT show enlarged afferent 
portions of the capillary loop, a finding that was 
not evident in matched patients without HHT.8 
More importantly, five of nine patients without 
visible macroscopic cutaneous telangiectases but 
having a clinical diagnosis of HHT showed 
enlarged afferent capillary loops. Although 
further studies are needed to validate this , nailfold 
capillaroscopy appears promising as a diagnostic 
aid when a definitive diagnosis of HHT can ' t be 
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Figure 2. Capillaroscopy findin gs in systemic scleros i . (A) Normal na il fo ld pattern . (B) Early sclerodetma 
pattern, w ith dil ated and giant capillari es . (C) Acti ve sc lerodem1a pattem hows frequent giant capill aries and 
hemorrhages . (D) Late sclerodc1111a pattem shows severe capill ary architecture di organiza tion. (Courte y of Dr. 
Soumya Chatterjee) 
made based on clinica l info m1ation alone (for 
exampl e, if it is suspected but not yet proven). 
Capillary Blood Flow Measurements and 
Glaucoma 
As one of the leading cau es of blindness in the 
world , g laucoma represents a s ignifi cant threat to 
ocular health and day-to-day fun ction. One of the 
most common subtypes, primary open-angle 
glaucoma (POAG; OMIM 137760), is known to 
have a signifi cant geneti c component, as the 
prevalence of POAG among those with a pos itive 
family hi story is 5- to 20-fold greater than the 
nom1al population.9 The progress ion of POAG is 
often insidious, and it is estimated that more than 
half of those with the di ease remain unaware of 
the ir condition until their vis ion begins to 
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deteriorate. 10 Thu , screening measures for those 
who have a family hi story of POAG and others at 
increased ri k have an important role in 
preventing the progress ion of glaucoma to v isua l 
damage and blindne s. Unfortunate ly, the class ic 
sign of developing g laucoma, a high intra-ocular 
pressure, i only detectable in about half of those 
with the di sease. 11 
Although the precise pathophys iology of 
POAG is complex and still not complete ly 
understood, it has been noted that abeiTations in 
systemic blood fl ow are often conelated w ith the 
incidence of glaucoma. 12 One such abnormality is 
the degree of periphera l capillary vasospasti c ity 
after a period of cooling. Using capill aroscopy, it 
is poss ible to mea ure blood flo w in the na ilfo ld 
vesse ls and estimate the extent to which flow 
stops in response to cold. Patients with POAG 
often show an exaggerated vasospastic response 
relative to normal controls , which may indicate a 
systemic abnormality of blood flow regulation .12 
Thus, capillaroscopic examination in patients with 
ri sk factors for POAG may be useful in research 
and eventually in screening for thi s di sease, 
especially when an elevated intra-ocular pressure 
is not detectable. 
Capillary Abnormalities and Psychiatry 
One of the more intriguing domains of 
medicine that can be examined with 
capillaroscopy relates to hereditary mental illness, 
namely schizophrenia. As early as 1939, 
researchers discovered that a disproportionate 
number of patients with schizophrenia exhibited 
abnom1alities of the nailfold capillaries and 
increased visibility of the nailfold plexus, the 
dense subcutaneous network of capillaries found 
prox imally adjacent to the fingernail , which is 
generally not visible past puberty.13 Typical 
findings upon examination of the nailfold include 
a highly visible capillary plexus (Figure 3), and 
oddly-patterned individual capillaries with 
numerous horizontal anastamoses. 14 
Subsequent studies in the 1960's and 
onwards aimed to establish an objective scale for 
measuring visibility of the plexus and 
concurrently found evidence that the 
endophenotype of high plexus visibility was 
positive ly correlated with familial , rather than 
sporadic, schizophrenia, 14 as well as more severe 
and more negative symptoms. 15 Conversely, it is 
estimated that 70% of patients with familiar 
schizophrenia have an elevated plexus 
visibility. 16This demonstrates that schizophrenia 
is a more complex disease, with abnormalities 
that extend beyond the brain in many patients. 
Taken together, these data suggest that an 
elevated plexus visibility has the potential to be a 
suitable non-invasive biomarker for those at ri sk 
of developing hereditary schizophrenia or 
schizotypic personality features. 17 Given the 
young age at which many patients with 
schizophrenia begin to show symptoms, the 
ability to screen for nailfold abnormalities could 
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possibly enab le families with a history of 
schizophrenia to be mindful of early 
manifestations of mental illness and seek 
appropriate treatment. Active research in thi s area 
is underway, and it is hoped that being ab le to 
identify a distinct subclass of people with 
schizophreni a may assist in future genetic studies 
aimed at di scovering the underlying etio logy for a 
truly debilitating disease. 
Figure 3. Nailfold venous plexus images w ith 
associated Maricq plexus visibility score (0 = no 
visib le plexus, 4 = high ly visib le plexus) . (A) 
Nom1al, 0/4 on Maricq scale. (B) Abnormal, 4/4 on 
Maricq sca le. (Courtesy of Dr. John Vuketich) 
Conclusion 
Nailfold capillaroscopy i a tried and true 
clinical method that has app lications to many 
disparate pathologies. While the usual 
investigations that comprise genetic workups 
cannot be replaced by a simple observation of 
nailfold capillaries, a thorough examination of the 
microvasculature can often yie ld clues that aid in 
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diagnosis and prognosi·s, wi.th f a mm1mum o 
expense and invasiveness. It is important to be 
aware that capillary abnormalities and other 
vascular signs can be missed if not sought and 
that magnification of the nailbeds in patients with 
m~ny diseases can be a useful and relatively easy 
skill to acquire. 
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DIAGNOSTIC REVIEW 
Osteoarthritis: An Old Disease Cast in a New Light through Greater 
Understanding of the Human Genome 
Rachel Bevan (Meds 2012) and jason Essue (Meds 2011) 
Faculty Reviewer: Dr. Andrew Leask 
The successful mapping of the human genome offers the potential to greatly advance our understanding of 
various disease processes. Osteoarthritis is a disease of particular interest because there is ignificant 
morbidity and societal burden associated with this condition . Furthermore, the prevalence of this disease is 
expected to rise dramatically with the aging of the baby-boomer generation (individuals born between 1946 
and 1964), with a concomitant elevation in health care costs in Canada and abroad. Osteoarthritis was 
previously viewed as a commonplace disease resulting from environmental 'wear and tear' , that was an 
inevitable part of aging. However, new advances have demonstrated that osteoarthritis is a surprisingly 
complex multi-factorial disease that is affected by both environmental and genetic variables. This review 
discusses some of the environmental and genetic factors that influence the progression of osteoarthritis. 
Recent advances in biomarkers that are associated with increased disease risk are also discussed. Finally, 
the potential impact of genetics on both early diagnosis of disease, and prediction of how a patient will 
respond to a particular pharmacological treatment is presented. 
Introduction 
Ever since the discovery of the three-
dimensional structure of DNA 1 the field of 
genetics has intrigued both sc ientists and the 
general public alike for its potential impact on 
disease diagnosis. Indeed, the concept of genetics 
as a primary player in the role of diseases is 
assumed by most of the lay public today. One of 
the goals of understanding genetic influences in 
the disease process is to aid in treatment of 
patients through the development of a 
personalized medical approach. Predictive genetic 
testing is one area that has garnered great interest 
in the past decade, especially since the sequencing 
of the human genome. 2 The goal of predictive 
genetic testing is to determine if an individual is 
likely to develop a disease state based upon the 
presence/absence of particular genes or 
biomarkers. Although challenging, determining 
how best to treat a patient based on their genetic 
make-up is simplified in the cases where a 
particular gene or mutation is the direct cause of 
particular disease. For example, cystic fibrosis is 
UWOMJ, Vol 78, Issue 3 
an autosomal recessive disease; for the disease to 
occur, each copy of the CFTR gene must have a 
mutation that renders the resultant protein non-
fu . I 3 4 nct10na . ' 
However, in many cases the disease 
process is not straightforward; the pre ence of a 
particular genetic variant doesn ' t necessarily lead 
to the disease. Instead, diseases, espec ially those 
of a chronic nature, are multi-fact01ial, resulting 
from a complex set of interactions among many 
different genetic and environmental factors. In 
general, there is no single gene that causes the 
disease, but genetic factors are likely to contribute 
to an increased probability of developing the 
condition. Thus, it is imperative to develop 
methods to identify individuals at risk. 
Osteoarthritis (OA) is one example of a 
multi-factorial disease that is influenced by 
genetic and environmental variab les. OA was 
previously viewed as a commonplace disease 
resulting from environmental 'wear and tear ' that 
was an inevitable part of aging.5 However, new 
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advances have demonstrated that OA is a 
surpri sing ly complex multi-factorial di sease that 
is affected by both environmenta l and genetic 
vari ables. 5•6 This review discusses some of the 
environmental and geneti c fac tors that influence 
the progress ion of OA. Recent advances in 
biomarkers that increase di sease ri sk are also 
discussed. Finally, the potentia l impact of 
geneti cs on both earl y diagnosis of di sease, and 
prediction of how a pati ent will respond to a 
parti cular pharmaco logica l treatment are 
presented. 
Disease Burden of Osteoarthritis 
OA affects 10- 12% of the adult popul ation 
in North America and is a leading cau e of pain, 
phys ical di sability, and use of health care 
services.7•8 OA is a degenerati ve di sease 
characteri zed by the earl y deterioration of 
arti cular cartil age from within the jo int, and later 
by complete loss of arti cular cartil age, damage to 
the subchondral bone, severe deformities, and 
di sabling pain.5·9•10 The consequences of disease 
are detrimental to overall qua li ty of life 11 in many 
ways, including fa tigue, reduced income due to 
impaired labour force engagement, 
hospitali zation, surgery, medication side effects, 
fa mily instabili ty, and decreased socia l 
parti c ipation.8 Alarmingly, the number of people 
affected by OA is ex pected to increase 
dramati cally as the baby-boomer generation ages. 
For instance, in Canada approximately 3 million 
people are currentl y li ving with OA. Thi fi gure 
is ex pected to rise to 5 million by the year 2026.11 
Unl ess better methods are developed to diagnose 
and treat OA, the direct and indirect costs 
associated with caring fo r such indi vidual will 
ri se substantia ll y with broader impli ca ti ons for the 
overa ll economic burden. 
Risk Factors for Osteoarthritis 
The ri sk fac tors fo r OA can be class ified 
as e ither systemi c or local-mechani cal. 13 The 
local-mechanical ri sk fac tor are then further 
cia sifted a intrinsic or extrinsic to the j oint in 
questi on. In accordance with thi s model, OA is 
w idely be li eved to be the result of local ri sk 
fac tors acting within the context of systemic 
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susceptibility.13 The intrinsic local-mechanical 
ri sk factors fo r OA include joint alignment, 
. . 5,13 
muscle weakness , and propnoceptwn. 
Extrinsic local-mechani cal ri sk factors include 
phys ical acti vity, occupations involving strenuous 
. . . . s 13 A 
repetiti ve motions, obes ity, and JOint lllJUry. ' 
number of systemic risk factors have been 
reported, including age, sex, et~icity , b~ne 
density, nutritional fac tors, and genetic factors . 
Biomarkers in Osteoarthritis: Targets for 
Personalized Medicine 
At present, the best way to characterize 
OA invo lves measuring j oint space narrowing on 
radiographs, evaluating clinical symptoms 
suggesti ve of OA (i.e. pa in), and direct 
arthroscopic visuali zation of the articular surfaces 
within the joint capsul e (particularly in the case of 
knee OA) .10•14 However, these methods are often 
only abl e to detect OA after irreparable joint 
damage has occurred. Thus, there is a need to 
identi fy more sensitive methods to detect OA 
prior to irreversible j oint damage, in order to 
improve morbidi ty outcomes. In parti cular, there 
is great interest in identi fy ing specific biological 
markers that will refl ect the biological changes 
that occur within the j o int during the earl y phases 
the A disease process. S ince OA primarily 
affects bone, cartilage, and synovial ti ssue, it is 
logica l to con ider the structural molecules 
deri ved fro m the e tis ue a potentia l biologica l 
markers of OA. 14 Notable candidate biological 
markers include: 
l. N-terminal cross- linked telopeptide of 
type l coll agen (NTX- l) as a marker of 
bone degradati on; 
2. C- terminal cross- linked telopeptide of 
type II coll agen (CTX-II) as a marker of 
carti I age degradation; 
3. G lucosyl-galactosyl-pyridinoline (Gic-
Gal-PYD) as a marker of synovium 
degradation.14• 15 
It should also be noted that the biomarkers 
described above represent the net outcome of 
di sease and do not indicate how the di sease 
? riginate? , n~r do they represent targets for drug 
mtervent1 on m OA . However, these biomarker 
are useful to clinicians to stage the disease 
process in patient . Furthermore, biological 
markers may enable clinicians to differentiate 
patients based on risk of experiencing rapid 
progression of OA as these individuals will be in 
greatest need of targeted early intervention .16 
Biomarkers are also expected to advance the 
process of drug development by providing cost-
effective and sensitive indicators of a drug ' s 
effectiveness. 15 Unfortunately, a single specific 
biological marker has yet to emerge to fulfill 
these lofty objectives, and it seems likely that it 
will be nece ary to u e a combination of markers 
in order to adequately characterize OA. 
Additionally, practical issues such as tissue 
specificity, clearance rates, potential circadian 
variations, 14 and differences due to gender, 
ethnicity, and age need to be resolved prior to 
widespread acceptance of candidate biological 
markers . 
It is also important to highlight that recent 
genome-wide linkage studies have identified 
several gene variants that appear to predi pose to 
OA. 14•17 In these studies, researchers relied upon 
microarrays capable of assessing 300,000 or more 
single-nucleotide polymorphisms (SNPs) in a 
given DNA sample. These microarrays examined 
interpersonal differences in inherited genetic 
variability by comparing the prevalence of gene 
variants among patients who have a given disea e 
with controls who do not have the disease.1 
Several chromosome regions and genes 
have been identified that are associated with OA 
prevalence (FRZB, BMP2, CD36, PTGS2, and 
NCOR2) or OA progression (CILP, TNFRSFllB, 
and ESRl ; ADAM12 is associated with both 
. ) 14 17 f h prevalence and progressiOn . ' Most o t e 
genes identified encode proteins that are involved 
in signal-transduction pathways. 14 This work 
should help to clarify the relationship between 
genetic susceptibility, the genomic expression of 
aberrant genes that predispose to OA via 
biological markers, and the actual manifestation 
and rate of onset of the disease process. More 
significantly, further clarification of such 
pathways in preclinical and clinical models of OA 
will lead not only to the identification of new 
clinically relevant biological markers, but help 
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achieve the ultimate goal of OA researchers in 
both academia and industry, which is to develop 
novel drug targets and therapies to combat thi s 
d b.1. . d. · 14 I S 17 e 1 ttatmg con ttiOn . · · 
Predictive Genetic Testing 
OA is a good example of a multi -factorial 
disease with a large societal burden for which 
predictive genetic testing could play a role in the 
future. In general, the goal of predictive genetic 
testing is to identify asymptomatic individuals at 
ri k for di ea e ba ed on particular biomarkers 
and/or genes that have been linked to 
predisposition to a particular disease. This differs 
from the majority of current medical tests, which 
are diagnostic, and thus seek to determine the 
etiology of a patient's current disease state . Thus, 
there is a fundamental uncertainty as to whether 
or not the di ease state will develop and how 
severe the disease will manifest if it does in fact 
develop. This is especially true in complex multi-
factorial diseases such as OA where it is difficult 
to make accurate predictions due to the influence 
of environmental factors ? 
Pharmacogenomics 
Genetic diagnosis and biomarker testing is 
important not only for current and future disease 
states, but also in predicting how an individual 
might respond to particular medications. The 
study of the genetic basis of differential drug 
response has been termed 'pharmacogenomics' . 
ln general, many genes play a role tn 
phannacokinetics and pharmacodynamics of 
various drug responses. Pharmacogenomics 
research eeks to elucidate the genetic basis of 
how individuals or sub-populations respond to 
different drugs in terms of side-effects, toxicity, 
and drug efficacy. Such knowledge can lead to 
the development of biomarker tests to predict 
which individuals will respond well to particular 
d 19 20 I . h l h I . . rugs. · t mtg t a so e p m targetmg drug 
development to specific sup-populations that may 
be more likely to respond to a patiicular 
therapy. 2 1 In general, knowledge of the genetic 
factors that relate to drug response will provide a 
powerful tool for treatment in the future .19•20 
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However, the development of detail ed 
geneti c test that can be linked to a population-
specific drug response is quite complex. A 
number of teps are involved, including: 
1. ldentifi cation of genes that are involved in 
the drug response (e.g. pharmacokineti cs 
and pharmacodynamic of the drug); 
2. Determining differing variants of these 
gene ; 
3. Determining whether or not these 
di ffe rent geneti c va ri ants corre late with a 
di ffere ntial drug respon e. 
One recent success of the fi eld is the drug 
warfa rin , whereby specific variants of parti cular 
genes were found to corre late with response to 
warfa rin at parti cular doses.n As of August 2007, 
the FDA has updated prescribing information fo r 
warfa rin to incl ude the in formation that the 
geneti c make-up of a patient may influence how 
they respond to warfarin . 23 However, it i not 
clear that the benefits out-weigh the costs. In a 
recent study on non-va lvular atrial fibrill ation , it 
was determined that there is little benefit to 
geneti c testing for warfarin do ing, based on an 
estimated cost of $400 (US) per geneti c te t, 
except in pati ents at the highe t ri sk for 
hemorrage. 24 Thi s is like ly to change as the cost 
of geneti c testing decrea e w ith the advancement 
of sequencing technologies25 , however it does ca ll 
into question the cost-effecti veness of 
personali zed medi cine. 26 
Personalized Medicine: Is it Realistic? 
The goa l of per ona li zed medic ine is to 
provide indi vidua li zed treatment to pati ent , 
based parti a lly on the knowledge of the geneti c 
profil e of an indi vidual ( including 
genes/biomarkers of di sea estate) and lmowledge 
of how pati ents might respond to di ffe rent 
medi cal treatments.27·28 
The complexitie of moving towards a 
persona li zed medi cine approach are immen e. 
Co t-effecti ve genome equencing techniques25 , 
methods for ana lyzing genome-wide 
gene/prote in/mRNA express ion profiles and 
interac ti on related to di sease tates23 , and the 
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complete human haplotype mapping proj ect (the 
HapMap project which provides a complete 
li sting of human SNPs)27•30 will he lp . in t~e 
acquisition of know ledge about the genettc basts 
for human disease. However, even these advanced 
techniques are not sufficient to deal with 
problems like incomplete penetrance, whereby 
presence of the di sease allele(s) does not 
d. "11 31 necessaril y mean that that tsease wt occur. 
Furthermore, models for the genetic basis of 
di sease should account for the effect of epigenetic 
control of gene express ion. 24 Epigenetic control 
of gene express ion (and problems with epigenetic 
control) have been hown to play a fundamental 
role in both Prader-Willi and Angelman 
diseases33 , and is thought to be implicated in the 
di sea e proces for many di seases, including auto-
immune di seases and p ychiatric di sorders34. 
Rea li zing the full benefits of personalized 
medicine and predicti ve genetic testing i till far 
in the future. 29 Nonetheless, it i important to be 
aware of these rapidly evolving fields as they hold 
the potentia l to revolutionize medicine. 
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ETHICS 
Ethical Implications of Germ Line Genetic Engineering 
Hassan Mir (Meds 2012) and Christina Morgan (Meds 2011) 
Faculty Reviewer: Dr. Lois Champion 
Following the recent decision by the Obama administrat ion to li ft strict limi tations on embryonic stem cell 
research, geneti c engineering has once again come to the forefront of scientifi c di scuss ion. An upcoming 
FDA-approved tria l using human embryonic stem cell s in recently para lyzed individuals has further 
prompted an analys is of the legal and ethica l issues surrounding the use of germ line geneti c engineering. 
Though prohibited g loba lly due to inadequate safety and effecti veness, it is inevitable that these concerns 
will one-day be met by continual technological advancements. Nevertheless, there remains a plethora of 
issues such as equal access ibility for all socioeconomic groups, autonomy of descendents, and effect on the 
human gene pool to name a few. In thi s di scuss ion, it is important to make the di stinction between germ 
line geneti c engineering used fo r therapeutic purposes (a ltering DNA to correct a geneti c defect before it 
manifests itse lf as a di sease) and enhancement purposes (a ltering DNA to improve an individual above 
" normal" functioning) . Although the use of thi s technology could be justifi ed fo r therapeutic purposes, it is 
very di ffi cult, if not imposs ible, to mora lly defend interventions fo r enhancement purposes. 
Introduction 
Geneti c engineering has once again come 
to the fo refront of scientifi c di scuss ion foll owing 
President Obama 's recent decision to lift stri ct 
limitati ons on human embryonic stem cell 
research set by the previous administration in 
America. Coinciding with thi s was the approva l 
of a phase I stem ce ll tri al by the Food & Drug 
Admini stration a imed primaril y at testing the 
safety of thi s therapy in e ight to ten complete ly 
para lyzed pati ents with severe pinal injuries.1 
The stem cell s, which were obtained from 
embryos that would have otherw ise been 
di scarded, will a lso be used to test for any s igns 
of functional recovery in these pati ents. 1 
A lot of controver y has surrounded 
a lterations made spec ifica ll y in the germ line 
(sperm or egg), s ince they affect every ce ll in the 
child and would be transmitted to all future 
descendants. 2 It is important to make the 
di stincti on between germ line geneti c engineering 
used for therapeuti c purposes (a ltering DNA to 
correct a geneti c defect before it manifests itself 
as a di sease) and enhancement purpo es (a ltering 
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DNA to improve an individual above "normal" 
average func ti oning). ~ 
Currently, many laws around the world 
prohibit the u e of germ line genetic engineering 
due to safety concern and the poss ible 
implicati ons for future generations. In addition , 
the fo ur principles of bioethics,3 - beneficence , 
non-malefi cence, autonomy, and justice 
influence the debate regarding the future use of 
thi s technology. This arti c le evaluates some 
re levant lega l and ethica l arguments that are 
important in determining whether gern1 line 
geneti c eng ineering should be utilized in humans 
in the future. 
Current Legislation 
There are well defined Canadian and 
international laws governing the use of germ line 
geneti c engineering. Canada 's Ass isted Human 
Reproduction Act (2004) prohibits the alteration 
of " the genome of a ce ll of a human being or in 
vitro embryo uch that the alteration is capable of 
being transmitted to descendants. "4 The 
prohibition is large ly due to the questionable 
nature of the safety, effectiveness, 
appropriateness and efficiency of the technology. 5 
This view is shared intemationally,6• 7 and thus 
there are currently no legal cases pertaining to this 
topic around the world. 
While the law dictates what can and 
cannot be done, the technology 's controversial 
nature makes it necessary to assess the many 
ethical issues involved. Laws often reflect 
changing societal values, and therefore are 
constantly evolving. As a result, ethical analysis 
becomes invaluable for future policy 
development. 
The Costs and Benefits of Germ Line Genetic 
Engineering 
The principles of beneficence and non-
maleficence constitute the backbone of 
bioethics.8•9 Beneficence asserts that there is an 
obligation to treat and improve the condition of 
others when it is possible to do so. Hence, altering 
the genome for therapeutic purposes on a 
permanent and heritable basis to prevent future 
genetic diseases becomes an obligation. This 
suggests that even within our limited capabilities, 
it is our duty to prevent any unnecessary harm 
and suffering and to improve the quality of life 
for future generations. The promise of 
enhancement to increase human functioning to 
above normal levels may seem very alluring and 
advantageous. Potentially favourable outcomes 
include a dramatic increase in life expectancy, a 
delay in the natural aging process, and increased 
tolerance and functioning of our immune 
system. 10•11 It is also fair to argue in favour of 
enhancements that improve health and mental 
acuity in general. Such enhancements will 
increase survivorship, quality of life as well as the 
c fu . 12 life expectancy 10r ture generatiOns. 
Nevertheless, the majority of techniques 
involved in this technology are in their early 
testing stages. This imposes numerous technical 
barriers that jeopardize the effectiveness and 
safety of such procedures, hence challenging the 
principle of non-maleficence; this principle states 
that a therapy should have a net benefit, loosely 
translating to "do no harm".9 Additionally, germ 
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line genetic engineering experiments invol ving 
animal models are hi gh ly inefficient and produce 
greatly variable offspring. The process requires 
breeding to be repeated through several 
generations until it results in a stable and 
pem1anent animal line with the desired properties. 
Not only would this be highly dangerous in 
humans, but because of the threat this presents to 
human dignity, it would also be impossible to 
justify morally. 10 Insertion or modification of 
certain genes may also have unknown and 
potentially harmful interactions with other genes 
in the recipient genome. Similarly, the removal of 
disease- linked genes may remove the beneficial 
effects of those genes. 10 Due to the unpredictable 
and largely unknown hazards of such procedures 
in humans, taking such risks is difficult to justify 
despite the potential benefits . 
Respecting the Right to Self-Governance 
Autonomy is the right to se lf-
determination, which embodies freedom and the 
ability to determine one ' s own future. 10 In germ 
line genetic engineering, one must consider 
autonomy of the parent, the child, and his or her 
progeny. According to the principle of 
reproductive autonomy, parents have the right to 
use whatever therapeutic means available to 
ensure that they have a normal pregnancy and a 
healthy baby. However, this principle excludes 
the parents ' attempts to enhance the traits of their 
genetically normal offspring. Similar to situations 
where parental autonomy can be taken away in 
cases of social concern (such as child neglect) , the 
American Association for the Advancement of 
Science has argued that s trict legislation should 
regulate and differentiate between germ line 
genetic engineering for therapeutic versus 
enhancement applications. 10 
The autonomy of the child and subsequent 
progeny must also be considered. Upon reaching 
adulthood, a child is considered a rational agent 
and it is therefore safe to assume that he or she 
would consent to most genetic augmentations .13 
While this argument may apply for therapeutic 
purposes, autonomy for enhancement ordeals is 
more complicated. Traits that a parent may 
choose to Improve (such as improved 
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mathematica l versus phys ical abilities) may not 
be what the child or their progeny would have 
chosen to enhance if given the choice as rational 
adults. In such instances, issues of informed 
consent and violation of autonomy ari se, leading 
to the poss ibili ty of lega l cases that challenge the 
reproductive autonomy of the parents versus the 
autonomy of the child . 
The Role of Justice 
Justi ce is another fundamenta l ethical 
concept and requires that harms and benefits be 
di stributed equall y among the whole population. 3 
If certain procedures become cl ass ified as 
therapeutic, it is reasonable fo r individuals to ask 
that such services be made universa lly ava ilabl e. 
It can be argued that getm line therapy is 
analogou to large ly access ible public health 
initiati ves aimed at preventing heart di sease and 
therefore should a lso be access ible to the majority 
of the populati on. Nevertheless, even if 
therapeutic germ line geneti c engineering 
becomes covered under a universal health plan, 
such as Medi care in Canada, long waiting li sts 
w ill like ly pose a myriad of problems. 
On the other hand, the prospect of germ 
line geneti c engineering for enhancement 
purposes becoming covered under public health 
insurance is highly unlikely. 10 Thus, the wealthy 
would have greater access to thi s technology, 
further expanding the di vide between different 
soc ioeconomic group in society. Thi s skewed 
access ra ises a few criti ca l concems. Those 
unable to afford thi s procedure would likely have 
some undes irable traits and could be viewed as 
abnonnal. 14 In contras t, those able to afford it 
would have greater contro l over shaping the 
human gene poo l by remov ing undes irable traits 
while enhancing benefi c ia l ones, leading to a 
form of eugenics within ociety. Additiona ll y, 
a lterati ons in the germ line would be carri ed on 
throughout the progeny of an indi vidual, 
mainta ining thi s inequa li ty throughout future 
generati ons. 
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Conclusions 
As we venture into the twenty-first 
century, technological advancements continue to 
expand the hori zons of human potential , while 
a lso ra ising important ethical issues; germ line 
genetic engineering is one such advancement. 
Although these procedures are legally prohibited 
due to their lack of safety and effecti veness, it is 
important to develop an understanding of the 
implications on society to help make more 
informed decisions about their future uses. 
Though by no means exhaustive, thi s paper aimed 
to analyze and discuss the four major principles of 
bioethics benefi cence, non-maleficence, 
autonomy, and justi ce - as related to germ line 
geneti c engineering. Through thi s analysis, it 
seems that though the use of thi s technology 
could be justifi ed for therapeutic purposes, it is 
very difficult, if not imposs ible to defend morally 
fo r enhancement purpo es. 
Among other concerns, the ava ilability of 
thi s therapy to the public would require extremely 
c lose monitoring of its health effects (harms and 
benefits in both the short and long term), as well 
as ensuring equal access for everyone in a timely 
manner regardless of their socioeconomic status. 
Failure to do so could result in deleterious 
situations from dire hea lth effects for pati ents and 
their progeny to di crimination based on ones 
genetic make-up. Though there are endless 
po sibilities in improving both the qua lity and 
quantity of human life, it is criti ca l to ensure that 
geneti c engineering i safe, effecti ve, reasonable 
for future generations, and equally access ible 
before it can become a viable component of both 
the sc ienti fic and g lobal community. 
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The Blameworthy Gene 
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W ith improved techniques of genetic analysis, medici ne is becomi ng increas ingly re liant on genes to 
diagnose and treat di sease. However, a geneti c diagnosis is a value-laden enti ty with s ignificant potentia l to 
change the way we categorize people as ill or hea lthy, fl awed or normal, and responsible for or a hapless 
victim of d isease. Nowhere are these va lue j udgements more prevalent than the fie ld of mental hea lth. 
This article will examine the meaning and implications of genetic diagnoses, and apply the theories to the 
example of alcoho li sm. 
"Genetic Diagnosis" Defined and Clarified 
' 'Help us fin d the gene fo r in ert disease 
here." Slogans such as thi s have become 
increas ingly common since the human genome 
was sequenced. These s logans seem to imply that 
once we have fo und the gene, the cure w ill 
natura lly fo llow. They also imply that we cannot 
be truly certain of a diagnosis until it is proven by 
geneti c technology. These attitudes have the 
potential to modify the way we conceptua li ze 
both the di sease and the patient. Is a person with a 
genetic diagnosis but no symptoms a patient? ls a 
patient with symptoms but no gene defect si mply 
a malingerer? The answers to these que tions 
have the potenti a l to change the way the person 
(or pati ent, depending on the in terpretat ion) ts 
categori zed, pa lli ated, and sti gmati zed . 
The term ' geneti c diagnosis ' i oft u ed in 
the li terature, but req uires evera l clarifica tions. 
The fi rst is the timing of the diagnosis. One may 
have a di sease and later discover that it has a 
geneti c component. This impac ts the patient by a 
process that has been termed 'genetic ization ' : the 
patients are re lieved of blame for the ir conditions, 
they are s imply victims of fa ul ty genes.18 Such a 
diagnosis, however, does not prevent susceptible 
indi viduals from looking ahead; there are 
implicati ons fo r fa mily planning as the condition 
could potentially be passed on to offspring. 13•14 In 
contrast, one may receive genetic testing befo re 
the onset of symptoms. When the geneti c 
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precedes the clinica l diagnosis, the individual 
may be prematurely thrust into the sick role .14 
This broadened defi nition of the sick ro le carri es 
with it societa l repercussions, a it increases the 
number of pati ents requiring intervention .14 A 
geneti c diagno is can carry permanent tigma and 
may damage one ' s fee ling of personal controi. 13•14 
Secondly, it is important to keep in mind 
which di sease is be ing examined with the 'geneti c 
diagnosis' . Certa in di eases have more ignificant 
geneti c contributions, thus affecting the potenti al 
fo r remedy.14 For instance, a geneti c diagnosis of 
Huntington ' s di ease corre lates we ll w ith clinical 
progress ion to the di sorder wherea depress ion 
has approx imately 40% heritability. 14 Mental 
illne ses carry both a high ocia l stigmati zation 
and a low geneti c determination, two conditions 
that Spri ggs el a / alleged require stringent 
j ustifi cation for geneti c te ting. 14 However, the 
low geneti c detem1ination means that 
identifi cation of a gene carri er need not be a 
diagnosis, rather it may be an opportunity for 
prophylacti c intervention.14 Thi s ha been termed 
the 'geneti c window ' .17 
The fi na l c larifi cation is the di stincti on 
between pathology and vari ation. There w ill 
naturally be vari ations in genes, but these 
di ffe rences need not be COITelated w ith di sea e. 12 
Therefore, a geneti c di agnosis may 
inappropriate ly label an indi vidual as "ill." The 
anti thes is of patho logizing the healthy 1s 
legitimizing the plight of the ill. Mental health is 
often viewed as a disorder, something that is the 
responsibility of the affected person or the 
consequence of poor moral fibre. 14 Once there is a 
genetic diagnosis, the disorder may qualify as a 
legitimate disease, one that is now the 
responsibility of the health care system. 14•16 Thus, 
genetic diagnoses must be approached with 
caution: they have equal potential to 
inappropriate ly or appropriately cast individuals 
in the sick role. 
Nature Versus Nurture 
The distinction between a clinical and 
genetic diagnosis hinges on the multi-factorial 
nature of disease. Specifically, the express ion of 
genes can be influenced by the individual's 
environment. In a document classic in the realm 
of health promotion, Hancock summarized these 
multiple influences in the Mandala of Health 
(Figure 1). The individual is viewed as the centre 
of a web of influence, with each spoke having the 
potential to create or treat disease. 15 Therefore, 
wh ile genes themselves cannot be altered by 
promoting healthy li vi ng, there is the potential to 
mitigate disease through environmenta l and 
lifestyle interventions. 12' 14 
Reactions to a Genetic Diagnosis 
Wi th the meaning of "genetic diagnosi s" 
clarified, the reaction to uch diagnoses can be 
examined. A genetic diagnosis can decrease 
blame and stigma as ociated with disease. 12 In an 
era of preventive health and personal 
responsibility , Minkler summarized these va lue 
judgements as "when ill is redefined as being 
guilty". 16 In the past, sufferers of mental illness 
were the victims of soc ieta l sti gma largely 
because mental pathology does not fit into the 
class ic Western biophys ical approach as there is 
often not one eas ily delineated causal mechanism. 
If there is a causal gene identified, however, the 
disorder becomes a biophysical disease and the 
~li'estj· l e 
i b~havttrur r
,/ Pe rsora l 
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THE MANDALA OF HEALTH 
Figure 1. Hancock 's Mandala of Health . The individual is viewed as the centre of a series of spheres of 
influence, each providing an opportunity for hea lth promotion interventsions. 15 
UWOMJ, Vol 78, Issue 3 Page I 23 
person now has legitimate claim to the sick role . 
Notwithstanding thi s pos itive reaction to a genetic 
diagnosis, there can also be negative 
ramifications.13 While there was nothing you 
could have done to prevent the disease, there is 
nothing you can do now. Minkler warns that a 
genetic diagnosis may be the same as labelling 
someone as fa ta lly fl awed.14 However, this 
fa talistic approach disregards the multi -factorial 
nature of most mental di seases.13 The same 
argument applies to those who receive their 
genetic diagnosis before the onset of clinical 
symptoms - the optimi m of environmental 
modification should temper the doom of one's 
biological lot. 
Given thi s spectrum of poss ible reactions, 
the impact of a genetic diagnosis must be 
considered at three levels: the pati ent, the hea lth 
care sy tern, and society. An indiv idual receiving 
a genetic diagnos is is now a candidate fo r early 
intervention and a legitimate actor in the sick role. 
Conversely, the geneti c di agnosis may tum a 
healthy individual into a ti cking time bomb, 
waiting anxiously for the onset of symptoms that 
now seems inev itable. 14 This emphas izes the 
importance of not viewing a geneti c diagnosis as 
a label of defecti veness nor as an immutable 
entity. These issues can now be considered in the 
contex t of a specifi c illness- alcoholism. 
Genetic Diagnoses in Practice: Alcoholism 
A number of studi es demonstrate that 
children of alcoholi cs suffe r from a vari ety of 
behav ioural and psychopathological prob lems, 
such as substance abuse, anxiety, depress ion, 
conduct di sorders and delinquency. 10 Thi s type of 
behav iour, however, is not consistent across a ll 
children of alcoholics. By developing a better 
understanding of these vari ations, clinicians can 
attempt to ensure that children of alcoholi cs will 
not succumb to potentia ll y avo idabl e hea lth 
problems. 
The mode of inheritance of an alcoholic 
"gene" is fa r from established, yet there is 
evidence to sugge t that alcoholism is indeed a 
disease of both geneti c and environmental 
etiology. ' Past research ha demon trated an 
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increased ri sk of alcohol abuse in the children of 
alcoholics.2'3'4 It is poss ible that this is due to 
"verti cal cultural transmiss ion"5 . This theory 
describes the transmission of disorders, or traits 
which lead to increased susceptibility to a disease, 
through parental-offspring learned behaviour. 
However, studies have demonstrated that 
behav ioural transmiss ion IS not the only 
contributing fac tor when the children of 
alcoholics develop drinking problems of their 
own. 
For exampl e, a twin-family study by 
Kendler et al examined the mode by which 
alcoholism was passed from parents to 
daughters .6 The results indicated that a solely 
environmental etiology was insufficient to explain 
alcoholi sm. Furthermore, the researchers found 
that in the best-fitting model, usceptibility to 
alcoholism was due in large part to a genetic 
predisposition. 
In a cohort study by Goodwin et al, the 
prevalence of alcoholism was compared in two 
group of adoptees: a group whose biological 
parents were alcoholics, and a control group 
whose biological parents were not alcoholics.7 
The researchers fo und that 18% of those adoptees 
whose biological parents were alcoholics suffered 
from the same di sease; nearly four times the 
preva lence found in the control group. These 
fi ndings offer further evidence of a genetic 
component of alcoholism. 
As there has not yet been a single culpable 
gene identified, one cannot be "diagnosed" with 
the potenti al fo r developing a lcoho lism. 
Notwithstanding, fa mil y hi story may be utili zed 
as a proxy by which to identi fy targets for health 
promotion intervention . For example, in a study 
of co llege students in the U.S., the children of 
problem drinker (COPDs) were identified and 
compared to a contro l group, and COPDs were 
17% more likely to engage in heavy epi odic 
drinking tha.n non-COPDs.8 Additionally, they 
were approx imately three times more likely than 
non-COPDs w ith similar drinking habits to eek 
help for their drinking problems. This was 
parti cularly true of students who had previously 
consumed a lcoholic beverages but had abstained 
from drinking in the past year. In light of these 
results , it stands to reason that when possible, 
COPDs, particularly those who have recently 
attempted to curtail their own drinking, should be 
targeted for counselling and treatment in order to 
prevent future alcohol dependency. 
Walker and Lee, however, caution that 
clinicians should not pathologize the children of 
alcoholics (COAs). 9 They indicate that COAs 
who come from "famil[ies] with strong emotional 
bonds and ... warm, supportive environment[s]", 
are able to maintain caring and empathetic 
interpersonal relationships , and will not 
necessarily develop psychiatric disorders , as has 
been suggested to be typical of COAs. The 
authors elaborate, explaining that alcoholic 
families may have " reservoirs of strength", which 
can come in a variety of forms , which clinicians 
should seek out and draw on in order to provide 
treatment. For example, sibling-sibling 
relationships within alcoholic families may be the 
only instance in which a family member is 
consistently emotionally available, and thus these 
relationships should be encouraged in an effort to 
promote healthy living and an avoidance of 
alcohol dependency . 
Walker and Lee emphasize the plasticity 
of human development and the fact that it can 
drastically influence the qualities exhibited by 
COAs; specifically, the exhibition of resilient or 
maladaptive behaviours.9 The key to this process 
is to determine which relationships (i .e. marital , 
parent-child, sibling-sibling) within the family are 
resilient, and then encourage the fostering of these 
relationships, the affirmation of belief systems, 
and the improvement of communication. Resilient 
relationships within families may be the 
counterbalance to genetic predisposition. 
Wemer 11 adds that COAs who do not 
develop serious problems tend to have good 
communication skills, are goal-oriented, have a 
positive concept of self, and believe in self-help. 
While these determinants may possess a 
somewhat innate component, they are also 
qualities which can be addressed in counselling. 
By encouraging the development of the 
aforementioned attributes, it is poss ible that 
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susceptible individuals may alter their 
envi ronments in such a way as to not fa ll victim 
to a genetic predisposition to alcoholi sm. 
Impact of a Genetic Diagnosis - Conclusions 
Genetic diagnosis can be costly not only in 
terms of the gene test itself, but in terms of 
treating the pati ents we have created. Before the 
advent of gene testing, these asymptomatic 
indi viduals did not consume health care 
resources. Ethical and politica l considerations 
arise of whether we have an obligation to treat 
those that we have identified as be ing ill or at 
risk, regardless of a lack of clinically recognizable 
disease. An additional societal consideration is 
the creation of the "other" - a group of genetically 
distinct individuals, almost a separate spec ies. 
This us-versus-them attitude sterns from the view 
of a genetic diagnosis as a fatal flaw and has the 
potential to perpetuate rather than reduce 
stigrna.13' 14 
On the other hand, early identification of 
at-risk individuals opens the poss ibility of health 
promotion and disease prevention interventions. 
Alcoholism is but one example of diseases which 
are all too frequently attributed to a lack of "will 
power" on the part of the ilL By acknowledging 
the sc ientifically demonstrated genetic component 
of this disease we can play a decisive role in the 
prevention of alcoholism in those who are most 
susceptible to the disease. 
Being cognizant of the issues discussed in 
this article is an important step in improving our 
understanding of the individual and societal 
implications of genetic testing. Furthermore, 
recognition that phenotypic expression of 
genotype is environmentally mediated prov ides 
an opportunity for health promotion interventions. 
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Vampire Projects or Long Ago Person Found? A History of Genetic 
Research in First Nations Communities 
Kate MacKeracher (Meds 2012) and Michael Livingston (Meds 2011) 
Faculty Reviewer: Dr. Michelle Hamilton 
Genetic research of Indigenous populations has been fruitful for scientists and the wider public, but has it 
benefited Indigenous communities themselves? We explore past (ab)uses of genetic research in Canadian 
First Nations communities through case studies. Although early projects were largely researcher-driven, 
the Human Genome Diversity Project of the 1990s catalysed a change towards participatory, community-
controlled genetic research in Canadian Aboriginal communities. 
Introduction 
Indigenous* peoples have often been 
subjects for biomedical research, and the benefits 
to mainstream society include improved vaccines 
and better understanding of type 2 diabetes 
pathophysiology. ' Genetic studies of Aboriginal 
populations have yielded dissertations and 
scholarly artic les on subjects ranging from 
rheumatoid arthritis,2 to breast cancer,3 to 
evolution and migration of human populations. 
But to what extent have Indigenous communities 
themselves benefited from this research? 
Through selected case studies, we explore the 
history of genetic research in Canadian First 
Nations communities, with a particular emphasis 
on the degree of community control. 
Why Community Control? 
In the late 1960s, Vine Deloria (Standing 
Rock Sioux) drew attention to research in 
Aboriginal communities that was driven more by 
researchers ' interests than by " the needs of the 
people."4 Given that these communities are often 
struggling for survival against the political , 
economic, and social consequences of 
colonialism, Deloria condemns "pure research" of 
Indigenous peoples that benefits only the 
• We use " Indigenous" and "Aborigina l" interchangeably. 
In a Canadian context, "Aborigina l peoples" include First 
Nations, Metis , and Inuit populations. 
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researcher: "We should not be objects of 
observation for those who do nothing to help us . "4 
Indeed, power disparities between a community 
and outside researchers can make the research 
process into a form of exploitation,5 undermining 
Aboriginal knowledge and overeignty: "The 
Indian explanation is always cast aside as a 
superstition," Deloria observes, " Indians must 
simp ly take whatever status they have been 
granted by scientists. "6 
Furthermore, research ethics in North 
America have traditionally focussed on individual 
rights , neglecting collective rights of groups. 7•8•9 
Yet many Indigenous communities consider 
infom1ation about the group to be communal 
property.10 Even something considered so 
individualistic, at least in mainstream Canadian 
society, a DNA may be seen as a common 
resource, as Debra Han-y (Northern Paiute) 
describes: " We ' re talking about something that 
has existed co llectively. It doesn't belong to the 
present generation." 7 Outsider researchers may 
lack the lmowledge to negotiate these political, 
cultural, and ethical complexities, and so the 
long-term distribution of benefits and harms from 
a project will be influenced by the degree of 
community controiY· '' 
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"He Used Us like Guinea Pigs" : Two Cases of 
Genetic Research 
In 1989, the Havasupai people of Ari zona 
gave blood to researchers from Arizona State 
University, seeking to understand the high 
prevalence of diabetes in their communi ty. In the 
earl y 2000s they rea li sed the blood had also been 
used for unrelated studies by severa l 
researchers. 11 Of parti cular concern to some 
donors was the use of their DNA in population 
evolution studies that contradicted their oral 
hi story; Havasupai Chairwoman Carletta Tilousi 
explains, "They challenged our identity and our 
origins wi th our own blood without te lling us 
what we were doing."7 Anishinaabeg scholar 
Winona LaDuke argues that such stud ies have 
politica l, as we ll as cultura l, signi ficance. 
Governments or others with interest in Aborig inal 
peop les' trad itional lands, she suggests, may use 
the authori ty of "genetic evidence" to portray 
Indigenous groups a migratory "settlers" w ith no 
higher claim to land rights.7 The Havasupai 
T ribal Council and several communi ty members 
have fi led multi-million-do ll ar lawsuits against 
the researchers and their uni versity. 12 
Members of Nuu-chah-nulth First Nations 
in Bri tish Columbia gave their blood to Ryk 
Ward, a genetic ist at the University of British 
Co lumbia (U BC), in the mid- 1980s, hoping to 
uncover the rea on for their community's hi gh 
rates of inflammatory arthriti s. 13 They heard 
nothing more until 2000, when the Nuu-chah-
nulth learned that Ward fa iled to find significant 
results in his arthriti s study and had taken their 
blood with him to new appointments at Utah State 
University and Oxford Uni ve rsity. He and 
colleagues rece ived fundin g fo r fu rther, unre lated 
analyse of the blood, including popul ati on 
evolution studie .13 Nuu-chah-nulth people, led 
by Larry Baird, one of the blood donors, have 
successfully lobbied for the return of the blood, 
and it i now stored at UBC. 14 Baird explained 
hi s efforts to retri eve the blood fro m Ward in a 
Nuu-chah-nult-run newspaper: " He profited at our 
ex pense. He published over 200 papers and 
became top guru in hi s fi e ld because he was 
carrying our blood around with him. He used us 
like cheap guinea pigs." 14 
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Note the diversity of communities' 
responses. Baird objected to a researcher ~rofit~ng 
from his community w ithout rectproctty; 
Havasupai donors protest the use of their DNA in 
population studies that contradict their oral 
hi story ; others, such as members of the 
Amazonian Yanomami people, have cultural 
be liefs aga inst the preservation of blood; 15 and 
di ffe rent groups w ithin communities may have 
confli cting responses to the secondary use of their 
samples.9 
What these cases have in common are 
researchers who stored, shared, and re-used 
geneti c samples without donors' knowledge. 
Geneti c ists treated the samples much as biologists 
treat bacteri al cultures: as scientific resources to 
be tudied and bared. But individual donors did 
not consent to these uses; and since geneticists 
were naming a specific Indigenous community in 
their analyses, research was a lso being done on 
the communi ty as a whole, without its consent. 
Perhap fo r the e researcher , operating re lative ly 
early in the genetic era, complex ethical reasoning 
had not yet caught up w ith scientific technique 
and curiosity. In an interv iew with Nature, Ward 
implie his secondary use of Nuu-chah-nulth 
samples was simply the "way people operated at 
the time ... it didn ' t cross anyone's mind -- we 
didn ' t mean to be ev il , and we are more careful 
,., 13 
now. 
" The Vampire Project" 
T he increas ing vig ilance of Indigenous 
communities , and corTesponding tendency of 
genetic ists to be " more careful now," developed 
over the 1990s in the context of the Human 
Genome Di versity Project (HGDP) controversy. 
Conce ived as a supplement to the Human 
Genome Project, the not-for-profit HGDP aimed 
to co ll ect samples from geneti ca lly isolated 
Indigenous communities around the world, create 
immorta li zed cell lines, and make the DNA 
available to not-for-profit scienti sts. The initi a l 
goa l was to facilitate study of population 
evoluti on and migration , 16 although later 
representations of the proj ect empha ised 
potenti a l health research.17 
An Indigenous resistance movement to the 
project developed very quickly. By 1993, the 
World Council of Indigenous Peoples had 
christened it "The Vampire Project" for the 
emphasis on retrieving blood, and the tenn stuck 
in North American Aboriginal newspapers .18-20 
HGDP organizers attempted to mitigate criticism 
by forming a North American Regional 
Committee with two Aboriginal members, and by 
drafting a Model Ethical Protocol for collecting 
samples.21 Nevertheless, Canadian and American 
government agencies ultimately declined to fund 
the project, and it has stalled in North America. 22 
Why did a project considered innocuous 
by its originators22 generate such resistance? 
Representatives of Indigenous organizations from 
the Americas outlined common problems with the 
HGDP in 1995 , including spiritual objections to 
immortalized cell lines, potential military or 
commercial abuses, and objectification of 
Indigenous peoples " to satisfy scientific 
curiosity" without benefit to the peoples 
themselves? 3 Was true informed consent from 
individuals and communities possible, given 
linguistic and cultural barriers?24 Would genetic 
research support population migration theories 
that dismissed community origin stories and 
undermined struggles for land and sovereignty 
rights?25 
One of the most frequent objections 
stemmed from the language of the HGDP's draft 
project proposal; genetically distinctive 
Indigenous populations are refen-ed to as "isolates 
of historical interest" whose genetic resources 
need to be collected immediately, before the 
1 . d. d. 1s 25-27 L D k popu at10ns 1e out or 1sappear. ' . a u e 
explains many Aboriginal individuals' outrage at 
the idea of salvaging genes instead of saving 
people: "Why would so many resources be 
involved in collecting the genetic materials from 
'vanishing populations ' rather than working to 
preserve those peoples and their cultures?"7 
As evidenced by the presence of lawyer 
Catherine Twinn (Sawridge First Nation) and 
anthropologist Russell Thornton (Cherokee) on 
the HGDP's North American Regional 
UWOMJ, Vol 78, Issue 3 
Committee, Indigenous opposition to the project 
has not been universal. Defences from Aborig inal 
persons in scholarly literature or the popular 
press, however, are difficult to find. The most 
prolific Indigenous writer on the HGDP in 
academia has been Frank Dukepoo, a 
Hopi/Lacuna genetici st. Citing the moral naivete 
of the project 's orig inators, the real ri sks and 
uncertain benefits to Indigenous peoples, and the 
lack of community control inherent in open-ended 
gifts of genetic resources, he has generally argued 
against the project.28 Yet he asserts that not all 
Indigenous individuals and communities rej ct 
genetic research per se; the HGDP 's mistake, he 
suggests, is its " paternalistic" approach to 
conducting " research on rather than with 
. d. I ,29 m 1genous peop e. 
Participatory Research 
Early in the 1990s, the people of Oji-Cree 
Sandy Lake First Nation (Ontario/Manitoba 
border) decided to address their community's 
high prevalence of type 2 diabetes. They formed a 
partnership with two physician-researchers that 
"incorporates the principles of participatory 
research," according to the project website .30 
Community leaders and researchers established 
goals determining community-specific 
prevalence and risk factors , implementing 
primary and secondary prevention programmes -
and continue to discuss all aspects of the project, 
from protocol designs to dissemination of 
results .30 Protocols must be approved by the Band 
Council, and research is conducted by trained 
community members.30 Preyalence of type 2 
diabetes was found to be five times the Canadian 
average, and a range of environmental and 
lifestyle risk factors were isolated; based on these 
findings , the project partners began to develop 
community-run, culturally-specific intervention 
programmes in 1995 .31 
The following year, the project organizers 
invited researchers from Robarts Research 
Institute at UWO to seek possible genetic 
components to diabetes in Sandy Lake First 
Nation. 32 Analysis of DNA from 728 community 
members showed that a mutation unique to this 
community in gene HNF JA increased the risk of 
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developing type 2 diabetes by up to 15 times in 
homozygous individuals, compared with 
communi ty members homozygous for the normal 
a ll ele.32 The clini ca l applicability of testing for 
thi s mutation was examined as a means for 
directing enhanced prevention support to 
genetica lly susceptible individuals.33 The re lative 
importance of geneti c and environmental ri sk 
factors for early onset type 2 diabetes in 
communi ty members was quantitati ve ly assessed, 
with the conclusion that "changes in environment, 
at the leve l of li fes ty le, could overturn geneti c 
susceptibility, probably rapidly, and in a ' low-
tech ' manner. "32 
The e genet ic studi e have not occurred in 
reductioni st iso lation, as a ll too often happens in 
bas ic science research, but rather are embedded in 
a communi ty-contro lled research proj ect that 
includes problem , causes, and community-
specific so lutions in its scope of inqui ry, and that 
requires results to be relevant and meaningful for 
a ll parti es. Canadian Mohawk scholar Marl ene 
Brant Caste llano observes that thi s sort of 
collaboration makes fo r more effecti ve research, 
and cites the Sandy Lake First Nation diabetes 
project as evidence that " Holistic awareness and 
highly foc ussed analysis are complementary, not 
d. , JO contra 1ctory. 
Long Ago Person Found 
In 1999, the body of a young man who 
died hundreds of years ago was fo und pre erved 
in a g lac ier on traditiona l Champagne Aishihi k 
First Nations (CAFN) land (BC/Yukon border). 34 
The F irst Nati ons assumed responsibility fo r the 
remains, in keeping w ith a 1995 treaty affim1ing 
their contro l over cultura l resources on the ir 
land.34 CAFN Elders named the remains Kwad'!Y 
Dan Ts' inchj (Long Ago Person Found),35 and 
together w ith the Band Council and other 
community members, dec ided to investigate hi s 
34 
on gms. 
After consulting with neighbouring First 
Nati ons, the CAFN Band Counc il signed a 
management agreement with the BC government 
to a llow for research on the remain .34 
Researchers would not be abl e to own geneti c or 
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other materials gathered at the discovery site and 
would return all samples after analys is.
34 T~e 
research included a compari son of mitochondnal 
DNA (mtDNA) in the remains to nearly 250 
35 Th. Aboriginal volunteers from the area. IS 
geneti c test suggested Long Ago Per~on Fo~nd 
has li ving re lati ves in CAFN and ne1ghbou~mg 
Aborig inal communities.35 Since the relat1ves 
identified by materna lly-inherited mtDNA are all 
members of the W olf/Eagle clan, Elders 
concluded their ancestor like ly was as well, given 
the matrilineal c lan structure of their nations. 35 
This identifi cation a llowed for a memorial 
potl atch to be planned by E lders of the correct 
c lan. 35 
Symposia at the Royal BC Museum and 
the CAFN reserve in 2008 and 2009 made 
info rmation gathered about the remains accessible 
to loca l Indigenous people and the genera l public. 
This included sc ientifi c and cultural talks, 
traditional accounts of lost travellers and trade 
routes to complement forensic analyses of 
clothing materi al and stomach contents, and local 
genealogies to fill m the gaps of high 
spec ific ity/low sens1t1v1ty mtDN A testing. 35 
Requested by the communi ty and contextualized 
with oral hi story and other studies, thi s DNA 
analysis demonstrates that community-controlled 
geneti c research can sometimes support 
Aborig inal peoples' psycho ocia l, as well as 
biomedica l, we ll-being. 
Jn thi s case, the community ' desire to 
know more about the ir ancestor coincided w ith 
outs ide researchers' curios ity , and DNA testing 
was deemed acceptabl e by Band Council, E lders, 
and bl ood donors. Not a ll Aboriginal peoples will 
make s imilar decision about remains found in 
their land, however, and interested genetic ists 
must not suppose that DNA analys i w ill a lways 
be welcomed or acceptable in these s ituations. 36 
Conclusions 
In response to the increasing power and 
voi ce Indigenous peoples have negotiated for 
themselves about re earch in their communities 
Canadian government funding agencies hav~ 
begun requiring special ethica l consideration , in 
addition to usual practices, from those seeking 
grants for research with Aboriginal peoples.8•9 For 
example, the 2007 CIHR Guidelines for Health 
Research Involving Aboriginal People emphasises 
community/group con ent, participatory research , 
ownership of biological pecimens and data by 
the community, and new informed consent before 
any secondary use of amples and data, among 
other requirements .9 
Although these regulations apply only to 
CIHR-funded researchers, Canadian First Nations 
communities are beginning to establish their own 
codes of conduct and research ethics boards. 10 
These efforts flow from Canadian Aboriginal 
peoples ' constitutional right to se lf-government, 
according to a report by the National Aboriginal 
Health Organization (NAHO), and reflect the 
principles of "OCAP": community ownership, 
control, access, and possess ion of research and 
biological samples.37 
When they learned how Ward had used 
their sample , the Nuu-chah-nulth Tribal Council 
formed a Research Ethics Committee chaired by 
Larry Baird, the community member most active 
in repatriating the blood. "We ' re not c losing the 
door on research ," Baird explains, noting that 
some Nuu-chah-nulth people are interested in 
renewing inquiry into the arthritis that still 
plagues their communities. 14 But the "way people 
operated" when Ward took their blood in the 
1980s will not be tolerated, Baird warns: " From 
'd '14 now on our eyes are w1 e open. ' 
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Introduction 
Huntington's Disease (HD) is an adult-
onset neurodegenerative disorder with significant 
motor, cognitive, and psychiatric manifestations. 
Symptoms are progressive, with no effective 
treatments currently available and death occurring 
15-20 years after onset. 1 HD is inherited in an 
autosomal dominant manner. Affected individuals 
display an expanded CAG trinucleotide repeat in 
the HD gene on chromosome 4.1 Given the 
devastating natural history of the disease and its 
hereditary basis, HD can present many challenges 
for patients, their families, and healthcare 
providers. In this article, we describe some of the 
complex issues that arise during key stages of the 
HD neurodegenerative process and emphasize the 
importance of comprehensive, interdisciplinary 
team management at each stage. 
Predictive Testing for HD 
Predictive testing for HD based on 
trinucleotide repeats has been available since 
1993, with a less definitive linkage ana lysis test 
avai lable in the mid-1980s. While some argue that 
the test can relieve uncertainty and enable 
planning for the future, only 4-24% of those at 
risk for HD go through with testing.2 Decisions 
regarding testing have many ethical, legal, and 
psychosocial implications and at-risk patients 
must find a way to navigate through these 
concerns. Patients must consider the psychosocial 
effects of declining or postponing testing, as well 
as the effects of undergoing testing and receiving 
either a positive or negative result. Moreover, the 
results of testing can have a significant effect on 
the patient's family, who may become future 
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caregivers or future patients due to their at-risk 
status.3 Patients also face the possibility of 
discrimination based on genetic information, 
particularly regarding eligibility for disability or 
life insurance and obtaining employment. While 
there are only anecdota l reports of genetic 
discrimination in Canada, the fear of 
discrimination remains a very powerful influence 
on patients and physicians.4• 5 
The healthcare team at this stage takes a 
primarily counselling and supportive role. Genetic 
counselling, often done by genetic counsellors or 
medical geneticists, is particularly important 
during this time. Counselling provides patients 
with disease information, takes them through the 
implications of testing, and offers psychosocial 
support. 6 Counse lling must provide the patient 
with all necessary and relevant information, 
because the far-reaching consequences of testing 
neces itate truly infom1ed consent for the 
procedure. Genetic counsellors must present 
information regarding HD and predictive testing 
in a balanced and non-directive manner, 
ultimately respecting the patient's autonomy. 5 
Patients must be assured of privacy and 
confidentiality. In order to support the patient 
through their decision of whether or not to 
undergo testing, other services that may become 
involved at this stage include social work, family 
support and counselling, psychology, psychiatry, 
neurology, and family medicine. Management 
should be specific to the individual patient, while 
taking the family and cultural contexts into 
account. 
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After Undergoing Testing for HD - Living 
with the Results 
The results of predictive testing for HD 
can have a profound impact on patients and their 
families. A Canadian study examining the 
p ychological consequences of predictive testing 
found that although psychological well-being was 
ignificantly improved for the majority of 
participants, 6.9% experienced clinically 
s ignificant adverse psychological events, 
including diagnosed clinical depre s ion and 
suic ide attempts. 7 The e adverse events occurred 
in individual g iven po itive and negative te t 
re ults. The paradoxical reaction of some patients 
with a nega ti ve test result (noncarriers of the HD 
gene) has been ca lled "survi vor's guilt" and 
involve psychological distress from be ing spared 
from HD.1 Patients receiving a po itive te t result 
(carriers of the HD gene) must come to tern1s 
with the meaning for their own health , as well as 
implication for their family, career, and life 
plans. Although fear, anxiety, and depression may 
be understandable responses to a positive test 
result, these are also poss ible psychiatric 
manifestation of HD and patients must be 
followed for earl y onset of symptoms. 3 A pos itive 
result can a lso have a tremendous impact on 
family dynamics, with studies showing hi gher 
divorce rate among carri ers than noncarriers in 
the 6 month following test results, and parents 
poss ibly experi encing guilt for having tran ferred 
ri sk tatus to their offspring.2 Thu for HD and 
other geneti c disease , the unit of care is often the 
family rather than the pat ient.3 
Following predictive testing for HD, 
patients are faced with new chall enges that may 
require multidi sciplinary invo lvement. It is c lear 
that psychologica l counselling and follow-up 
mu t be available to all patients undergoing 
predictive testing regardl ess of test result, and 
psychiatric care may also be required at thi s stage. 
Support and education hould be offered to the 
patient 's family and may require the he lp of social 
workers, nurses, psychologists, and therapi st . 
Early collaboration between the family doctor and 
a spec iali t in HD can monitor for onset of 
di sease symptoms. Physicians must also 
formulate a plan with the patient for future 
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management.3 In addition to the formal healthcare 
team, patients and their families may benefi~ from 
joining a support network like the Huntmgton 
Society of Canada. 
Reproductive Decisions 
HD presents complex dilemmas for 
patients and their families with respect to 
reproductive decision-making. Although HD 
follows autosomal dominant inheritance, the 
penetrance of the disease varies with the extent of 
the CAG triplet expansion. Triplet repeats of 40 
or more are fully penetrant, those 36 - 39 are 
thought to be variably penetrant and those less 
than 35 repeats do not typically manifest as 
disease. The expansion (and, in some cases, 
contraction) of the repeats during gametogene is 
further complicates reproductive choices and can 
pre ent a challenge for health care professionals 
when communicating risk . 
Qualitative research has identified several 
difficult deci sions facing patient and their 
healthcare team : whether to have children at all, 
whether to undergo prenatal testing or pre-
implantation genetic diagno is, and whether to 
abort gene-po itive fetuses. Many patients who 
wish to have children expre s opposition to giving 
birth without attempting to prevent pa ing on the 
di ease; how ver, thi concern is often superseded 
by patient ' fears of their illness preventing them 
from providing for and rai s ing children. 8 For this 
rea on, pati ents must be coun elled with 
con ideration and potenti al involvement of their 
partners, families, and wider social support 
networks. Thi in tum can be a concern for 
patient , as many report the influence of others a 
a major factor in deci ion-making.9 Thi includes 
the influence (whether or not intentional) of the 
healthcare team, which is an important 
con ideration in light of a recent tudy which 
indicated that 38% of Mexican neuroloa ists 
0 ' psychologists and psychiatri sts felt that those with 
the HD mutation should not have off: pring.10 
Prenatal testing for HD currently exists via 
amniocentesis . or chorionic villu sampling. 
However, testmg rates for those at risk for HD 
remain low; within the United Kingdom and 
Australia only 5 - 25% of at ri sk populations 
undergo prenatal testing.8 Within Canada, a 
survey examining 15 of the 22 centres offering 
testing found that only 15 prenatal tests were 
completed between 1987 and 2000. The 12 
families who underwent these tests were 
estimated to represent approximately 0. L% of the 
at-ri sk population.11 W omen were shown to be 
more like ly to request prenatal testing as we ll as 
predicti ve testing for themselves. 11 More recently, 
pre-implantation genetic diagnosis has become 
ava ilable to ensure only mutation-negati ve 
embryos are implanted. This process, however, 
can be di ffi cult fo r many couples and may not be 
an option for many due to personal beliefs and 
preferences. 12 Pre-implantation genetic di agnosis 
is now also offered without infom1ing the parents 
of their own HD gene status, which is preferabl e 
to some patients who des ire certainty that they are 
not pass ing on the disease to their children, but do 
not want to detem1ine their own gene status. 
Despite these difficulti es, many HD 
patients and carri ers do opt to have children. A 
European study demonstrated that L 4% of HD 
carriers had subsequent pregnancies following 
predicti ve testing, compared to 28% of non-
carriers. 12 Furthermore, many pati ents consider 
adoption as a potential a lternati ve depending on 
their expectations of disease onset. 8 
Interdisciplinary Care of the Symptomatic HD 
Patient 
The management of symptomatic HD 
patients is a broad topic, and in its entirety is 
beyond the scope of this overview; instead, a brief 
outline of the interdisc iplinary nature of HD care 
is presented here. 
The nature of HD requires a team-based 
approach to symptom management. An optimal 
healthcare team includes leadership not only from 
a neurologist or psychiatrist specia lizing in HD, 
but also a family physician to monitor 
complications in the late stages of the disease.3 
Allied health care profess ionals, including nurses, 
dentists, dieticians, physical, occupational and 
speech therapists, psychologists, and social 
workers also play maJor roles. Advance care 
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plann ing is also extremely important in 
establishing quality of life goals and end-of- life 
care di rec ti ves. 
The stages of symptomatic HD dictate the 
need fo r each of these team-members. The 
Shoulson-Fahn scale, origina lly designed for 
research, has become usefu l in eva luating the 
severi ty of HD. The fi ve stage scale is based on a 
Tota l Functional Capac ity (TFC) score fro m 0 to 
13 that assesses the patient's fu ncti onal skill s and 
ability to carry out activities of da ily li vi ng. In 
stages I through 3, the focus of care inc lude 
treatment of chorea, sleep disturbance, 
depress ion, anxiety, impulsivity, irri tabili ty and 
o ther psychiatric symptoms.3'13 In these tages the 
phys ician members of the team are foremost. 
However, the ro le of psychologists and social 
workers may be crucial in the transition fro m 
working li fe to di sability status for some patients 
and their fa milies. It has been suggested that one 
of the most preva lent deficiencies in HD 
treatment i di sproportionate focus on minor 
findings of chorea, without proper management of 
depress ion and deterioration of fa mily 
re lationships. 13 Medical therapy including anti -
depressants and mood stabilizers may be of va lue 
and neuro leptics may be warranted in cases of 
. b l . 13 more aggress1ve e 1avwur. 
Mid- to late-phase HD requires fo llow-up 
v1s1ts to phys icians to assess for complications, 
but also increased involvement of other healthcare 
profes ionals. Occupational therapi sts may be 
invo lved in assess ing driving ability and 
determining necessary restrictions. Pati ents often 
have large appetites, and may have di ffi cul ty 
meeting nutriti ona l requirements given increas ing 
dysphagia and lack of coordination (aspiration 
and subsequent pneumonia are often the terminal 
events for HD patients) . For thi s reason, 
d ieticians' expertise and nursing or persona l 
support worker ass istance with feeding can be of 
great benefit. Phys ician fo llow-up may involve 
the reduction of medication for chorea, whi ch 
paradoxically decreases in the late stages and is 
supplanted by rigidity and dystonia. These 
symptoms are often worsened by excess 
pharmacotherapy for chorea, which must become 
more judicious. 13 Phys ic ians must a lso he lp 
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patients and familie deal with increasing 
cognitive impairment and mood a lterations, and 
a such, behavioural coun e lling is often 
required. 3 In the end stage of the disease, hospice 
nursing and palliative care specialists ensure 
patients are as comfortab le as possible and assist 
familie with the patients ' death . 
Conclusion 
Huntington 's di sease pre ents significant 
challenges for the healthcare team. Despite the 
paucity of treatment ava ilable to delay di sease 
progre ion, a well-coordinated, multidisc iplinary 
team can as ist patients and their famili es with 
managing the evolving nature of their illness and 
help them make informed dec isions. Through 
appropriate collaboration, care can be optimized 
and the burden of thi multi-faceted di sease can 
be reduced. 
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MEDICINE AND THE LAW 
Who's in Your Genes: A Physician's "Duty to Warn" Patients' Relatives 
about Genetic Risk 
Colin Meyer- MacAulay [Meds 2012) 
Faculty Reviewer: Dr. Victoria Siu 
The genetic information of a patient as it relates to disease risk may prove invaluabl e to blood relati ves who 
may wish to use it to make informed decisions about health care or reproduction. On the other hand, 
diagnosis of a genetic disorder may carry with it a certain social stigma, as well as concerns about 
discrimination with regards to employment and life insurance. Furthermore, genetic risk cannot be altered 
nor is it caused by the actions of the patient. A physician 's "duty to warn" individuals who may be put at 
risk by the actions of a patient has been recognized in the context of both infectious disease and psychiatric 
illness. However, it is unclear whether these same precedents may apply in the context of genetic 
information. Nonetheless, a number of lawsuits in the United States have been brought against physicians 
for their alleged failure to warn relatives of genetic risk. Canadian Policy deci sions on this issue must be 
made based on an understanding the benefits and limitations of genetic medicine, as well as a clear 
appreciation of the physician's dual duties to maintain confidentiality and prevent harm . In light of this, this 
article reviews the available literature to address legal and ethical issues as well as potential policy 
directions surrounding a physician 's "duty to warn" patients ' relatives about genetic risk. 
Introduction 
Recently, well-known Harvard professor 
and bestselling author of The Stuff of Thought, 
Steven Pinker, allowed his entire genome not 
only to be sequenced, but also to be posted on the 
Internet for the world to see. 1 In so doing he has 
given celebrity status to key questions in the era 
of personalized genomics. These include whether 
one has a responsibility to disclose the results of 
genetic tests to family members who might 
likewise be affected,2 and who should protect the 
consumers of the health care system from what 
has become known as "genetic discrimination".3 
To date, instances of so-called genetic 
discrimination have been scarce in the United 
States3 and nearly unheard of in Canada, aside 
from the odd account of discrimination with 
respect to life insurance. Furthermore, this topic 
has been well covered by this publication in a 
previous article and will not be expanded upon 
further. 4 However, an issue that does warrant 
further investigation is whether physicians have 
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an ethical and legal obligation to warn the 
relatives of patients with a positive genetic test if 
that information may benefit them. A thorough 
understanding of the theoretical benefits and 
limitations of genetic testing, as well as how these 
translate to our patients in practice, will ultimately 
have to guide policy in this matter. 
Genetic Testing 
According to Knoppers et a!. (2004), 
genetic tests can be defined in a legal sense as 
either those tests that are based on "the presence 
or absence of pecific genetic abnormalities" or 
more broadly, those that include " tests based on 
the end products of most genes." Knoppers et a!. 
argues that in the latter case, genetic risk factors 
amount to nothing more than probabilities, and 
thus are difficult to distinguish from other routine 
predictive tests performed by a family physician.5 
Some diseases can be conferred by a single gene 
mutation, or the inheritance of two mutated genes 
at the same genetic locus. In contrast, many 
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common diseases such as diabetes, cancer, and 
heart di sease have a multifactorial etiology, 
invo lving the interaction between genes and the 
environment. Up to now, most genetic tests have 
been a imed at detecting s ingle gene di sorders, and 
often prov ided definiti ve diagnoses when the 
clini ca l pi cture was suggesti ve of genetic di sease . 
With the advent of whole genome sequencing, 
tests that enable clinicians to assess geneti c ri sk in 
much the same way as a fa mily history are 
increa ing ly ava ilable.6 
Genetic Medicine 
Medical uses of geneti c info rmati on are 
nearly as di verse as the defi niti on of genetic 
testing is broad. Phys ician can use geneti c 
info m1ation to make diagnoses in newborns (e.g. 
phenylketonuria, PKU), to identi fy future health 
ri sks (e .g. BRCA l and 2 mutation ), and to 
predict drug respon es or even to predict health 
ri k to children not yet bom .6 Most pertinent to 
the current di scuss ion are those geneti c diagnoses 
or predi cti ve genetic te ts that may indicate a 
fa mili a l ri k of di sease. Often some of thi s ri sk 
can be mi tigated through ea rl y recogniti on of a 
geneti c risk fac tor. Converse ly however, there are 
geneti c di eases where pre-symptomatic diagnosis 
confe r no progno ti c advantage, but which may 
carry a ignificant assoc iated burden of di sease, 
such a Huntington di ease (HD).6 
Centra l to the ethica l dilemma of 
predicti ve geneti c tes ing i what the infonnation 
will actua ll y mean to the pati ent in terms of hea lth 
care opti ons. ln fac t, accord ing to Wylie Burke 
only about 20% of tho e at ri sk fo r development 
of HD in the UK had opted for predicti ve testing 
as of 2002.6 T his reluctance to pur ue predicti ve 
tes ting fo r an incurable di ease may li e in the 
p ychosocia l consequence of an unfavo rable 
result. One study by Giargiulo et a/. found that of 
I 19 pati ents who underwent predicti ve testing for 
HD, a s ignificantly greater number of pre-
symptomatic carri e rs experienced depres ive 
epi ode than those fo und to be non-carri ers. 7 
Those people who do choose to pursue predicti ve 
te ting often do so in order to make informed 
decis ions about reproduction, rather than for the 
hope of treatment.7•8 ln thi s sense, predi cti ve 
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genetic testing can be used to make decis!ons t~at 
limit the poss ibility of birthing a chtld wtth 
significant ri sk of di sease development. On the 
other hand, many geneti c di sorders show 
incomplete penetrance, with some indi_v iduals 
having an a ltered genotype but showmg no 
evidence of di sease.6 
Confidentiality and the Duty to Warn 
Phys icians have a duty to protect the genetic 
info rmation of a pati ent from unauthorized 
disc losure to any third party. However, under 
certa in circumstances confidentiality may be 
justifi ably breached, as is the case when 
legis lation mandates it, or when it is breached 
with the aim of preventing harm to a third party.9 
N umerous legal precedents, including Tarasoflv. 
Regents of the University of California10 and 
Pitman Estate vs. Bain 11 recognize a phy ician 's 
"du ty to warn" under circumstances where 
"di sclosure is essential to avert danger to others".9 
Furthermore, the Per onal Health lnfom1ation 
Protection Act provide that physicians or other 
health care worker " may di close personal health 
informati on if there are reasonable grounds to 
be lieve that the di c losure i necessary to 
e liminate or reduce a ignificant ri k of serious 
bodily harm to a person or a group of persons." 12 
It is important to understand thi di tinction 
when con id ring whether or not a family 
member may be entitl ed to know about a patient' s 
geneti c infom1a ti on. An excu able breach of 
confidentia li ty i techni ca ll y illegal, though the 
court may choo e not to mandate compensation 
or punishment ba ed on well- intentioned 
moti ves. 9 Thu , a pati ent ' ri ght to confidentia lity 
is lega lly protected in genera l, though the courts 
recogni ze that under certa in c ircum tance it may 
be ethica lly nece sary for a physician to breach 
thi s confidentiality. By contrast, a phys ic ian ' 
"duty to wam " refer to a legal obligation to 
inform a third party of imminent ri sk to the ir 
we ll -be ing, regardle s of a patient' s ri ght to 
fid . 1' 'l 9 13 con 1 entra rty. ~ · · Whether or not uch a breach 
of confidenti ality might be ju tified in the case 
where di sc losure of geneti c information to family 
members may enable them to decrease their ri sk 
of di sease development remains to be determined 
by the courts.2'9 On the other hand where genetics 
is concerned, physicians become pri vy to 
information that has implications to both the 
patient and their relatives. In thi s sense, the 
calculation of genetic risk in one person may 
violate another's right to personal autonomy 
where health care decisions are concerned.9 Thus 
Dickens et a/. argue that health care profess ionals 
may take on a new and very real set of duties as it 
pertains to sensitive information that may be very 
beneficial to individuals who may in fact not be 
their actual patients. 9 
While a "duty to warn" has been 
recognized in the context of both psychiatric 
illness 10 and infectious disease, 11 Canadian courts 
have yet to set similar legal precedents where 
genetic information is concerned. 2 Whether or not 
the aforementioned precedents might apply to 
cases where disclosure of genetic information 
may benefit a third party is questionable. Disease 
ri sk conferred by your genotype is not 
preventable, nor can relatives be viewed as 
potential victims of the patient (i.e. the patient 
does not directly cause the risk).2'9 Finally, less 
than 1% of physicians surveyed in the US 
believed a "duty to warn" was reasonable in 
instance where no valid medical therapy exists.13 
Notwithstanding, as of 2004 failure to 
warn a relative of genetic risk had already 
resulted in 3 lawsuits against physicians in the 
United States. 13 In all three of these cases, State 
Appellate courts ruled in favor of the plaintiffs, 
asserting that physicians must ensure that 
immediate family members are warned of 
impending genetic ri sk (though in one case the 
actual jury eventually decided in favor of the 
physician). 13 Currently in Canada there is no 
obligation to warn family members of genetic 
ri sk, and disclosure could even potentially be 
punishable by courts or profess ional regulatory 
bodies.2 Some strategies aimed at resolving this 
issue include: strict confidentiality, a universal 
duty to warn, and informed consent or as Offit et 
" . M. d · , 2 t3 a!. would say a genetic Iran a warnmg. ' 
This third strategy involves physicians informing 
their patients of the circumstances under which 
they would be obliged to disclose information 
prior to genetic testing. While the first strategy 
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does not adequately protect the interests of the 
family members, the latter two strategies are 
coercive and do not respect the patient 's right to 
make autonomous deci ions about health care. In 
addition, it is like ly that they would adverse ly 
affect patient utilization of predictive testing 
because of perceived genetic discrimination .2' 13 
Thus, the cun·ently accepted strategy is to adopt 
an " intermediate position" whereby 
confidentiality is respected as a rule, but it is 
recognized that circumstances exist in wh ich 
disc losure of genetic information may be 
justifiable?·9 
Conclusion 
While no formal lega l duty to warn 
currently exists in Canada, there is a general 
consensus that phys icians should make a va li ant 
effort to inforn1 their patients that genetic 
information may prove inva luable or even life 
savmg to their relatives . In cases where 
penetrance is hi gh, ri sk of imminent and severe 
harm is great, and viab le treatment options do 
exist, the benefits of disclosure to a third party 
may so far outweigh the potential harm to the 
patient as to make it justifiable in a court of 
Iaw.2•9•13 Thus the phys ician 's dual duties to 
maintain confidentiality while simultaneously 
acting in a spirit of beneficence continue to be at 
odds in thi s matter. Unfortunately it is likely that 
they will remain so until more is known about the 
circumstances under which knowledge of their 
relative's genetic risk might actually prove 
beneficial to an individua l. 
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Personalized Cancer Management 
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The aggression of cancer is characteri zed by its multigenic and heterogeneous nature. With the complet ion 
of the Human Genome Project in 2003, there has been growing interest in the fie ld of persona lized 
medic ine fo r cancer management, using an indi vidual's geneti c composition to d irect prevention, detection, 
prognosti c, and therapeutic efforts. Thi s review will provide an overview of some of the mo lecular profi ling 
techniques that are cutTently in use, includ ing transcriptomi cs, proteomi cs, and genom ics using asse ment 
of sing le nucleotide po lymorphisms (SNPs), copy number vari ati on (CNV) and high- throughout gene 
sequencing. Some recent exampl es of personalized medic ine appli cat ions in the screening, d iagnos is, tumor 
class ification, and targeted therapy of various types of cancer wi ll a lso be discussed. Although more 
va lidation and con olidation of these research studies is req uired before personalized medicine is w ide ly 
used for cancer management, its potentia l benefits hold implications for pharmaceutica l companies, 
di agnosti c agencies, healthcare providers, and most importantly, pati ents . 
Introduction 
A diagnos is of 'cancer ' is a life-changing 
event for pati ents. An es timate of over I 0 million 
people g lobally will die annuall y as a result of 
cancer in the year 2020.1 It is not surpri sing that 
there is a drive to furth er our understanding of the 
disease mechani sms, pathophys iol ogy, and 
treatment of cancer. The multigenic and 
heterogenous nature of cancer has long been 
recogni zed, and this heterogeneity can determine 
the aggress iveness of cancer in an indi vidua l 
patient. 2•3 The completion of the Human Genome 
Project in 20034'5 has brought forth the hope of 
advancing medical practice into a "genomic era" 
that w ill identi fy key therapeutic targets and 
disease biomarkers for cancer. Despite these 
advancements, much of the systemic therapy for 
cancer pati ents is still empirical6 and two pati ents 
who may be at apparentl y 'identical' stages of 
cancer and harbor the 'same' tumor type w ill 
exhibit significantly di fferent clinica l outcomes as 
measured by surviva l and therapy response.7 
Instead of continuing to progress down the 
traditional ' trial and error ' method of testing for 
new therapeutic agents, the personalized medicine 
model has been proposed because of its 
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theoretical appeal: in thi s mode l, an indi vidua l's 
geneti c compositi on he lps foc us and direct 
prevention, detecti on, prognosti c, and therapeutic 
efforts .7 This article w ill provide an overview of 
the current status of molecular profiling 
techno logies and their current applicati ons in 
persona lized medicine, fro m the initi a l stages of 
identi fy ing signifi cant causati ve and modula ting 
genes to the integration of multiple genes w ithin a 
personalized profil e that w ill direct therapy in the 
sub-population of cancer pati ents. 
Molecular Profiling Techniques 
The main mo lecul ar pl atfom1s cun·ently 
w ide ly used in personalized medicine are 
tran criptomics, proteomi cs and genomics, w hich 
includes the ana lys is of ing le nucleotide 
polymorphisms (SNPs), copy number variati ons 
(CNVs) and high-throughput gene sequencing.7 
Of course, these are often not mutua lly exclusive 
and one of the current goa ls in personalized 
medi cine is to develop an approach to utili ze and 
integrate the info m1ati on fro m d iffere nt 
techniques. 
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Transcriptomics, the study of altered 
express ion of the levels of messenger RNA 
(mRN A) within cancer ti ssue samples or biopsies, 
has led to the development of Internet-based 
resources such as Oncomine Research Platform8 
that maintains a cata logue of published 
transcriptome profi les so that clini cians and 
sc ienti sts can eas ily access the information. 
A lthough microarray technology, the main means 
of transcriptome profiling, is cost-effecti ve and 
accurate, it is till inhibited by sample 
heterogeneity and the absence of a high-quality 
multi- inst itu tional tumor ti ssue library that would 
be necessary to cater to a large population. 
Proteom ics also expl ores genetic 
express ion, but at the level of translated protein 
quantity, structure and fun ction w ithin cancer 
tissue samples . While techni ca lly more d iffi cul t 
than transcription profi ling, proteomic analys is 
has the advantage of more di rectly examining 
molecular machinery of ce ll physio logy, post-
translati onal modifi cations, and protein-protein 
compl exe .9 Mass spectrometry and protein 
microarrays have also been used to target specific 
biomarker in s ignaling cascades, a lthough there 
are some limitations with respect to di ffi culti es in 
large-sca le target identi fica ti on as the exact 
number of polypeptides produced 1s still 
uncertain .10 
Finally, there is a wide range of genomic 
DNA vari ations that predi spose or propagate the 
development of cancer. Exampl es include ing le 
nucleoti de polymorphisms (SNPs) , whi ch are 
geneti c va ri ations in the DNA sequence due to the 
di ffe rence of one nucleotide among indi viduals. 
Copy number vari ati on (CNV ) refer to larger-
scale changes, inc luding gene duplication, 
de letion, invers ion or translocation events. Both 
SNPs and CNVs have been linked to a wide range 
of di fferent physio logical phenotypes and 
di seases. However, thi s is only an initia l step; the 
examinati on of genomi c DNA in a pati ent 's 
germline or in somatic ce lls taken from cancerous 
ti ssue can strati fy ri sk and identi fy new causati ve 
gene and path ways, but thi s infom1ation a lone is 
not suffi c ient to define mechanisms of di sease or 
therapeutic approaches. 
Page 142 
The ultimate genomic assessment is 
whole-genome sequence analysis, in which all 3 
billion nucleotides of genomic DNA from an 
indi vidual patient or the cancer tissue sample are 
analyzed using automated nuc leotide sequencers 
to determine potential fun ctiona l changes from a 
normal reference sequence. There have been 
many initiatives such as the Human Cancer 
Genome Proj ect and Cancer Genome Anatomy 
Proj ect to use high throughput gene sequencing to 
identi fy novel di sease-associated mutations at a 
I I h . h genome-w ide leve l. Much of t e attentiOn as 
shifted from mastering the technologies 
themselves to extracting biologically relevant 
infom1ation - a fi e ld called " bioinfom1atics" -
such as pairing screen results with functional 
assessments of a specific neoplastic process. 7 
Despi te the more comprehensive sequence 
information at the expense of a higher cost, there 
have been some applications of genomic and 
bioinfo rmati c analy i in tumor c lass ification.12 
Screening and Diagnostics 
Preventi ve measures taken aga inst cancer 
can u e per ona lized medi cine to screen for one's 
predispos ition to cancer, which is important in 
prov id ing a wider range of therapeutic options for 
the pati ent and guiding in clinical deci ion 
making. Geneti c screening is parti cularl y useful 
for indi viduals with a fa mily hi story of cancer, 
where the presence of oncogenic mutations such 
as APC (adenomatous po lyposis co li ), BRCA J 
(breast cancer l , early onset), and BRCA2 (breast 
cancer 2, earl y onse t) can be used as ri sk factors 
before any ymptoms or even cellular dyspla ia 
occur .
13 Celecox ib, the current chemopreventive 
agent of choice for colorecta l cancer, is only 
recommended for hi gh-ri sk pati ents with famlial 
adenomatous po lypo is linked to the APC 
oncogene mutation.13 There is a lso a drive to 
utili ze persona li zed medicine m clinical 
di agnosti cs. Although the pro tate-specific 
antigen (PSA) is the gold-standard for detecting 
prostate cancer, greater diagnosti c accuracy m 
unscreened populati ons can be achieved if 
biologicall y-based prediction mode ls are used to 
link biomar~er levels to other individua l fac tor 
such as age. 
Prognosis and Tumor Classification 
Another important goal in personalized 
medicine is to consolidate infonnation from 
traditional prognostic factors and genetic profiles 
in order to optimize treatment for patients. An 
important prognostic biomarker for breast cancer 
is the human epidermal growth factor receptor 2 
(Her2) , which encodes a transmembrane receptor 
protein that is overexpressed in breast cancer 
cells. 15 Specifically, these levels can be used to 
predict clinical outcomes; serial changes in the 
circulating Her2 extracellular domain (ECD) 
levels have paralleled the clinical course of 
disease regardless of the treatment. Specifically, 
higher ECD levels have been correlated with 
earlier recurrence of breast cancer. 15 There is also 
a 186-gene "invasiveness" gene signature (IGS) 
generated from differentially expressed genes that 
has been found to be strongly associated with 
metastasis-free survival and overall survival of 
medulloblastoma, lung cancer, prostate cancer, 
and especially breast cancer. 16 Hence, 
bioinformatics-centric prediction models have 
been gaining ground in predicting the therapeutic 
response of common tumors based on their gene 
expression profiles. 
Targeted Therapy 
Current research has been progressmg 
towards a consolidation of our current knowledge 
on diseases, genetic alterations, and drug 
responses, allowing both the creation of new 
chemotherapeutic drugs and expanding existing 
ones on the market. For instance, imatinib 
meyslate (Gleevec) is a drug that was initially 
approved by the Food and Drug Administration in 
2001 to treat chronic myelogenous leukemia 
(CML) by targeting the BCR-ABL protein.17 
Later, Gleevec became the first specific effective 
treatment against advanced gastrointestinal 
stromal tumors (GISTs) after researchers found 
that the link between the mutant KIT protein, 
which shows similarities to the BCR-ABL 
protein, and GIST aggression. 1 However, 
researchers are still looking into ways to probe 
into individual resistance mechanisms to combat 
. . . 19 
the issue of Gleevec res1stance m patients. 
Gefitnib (Iressa) is another anticancer drug that 
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targets the epidermal growth factor receptor 
(EGFR), an important component leading to lung 
cancer aggression. The concept of personalized 
medicine may explain why there were largely 
negative results of clinical trials as only 10-15% 
of the test patient population carried the EGFR 
gene mutation or gene amplification.20 Hence, 
clinicians are looking into the possibility of 
conducting more targeted trials that restrict 
e ligibility of subjects to those whose molecular 
profile predicts a better re ponse to a particular 
chemotherapeutic agent. 
Challenges and the Future of Personalized 
Medicine 
Although there is much hope regarding the 
potential of personalized medicine, there are still 
many barriers preventing its widespread usage. 
Duffy et a/. 6 illustrate some of the key challenges 
in the field, including underpowered studies, 
invalidated results from independent patient 
populations or prospective trials , multiple end 
points and subsets of patients used, and poor 
quality of design and unreliable data. These 
problems can be addressed in part by better 
coordinated multi-centered prospective studies 
using much larger patient cohorts than have been 
studied to this point. Nonetheless, the potential 
benefits of personalized medicine - with respect 
to improving positive outcomes and minimizing 
side effects and costs of treatment - are worth 
taking the time and effort to pursue. This holds 
implications for pharmaceutical companies, 
diagnostic agencies, members of the healthcare 
profession, and most importantly, patients. 
Indeed, there is a movement towards focus on the 
individual and not just the disease- what has 
been a barrier to treatment in the past may very 
well be the key to unlocking mechanism of 
di ease to combat cancer in the future. 
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THINKING ON YOUR FEET 
Marfan syndrome was first described in 1896 by Antonine-Bernard Marfan, Professor of Pediatrics in Pari s. 
It is a relatively common inherited connective tissue disorder with an incidence of 1 in 10,000 individuals. 
The condition is inherited in an autosomal dominant pattern , with an equal di tribution in males and 
females. 
Case 
The following case is meant to serve as a prompt 
to guide the discussion on the clinical aspect of 
Marfan Syndrome. 
An 18 year old man develops sudden chest 
pain while playing basketball. He is noted to be 
quite tall at 6'5" and has long fingers and 
toes. Does he have Marfan syndrome? What are 
the diagno tic criteria? If he has Marfan 
syndrome, what are 3 possible causes of his chest 
pain? It wou ld be relevant to note whether the 
patient wears contact lenses as individuals w ith 
Marfan syndrome are often near- or far-sighted 
and/or have other eye abnorma lities. 
Clinical Presentation 
Most patients who have Marfan syndrome 
are usua lly diagnosed incidenta lly. Typically, 
patients with Marfan syndrome present with tall 
stature, lens dislocation (ectopia len ti s), aortic 
root dilatation and a positive family history. Less 
common presentations include: 
• Dominant ectopia lentis with variab le 
skeletal and negligible cardiac 
involvement 
• Mitral valve prolapse without skeletal 
features 
• Dominant aortic aneurysm without 
ske leta l and ocular features 
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• Presentation at birth, rapid aortic 
dilatation, deformities (such as pectus 
deformities, where the breastbone 
protrudes inward or outward), and death 
• Sudden death 1 
Pathogenesis 
The genetic basis for Marfan syndrome is 
a mutation in the gene encoding fibrillin-1 (FBN-
1) found on chromosome 15 . Fibrillin is a 
g lycoprotein that is an integral part of microfibril s 
found in the connective ti ssue of the body. 
Microfibrils function as the main component of 
elastic fibres, anchoring fibres between the dermis 
and epidermis, as we ll as in the lens of the eye. 
C lassically, it was thought that the ubiquitous 
features of Marfan syndrome could be attributed 
. . ., 
to weak or deformed connective tissue.- However, 
recent re earch sugge t that a defect in the 
fibrillin-1 structure reduces its abi lity to bind to 
the cytokine TGF-8 , which results in increased 
ex pres ion of TGF-8. 1n mouse model s, increased 
TGF-B signaling was associated with 
myxomatous mitral va lve leaflets and aortic 
dilatation, both feature of Marfan syndrome. 
Furthermore, by admini tering an antibody that 
binds TGF-8, it was shown that these common 
features cou ld be prevented.3 Thus, it IS now 
thought that it is the over-expres ion of the 
cytokine TGF-B, due to the inability of the 
defective fibrillin-1 that would m norn1al 
circumstances bind TGF-8 , that results in the 
features of Marfan syndrome. 
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Marfa n syndrome has diverse 
manifesta tions that can affect many organ systems 
such as the skeleta l, ocular, cardiovascular 
systems and can a lso invo lve the skin, lungs and 
muscle ti ssue - an example of ple iotropy. 
Clinical Diagnosis 
The d iagnosis of Marfan syndrome (MFS) 
is usua ll y ba ed on cl inica l fea tures and fa mily 
history.4 The fea tures of Marfa n syndrome may 
overlap with other connecti ve ti ssue di sorders and 
the presentation of Marfan syndrome vari es 
w idely, even among fa mily member . 
Nonethe less, the development of a set of 
guide lines, known as the Ghent cri teri a, has 
brought c larity to the issue.4 
• If an ind ividua l has a fi rst-degree relative 
affected by Marfan syndrome, a diagnos is 
of Marfa n syndrome requires maJor 
invo lvement in one organ system 
(ske leta l, cardi ovascular, or ocular) and 
minor invo lvement of a second organ 
system. 
• In the ab ence of a fa mily history fo r 
Marfa n syndrome (or ambiguous family 
hi story), a diagnosi of Marfan syndrome 
require major criteri a in two di ffe rent 
organ systems and minor invo lvement of a 
third . 
Please refer to Tab le I attached at the end 
of the arti cle for more deta il s on the c linica l 
fea tures that would constitute major or mmor 
invo lvements in di ffe rent organ systems. 
As a s implified guide line, fo r a pati ent 
suspected of hav ing Marfa n syndrome orne 
investigati ons that are he lpful in making a c lini ca l 
di agnos is inc lude: 
• Examination by an an ophtha lmologist to 
look for lens di slocation or subluxation; 
often pati ents with Marfa n yndrome are 
near-sighted (myopia) and at increased 
ri sk for developing cataracts and 
g laucoma 
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• Referral to a cardiologist for an 
echocardiogram to assess if there are any 
cardiovascular abnormalities such as 
mitra l valve prolapse, aortic root dila tation 
or a011ic dissection 
• Phys ical exam to assess ske leta l fea~re~ : 
ratio of arm span-to-he ight ratio w hich IS 
cons idered significant if it is greater than 
1.05, or wrist and thumb signs. (A 
pos itive wri st sign is present if the thumb 
and fifth finger overlap when encircling 
the opposite wri st. A pos itive thumb sign 
is present if the entire thumbnail protrudes 
beyond ulnar border of hand when the 
thumb is adducted across the pa lm.) 
Differential Diagnosis 
The di fferential diagnosis for MFS 
includes homocystinuria, congenita l contractura l 
arachnodacty ly, mild aorti c root dilatation-
skeleta l-skin (MASS) syndrome, Ehlers-Danlos 
syndrome, Sti ckler syndrome, congenita l bicuspid 
aorti c va lve di sease, aorti c coarctation, Loeys-
Dietz yndrome, and fa mili al thoracic aortic 
aneury m wi th aortopathy. The most s imilar 
di ffe rentia l i homocystinuria as the two diseases 
share a imilar phenotype. Fea tures that overlap 
between Marfan syndrome and homocystinuria 
inc lude ectopi c lenti s, severe myopia, mitra l va lve 
pro lapse, and ke leta l abnom1alities, such as body 
habitus, chest deformiti e , and spine defom1ities. 
Pati ents w ith homocys ti nuri a are at an increased 
risk for th romboembolic events, but many 
pati ents w ith thi s condition are respon ive to 
pyridox ine. Thus, it is important to screen for 
homocystinuria w ith measurement of urinary 
amino ac ids, as there are implications for 
rna nagemen t. 5 
Management 
Overall, the prognos is for M arfan 
syndrome is re lati ve ly favo rable. Activ ity 
restri cti ons, medi cations, monitoring, and e lecti ve 
surgica l intervention were associated w ith an 
improved life span for MFS patients from 4 1 
years in 1993 to 61 years in 1996.6•7 
Aortic disease is the most significant 
source of morbidity and mortality for patients 
with MFS. Untreated MFS can be associated with 
an aortic dissection spanning the entire length of 
the aorta . Aortic dissection occurs earlier among 
patients with MFS compared to the other cases of 
aortic dissection. Assessment for aortic root 
dilatation and regurgitation can be performed by 
thorac ic echocardiography; however, if that yie lds 
incomplete or insufficient information, 
transesophageal echocardi ography can be used. 
Routine measurements ca n be performed annually 
as long as the aortic root diameter increases 
proportional to increases in body surface area. If 
Table l. Ghent Criteria for Diagnosis ofMarfan Syndrome* 
System Major 
Family/genetic 
history 
Skeletal 
Ocular 
Cardiovascular 
Pulmonary 
Skin and 
integument 
• Having a first-degree relative who meets 
these diagnostic criteria 
• Presence of a mutation in FBN I known to 
cause Marfan syndrome 
• Presence of at least 4 of the following 
manifestations: 
• Pectus carinatum 
• Pectus excavatum requiring surgery 
• Reduced upper-to-lower segment ratio or 
arm span-to-height ratio > 1.05 
• Wrist and thumb sign 
• Scoliosis > 20 degrees or spondylolisthe is 
• Reduced extension at elbows ( < 170 
degrees) 
• Medial di splacement of medial malleolus 
causing pes planus 
• Protrusio acetubu lare of any degree 
• Ectopia lenti (dislocated lens) 
• Dilatation of ascending aorta with or 
without aortic regurgitation and involving 
at least the sinuses of Valsalva or 
di ssection of ascending a011a 
• None 
• None 
Minor 
• None 
• Pectus excavatum of moderate severity 
• Joint hyperrnobility 
• Highly arched palate with crowding of 
teeth 
• Facial appearance (dolichocephaly, malar 
hypoplasia, enophthalmos, retrognathia, 
down-slanting pa lpebral fi ssures) 
• Abnormally flat cornea 
• Increased axial length of globe 
• Mitral va lve prolapse with or without 
mitral va lve regurgi tati on 
• Dilatation ofthe main pulmonary a11ery, in 
the absence of valvular or peripheral 
pulmonic tenosis or any other obvious 
cause in patients < 40 year 
• Calcification of mitral annulus in patients 
<40 year 
• Dilatation or di ssection of the descending 
thoracic or abdominal a01ta in pati ents < 50 
years 
• Spontaneous pneumothorax 
• Apical blebs 
• Stretch marks not assoc iated with weight 
changes , repetitive stress 
• Recunent incisiona l herni as 
Dura • Lumbosacral dural ectasia (by CT or MRI) • None 
*Adapted from Rangasetty UC, Karnath BM. (2006) 1 
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the increase is di sproportional, or if the aorti c root 
diameter is greater than 45 mm, biannual 
measurements should be performed. 
The European Society of Cardiology has 
publi shed recommendations for the treatment of 
pati ents with MFS. 8 The standard of care invo lves 
beta blockers which can delay the progress ion to 
aorti c di ssection . Beta blockers decrease 
myocardia l contractili ty and pulse pressure and 
may a lso improve the e lasti c properti es of the 
aorta , parti cularly in pati ents with an aort ic root 
diameter <40 mm.9·10 In a randomized tri a l, 
treatment with propranolo l was as oc iated with 
delayed progress ion of aort ic dilatation, and 
higher surviva l at approx imate ly fi ve years. 
Longer term surv ival di ffe rences between 
propranolo l and pl acebo were Ies c lear. 11 No 
randomized tria ls have been done to establish the 
efficacy of beta blockers in children.12 However, 
many c li nic ians would give beta blockers to a ll 
children with MFS. In the fu tu re, therapy di rected 
at the renin-angioten in-a ldosterone system may 
prove benefi cia l, but the ro le of these drugs in 
MFS ha not yet been e tabli hed . 13 ' 1 ~ 
Patient w ith MFS may parti cipate in low 
to moderate in tensity, non-competiti ve exercise 
uch a bowling, go lf, tationary bike, or modest 
hiking. Strongly di couraged acti vities include: 
weight li ft ing, ice hockey, rock c limbing and 
surfing.15 The choice of permi ss ibl e acti vitie 
requi res indi vidual assessment. For children to 
comply with these actjvity re tri ctions, there must 
be coordination between parents, school offic ials, 
and physical educators. 
Electi ve surgical repair fo r an aorti c 
dil atation is assoc iated with reduced mortality 
compared to urgent or emergent repairs. For 
adults and children, surgical repair should be 
considered at an aorti c root diameter of 2':50 
mm.16 Uncertainties exist regarding the root 
diameter fo r perfo rming e lecti ve surgery. The 
2006 American Co llege of Cardio logy/American 
Heart Assoc iation (ACC/ AHA) guidelines 
recommend e lecti ve surgery for an aorti c root 
diameter 2':50 mm, while European Society of 
Cardio logy (ESC) recommends surgery fo r an 
17 I dd . . aorti c root di ameter of 2':45 mm. n a 1t1 on to 
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the absolute size of the aortic root diameter, other 
considerations are a family history of aortic 
di ssection or a rapid increase in aortic size (i.~ ., 
18 . rt 2':5 mm per year). Some suggest usmg ao tc 
root dimensions re lati ve to body surface area. 
This factor is parti cularly important for children. 
For children, the only clear indications for 
surgical intervention are: an aortic root diameter 
of 2':45 mm ("giant aneurysm"), rapid enlargement 
of > l 0 mm/year, or progress ive aortic 
insuffi c iency. Other cut-offs for aortic root 
diameter are less clear. 
A few opti ons exist regarding the surg ical 
technique and the choice depends on patient 
factors. One approach invo lves tota l replacement 
of the aortic root. 19 Alternati vely, for patients 
with structura ll y normal va lves the nati ve aortic 
va lve may be reta ined using remodeling and 
. I . h . 20 2 1 I h. I re1mp antat10n tee mques. · n t IS atter 
opti on, li fe-long anti-coagulati on is not required; 
however, repeat operati ons may be necessary . 
An tibiotic prophylax is hould be indi vidua lized. 
As other sites throughout the aorta maybe 
invo lved, fo llow-up radiography using MRI or 
CT angiography is requi red indefinite ly.~ 2 
Ocular and mu keloskele ta l problems also 
require attention. Eyeglasses can correct myopi a, 
while arti fic ia l lens insertion should only be 
undertaken when growth of the eye is complete . 
Further, photocoagulation can correct retinal tears 
and detachment. If intervention w ith phys ical 
therapy and brac ing fa il s, sco li os is may require 
urgical tabilizat ion of the spine. Orthoics can 
correct fl at foot, whi ch i as ociated w ith muscle 
cramps and leg fa ti gue. 
Answers to Case 
Diagno is would be made based on Ghent 
criteri a. Poss ible causes of che t pa in are : 
muscle/ ligament tra in , aorti c root di section , and 
pneumothorax . 
Glossary 
pectus carinatum: deformity of the chest 
characterized by protrusion of ribs and temum 
pectus excavatum: deformity in which several ribs 
and the ste rnum grow abnormally, producing a 
concave appearance in anterior ches t wall 
protusio acetabulare: protrus ion of the 
acetabulum (socket that receives femoral head to 
make the hip joint) 
pes planus: flat foot 
dolichocephaly: elongated s kull 
enophthalmos: recess ion of eyeba ll within the 
orbit 
sinuses of Valsalva: al so known as aortic s inus; 
the space between each semilunar va lve and the 
wa ll of the aorta 
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Human Statues: Challenges in Management of Patients with 
Fibrodysplasia Ossificans Progressiva 
Anna Burianova (Meds 201 2J Ashley Brown (Meds 2011J andjenna Ashkanase (Meds 2011) 
Faculty Reviewer: Dr. Kathleen Hill 
Fibrodysplas ia oss ificans progress iva (FO P) is a rare geneti c di sorder in which soft tissues transform into 
bone, caus ing pati ents to gradua lly become entombed in their own bodies. Early symptoms typically 
invo lve inflammatory les ions that are often confused with a vari ety of tumours and other conditions, 
leading to delays in d iagnos is and medical procedures that may cause significant detriment. The recent 
di scovery of the FOP gene may help to allev iate thi s issue, as DNA testing can allow for earlier 
identi fica ti on of the condition. A case study is presented to exempli fy the challenges faced when treating a 
pati ent with FOP, and po sible compli cations are detailed to emphasize the consequences if precautions are 
not taken. With a specifi c gene target in s ight, it is hoped that treatments can extend beyond supportive care 
and be able to prevent or halt thi debilitating condition. 
Introduction 
Metamorphosis IS defined as the 
transformation of one normal ti ssue or organ 
system in to another through a pathologica l 
process. 1 Within its rea lm, heterotopi c 
oss ifi cati on (HO) describes the abnormal 
formation of true bone within ex traske leta l soft 
tissues. Fibrodysplas ia oss ificans progress iva 
(FOP) is an exceeding ly rare geneti c di sorder 
whi ch has , until recentl y, been one of medic ine' 
most e lusive mysteri es and the most di sabling 
conditi on of extraskeleta l os ification known in 
humans.2·3 
Genetics 
FOP is an ex tremely rare condition, 
occulTing at a popul ati on frequency of about I per 
2 million with no ethnic, rac ial, gender or 
geographi c predispos iti on. 1'2 The severe di sability 
of FOP results in low reproducti ve fitness and 
fewer than ten multi generational fa milies are 
known worldw ide. 1 Most cases of FOP are 
sporadi c w ith onl y one affected indi vidual in a 
family, though when ob erved, geneti c 
transmiss ion is autosoma l dominant. 1 • 2 
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A recent breakthrough in the study of FOP 
was attained with the identification of a recurrent 
s ing le nucleotide mi ssense mutation in activin 
receptor INacti vin-like kinase 2 
(ACV R l/ A LK2). 1 Thi bone morphogenic 
protein (BMP) type I receptor causes skeletal 
morphogene is, and is therefore the fir t 
identified human metamorphogene. u The 
mutati on ha been reported in a ll sporadic and 
fa milia l case of class ic FOP worldwide, making 
it one of the mo t highly specific di sease-causing 
mutations in the human genome.3 
Clinical Features 
The c lass ic presentati on of FOP is defined 
by two clini ca l features: congenital ma lformation 
of the great toes and progress ive H0.3 Congenital 
malfonnation of the great toe i the earli est 
phenotypic fea ture present in a ll class ically 
affected individuals, who appear otherwise 
unremarkable at birth .1 • 2 Other keleta l anomalies 
often associated with FOP inc lude developmental 
anomalies of the cervica l spine, short malfonned 
thumbs, clinodactyly, hort broad femoral necks 
and proximal media l tibia l osteochondromas. 1 
During the first decade of life, children 
with FOP develop painful and highly 
inflammatory soft ti ssue swellings (or flare-ups) 
that progress ive ly and permanently transform 
connective ti ssues into heterotopic bone. 1'3 The 
ossification in FOP progresses in characteri sti c 
patterns that mimic normal embryonic skeleta l 
development, with the first episodes typica lly 
occurring along the upper back and neck. 1 •2 
However, several musc les including the 
diaphragm, tongue, extraocular and cardiac as 
well as smooth muscle are enigmatically spared 
from the FOP process. 1 
Interestingly, the clinical features of early 
involvement in the ax ia l regions differ from those 
seen in the appendicular regions. 1 '3 Even though 
swelling appears more rapidly than typically seen 
with neoplasms, the bulbous les ions which appear 
on the neck and back are often mistaken for 
tumours. 1,3 In the limbs, on the other hand, the 
swelling is often diffuse and may be mistaken for 
acute thrombophlebitis.1•3 
The natural progress ion of the disease can 
also be altered by environmental factors, as any 
trauma leading to ti ssue injury has the potential to 
induce HO. This leads to epi sodes of explosive 
and painful new bone growth, with cumulative 
immobility. 1'2 
Case Report 
An 18-month-old boy from Brita in 
presented w ith a brainstem les ion in need of 
neurosurgery. He had recently been diagnosed 
with FOP, and physical exam prior to surgery 
revealed heterotopic ossification of the dorsal and 
lumbar paravertebral muscles, the left 
sternocleidomastoid, and fusion of the C4-C6 
vertebrae. Although the brainstem lesion was in 
this case unrelated to his FOP, his condition 
nonetheless complicated the procedure to remove 
it. His montelukast was switched to predni sone to 
prevent inflammation 24 hours before surgery and 
continued until four days post-op. Direct 
laryngoscopy was not possible due to the fusion 
of his cervical vertebrae, therefore fiberoptic 
broncoscopy via the nostril was necessary to 
intubate him. Traumatic injury was avoided by 
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using sili con carpets and a headrest, as we ll as by 
padding every point of contact w ith cotton woo l. 
Because hi s FOP was recognized and attended to 
properl y, the procedure produced a favo urable 
outcome and the child had no signs of progress ion 
of the di sease at two months post-op.-1 
Complications of FOP 
The case report above illustrates some of 
the diffi culties in managing pati ents with FOP. 
Since it is crucial to prevent exacerbations, one of 
the mainstays of proper care is to avo id the 
trauma associated w ith certain medical 
procedures . Surgeri es in parti cular pose 
di ffi culties for patients if, as in the case report, 
fu sion of the cervical vertebrae has occurred and 
impedes intubation. Anesthes ia in an FOP pati ent 
can also be extremely di ffi cult if anky los is of the 
jaw is present, which could be triggered by 
something as simple as minor dental 
procedures.4•5 Biopsies are also contraindicated, 
but since they are the investigation of choice for 
most tumours, they are often performed before a 
diagnosis is made. 
One of the most severe complications of 
FOP is cardiopulmonary compromise. FOP can 
lead to ankylosis of the costovertebra l j oints, 
oss ificati on of the intercostal and paravertebral 
muscles, and progress ive spina l deformity such as 
kyphoscoliosis or thorac ic lordosis. Chest 
expansion is drasti ca lly limited, resulting in 
reduced vital capacity and restri ctive lung disease. 
Ri ght ventricular hypertrophy can also occur due 
to the thoracic insuffic iency.5•7 
Patients with FOP are also more prone 
than the general population to kidney stones as 
well as conductive hearing loss due to fusion of 
the bones of the middle ear. They are also prone 
to fracture of heterotopic bone, which requires 
closed reduction and splinting, as well as 
analges ia, as in fracture of normotopic bone in 
any patient.5 Thus, patients should be educated 
about ri sk factors for fa lls to avoid precipitation 
of a cycle in w hi ch a fa ll leads to further 
ossification and joint ankylosis, which in tum 
increases the ri sk of future falls. 5·6 
Page I 51 
Discussion 
FOP is an extremely debilitating di sease. 
Most affected people are wheelchair-bound by 
their 20s and life expectancy is less than 40, as 
thoracic insuffi ciency usua lly occurs by thi s 
. 4 . 
pomt. Pat1 ents must li ve with the constant 
know ledge that they have a progress ive di sease. 
As more and more joints and muscles become 
permanently oss ified over time, pati ents with FOP 
are essenti ally trapped in ide the ir own bodies 
until they can no longer move or even brea the. 
The recent breakthrough di scovery of the 
FOP gene has identi fied a specific target fo r 
pharmaco logic therapy and a ll owed for the 
development of a DNA diagnosti c test which 
expedites diagno is . and limits ham1ful 
interventi ons. 2 However, the opportuniti es fo r 
insight provided by studying the FOP gene extend 
fa r beyond thi s rare di sorder a lone. That is, 
characteri zation of the underl ying mechani sm 
causing HO in FOP has much broader 
impli cati ons fo r pati ents with more common 
forms of HO and fo r developing tissue 
engineering strategies for skeleta l bone and 
cartil age repair. 2.3 
Conclusions 
Due to th e rarity, variable severity and 
epi sodi c c linica l course of FO P, clini cians often 
fail to assoc iate the rapidly deve loping ax ia l soft 
ti ssue swellings witb the di stincti ve malformed 
g reat toes. 3 When such assoc iati ons are not made, 
FOP is commonl y mistaken for other conditions, 
de lay ing pro per trea tment. 1' 3 Not surpri sing ly, 
mi sdi agnosed indi viduals often undergo a battery 
of unnecessary biopsies and tests that exacerbate 
progress ion of the condition. Earl y diagnosis and 
cautious management of pati ents with suspected 
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FOP are therefore very important. Finally, 
although the current medical management of FOP 
is largely supportive, the goal of research 
continues to be the deve lopment of treatments 
that will prevent, halt or even reverse progressiOn 
of the di sease.3 
References 
l. Kaplan FS, Shen Q, Lounev Y, Seemann P, 
Groppe J, Katagiri T, Pignolo RJ, Shore EM. 
Skeletal metamorphosis in fibrodysplasia 
oss ifica ns progress iva (FOP). J Bone Miner 
Metab. 2008;26(6):52 1-30 . 
2. Shore EM, Kapl an FS. Insights from a rare 
genetic di sorder of extra-skeletal bone formation, 
fib rody plasia ossifica ns progress iva (FOP). 
Bone. 2008 Sep;43(3):427-33. 
3. Kaplan FS, Le Merrer M, G laser DL, Pignolo RJ, 
Go ldsby RE, Ki tterman JA, Groppe J, Shore EM. 
Fibrodysplas ia o ificans progressiva. Best Pract 
Re Clin Rheumato l. 2008 Mar;22( 1): l 9 l-205 . 
4. Tumolo M, Mo catelli A, S ilve triG . Anaesthetic 
management of a child with fibrodysplas ia 
os ificans progress iva. Br J Anaesth . 
2006;97(5) :70 1-3. 
5. The International lin ical Consortium on FOP. 
The medica l managements of fibrodysplas ia 
os ifi cans progress iva: current treatment 
con idera ti on . Clio Proc Inti C lin Consort FOP. 
2008;3(2): 1-85 . 
6. Lanchoney TF, Cohen RB, Rocke DM, Zasloff 
MA, Kaplan FS . Pem1anent heterotopic 
o ification at the injection si te after diphtheri a-
tetanus-pertus is immuniza tion in children who 
have fi brody pia ia oss ificans progressiva. J 
Pedi atr. 1995 ;1 26 :762-4. 
7. Ku smaul WG , Esmail AN, Sagar Y, Ross J, 
Gregory S, Kaplan FS . Pulmonary and cardiac 
function in advanced fib rodysplas ia ossificans 
progressiva . C lin Orthop Re lat Res . 
1998;346 : 104-9. 
FEATURE 
Quality of Life Consequences of Long QT Syndrome 
lshvinder Chattha (Meds 2011) and Caleb Zeleniel::: (Meds 201 1) 
Faculty Reviewers: Dr. Raymond Sy and Dr. Andrew Krahn 
Long QT syndrome (LQTS) is a genetic condition characterized by abnormal repolarization of cardiac 
ventricular myocytes predisposing the individual to ventricular tachyarrhythmias. The first manifestation of 
LQTS is typically syncope and less frequently cardiac arrest or sudden cardiac death. This article examines 
the effect of LQTS on patients' quality of life. This includes the psychosocial and physical consequences 
that may result from both the diagnosis of a potentially lethal genetic disease and its subsequent 
management. Current guidelines are based on expert consensus and recommend moderate and at times 
strict exercise restriction, even in asymptomatic patients. Broad exercise restriction affects the social 
development of children and also removes the protective effect that exercise has against developing both 
psychological and physical health problems related to inactivity. Due to the potential decline in a patient's 
quality of life resulting from strict exercise restriction, future research should focus on determining the 
effectiveness of exercise restriction in the prevention of ventricular arrhythmias. 
Introduction 
Genetic disorders are unique in their 
impact on patients. Often incurable, patients not 
only need to deal with the wide array of feelings 
surrounding the initial diagnosis, but there is 
often guilt related to the possibility of passing the 
disorder onto their children. 1 Given the 
implications for family members, genetic testing 
and resultant therapy is offered to relatives. The 
diagnosis can also influence family planning. 
These consequences are in addition to the effects 
of the disease itself. 
This is the reality for patients diagnosed 
with congenital long QT syndrome (LQTS). In 
addition to the difficulties related to the 
acceptance of a lifelong and incurable disorder, 
LQTS management imposes a potentially 
significant decline in quality of life. Severe 
exercise restriction is currently recommended in 
patients with LQTS to prevent symptoms from 
arising. 2 This sudden change in lifestyle can be 
especially devastating for children, as it can leave 
them feeling like outcasts (Figure 1). This article 
examines the impact of LQTS on the quality of 
life of patients and their families. 
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Long QT Syndrome 
The QT interval, seen on the 
electrocardiogram, is a measure of ventricular 
depolarization and subsequent repolarization. 
LQTS is characterized by abnormally delayed 
repolarization of ventricular myocytes. Lt is 
caused by abnormalities of cardiac ion channels 
which result in abnormal amounts of sodium or 
potassium moving across the cell membrane, 
interfering with the normal action potential. At 
least 12 ubtypes of congenital type long QT 
syndrome have been described resulting from 
mutations in any one of nearly a dozen genes 
controlling the expre sion, regulation, or 
assembly of cell membrane ion channels.3 
Subtypes are classified based on the gene 
affected, with LQTL (KVLQTI mutation) 
accounting for approximately 50% of cases, 
LQT2 (HERG mutation) nearly 40%, and LQT3 
(SCNSA) about 5%.3 
Although most patients remam 
asymptomatic, the first manifestation of LQTS 
may be syncope, cardiac arrest or sudden cardiac 
death. Specific actlvtttes or triggers can 
precipitate cardiac events in LQTS patients -
these include startling auditory stimuli such as an 
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Figure l . Picture drawn by a young male di agnosed with LQTS. The patient experi enced yncope during 
an ice hockey game which led to the subsequent di agnos is of LQTS. A a result of the diagnosis and 
resultant exercise restri ction, the pati ent quit hi s ice hockey team and abandoned his dream of play ing 
profess ional hockey. Pati ent identifiers have been removed fro m the drawing. 
a lann c lock or loud door be ll , emotiona ll y 
charged events, or even phys ical exertion as brief 
as running to catch the bus.4 Commonl y 
presc ribed med icati ons inc luding certa in 
antibi otics, bronchod ilators, hypertens ion 
medications, and antidepressants can cause 
furth er pro longati on of the QT interva l and 
increase the ri sk of cardi ac atThythmia in 
susceptibl e pati ent . While 50% of pati ents 
remain asymptomati c th roughout their lifetime, 
the severi ty of the symptoms has crea ted a focu 
on preventati ve medicine as an important aspect 
of management. 
Quality of Life lssues- Impact on Patients and 
Families 
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The diagnos i of LQTS can be quite 
devastating to indi vidua ls. The implications that it 
has on longev ity, menta l state, and day to day life 
are immense. Famsworth et a/. (2006) conducted 
a eri es of interview with parents w ith LQTS, 
and one pati ent 's descripti on was: "your w hole 
li fe is shattered. You fee l w hammi ed off thi 
earth ."4 Another parent described the chanoes in 
0 
her son after being diagnosed : " He is sport -
ori ented, oc ia l, and wants to fly for the A ir 
Force. He can ' t pl ay hockey now .. .. He can ' t fl y. 
He is on ho ld, hoping thi w ill a ll go away."4 
Sudden cardiac death ts the first 
manife ting symptom in a lmost 12% of cases. 
Because of thi s, pati ents constantly li ve w ith the 
uncerta inty of the ir own future a we ll a the 
future of their loved ones in the context of a 
genetic disorder. 4 Two thirds of parents 
interviewed by Farnsworth et a!. (2006) expressed 
fear of their children dying. For example, one 
interviewee said, "When I walk into their rooms 
in the morning to wake them I am always aware 
in the back of my mind ... will they be cold?"4 
The management of unrelated medical 
conditions such as infections may also create 
anxiety because certain prescribed medications 
may prolong cardiac repolarisation as a side-
effect. There are over 130 recognized drugs, 
ranging from anti-hypertensives, to antibiotics, 
heartburn aids, and antidepressants, that should be 
avoided by LQT patients as they have been shown 
to further prolong the QT interval, thus increasing 
the risk of a cardiac arrhythmia. Furthermore, 
cardiac events may be precipitated by dehydration 
and inadequate nutrition, which are commonly 
seen in many disease states. The fear of 
precipitating a cardiac event is always present: 
"Anytime she gets sick it is a big deal. It is a 
totally different ballgame. Medications are a big 
deal.. .. We do flu shots every year. I am more 
worried, it is always in the back of your mind." 4 
Quality of Life Issues -Impact of Treatment 
Once diagnosed, a management strategy 
focusing on prevention of LQTS related cardiac 
events is implemented. Management is 
multimodal , combining lifestyle modification, 
medication or even surgical options. Lifelong beta 
blocker therapy is the mainstay of medical 
treatment for LQT1 and LQT2 subtypes. 2 Trigger 
avoidance is also important for successful 
prevention. The most common trigger is physical 
exertion. As a result, the American Heart 
Association guidelines recommend severe 
exercise restriction for LQT patients (Table 1 ). 
These restrictions may range from withdrawal 
from all competitive sports to students potentially 
sitting out of physical education class. Such broad 
exercise restriction may impair physical as well as 
psychological wellbeing. 
Individuals that are physically active are 
less likely to suffer from mental health problems. 
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Physical activity improves se lf-esteem, can foster 
identification with peers, reduces stress, and is 
inversely related to adolescent depress ion.5 
Exercise deprivation has been shown to lead to 
increased symptoms of pain , fatigue , cognitive 
problems, and negative mood. 6 With children 
there is added danger because proper soc ial 
development requires common identification with 
peers, and thus this targeted exclusion from team 
activities can have a significant negati ve 
psychological impact (Figure 1).7 The elderly are 
also at particular risk from exercise restriction as 
exercise has been shown to reduce CNS 
dysfunctions such as cognitive decline. 8 
With the rising prevalence of obesity, the 
physical health benefits of exercise have been 
given increased attention. Physical activity is 
unanimously recognized as an essential element 
in combating the obesity epidemic.9 Research has 
repeatedly shown regular exercise decreases lipid 
profiles, obesity, hypertension, and development 
of some cancers and cardiova cular diseases, and 
it increases bone mineral density. Physical 
activity is also used in the management of 
numerous chronic diseases. 10 
Physical activity rates are decreasing in 
Western populations. Numerous community 
interventions are being implemented to promote 
regular exercise to achieve the recognized 
benefits . The diagnosis of LQTS presents another 
road block in achieving a healthy lifestyle. 
Participation in competitive sports as a child, an 
activity shown to be predictive of physical 
activity levels in adulthood, is not permitted in 
patients with LQTS.5 
Participation in sports is an enjoyable 
method of physical activity. Participants repot1 
enjoyment stemming from affiliation with peers, 
competitive excitement, gaining competency, and 
a source of psychosocial support.11 ' 12 On the field 
people can learn sportsmanship, fair play, 
personal responsibility, and moral reasoning.13 
Because LQTS patients are not permitted to 
participate in popular sports such as basketball , 
hockey, soccer and football, these key elements of 
personal development are potentially missed. 
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Table l . Permissibility of common physical activities for LQTS patients2 
Activity 
HIGH INTENSITY 
Basketball 
Body building 
Ice hockey 
Racquetball/squash 
Rock Climbing 
Running 
Skiing 
Soccer 
Tennis (singles) 
Touch football 
Windsurfing 
MODERATE INTENSITY 
Baseball/softball 
Biking 
Motorcycling 
Jogging 
Sailing 
Surfing 
Swimming 
Treadmill 
Weightlifting 
Hiking 
LOW INTENSITY 
Bowling 
Golf 
Horseback riding 
Scuba diving 
Skating 
Snorke lling 
Brisk Walking 
Not Permitted 
Guidelines 
Maybe 
Permitted Permitted 
Conclusions 
Long QT syndrome has a large impact on 
patients and their families on multiple leve ls. 
Physicians need to understand the psychological 
stress of parents facing the poss ibility of cardiac 
arrest or sudden cardiac death in the ir children. 
Physicians should educate patients and their 
familie on the genotype-specific triggers and 
encourage them to take an active part in managing 
this disease. Patients also need to be aware that 
certain prescribed medications prolong the QT 
interval putting them at increased risk for cardiac 
events, and they should be instructed to screen all 
their future medications against a list of known 
QT-prolonging drugs (www.qtdmgs.org). 
The American Heart Association (AHA) 
has published recommendations for the 
management of LQTS. They call for severe 
exercise restriction as a preventative measure. 
The premise is based on athletes not using proper 
judgement in extracting themselves immediately 
from the physical activity, even upon realization 
that medical attention may be needed. Due to the 
unique nature of sports, the AHA consensus 
statement asserts that cardiac symptoms such as 
palpitations, fatigue, and dizziness can incorrectly 
be attributed to the sensations which accompany 
. . ? 
mtense exerc1se.-
The AHA recommendations are based on 
the experience and insights of a panel of experts 
and by their own admission, are not specifically 
from scientific evidence. With the negative 
psychological and physical health effects that 
exercise restriction can have on patients, it is 
important for future research to focus on this area, 
which might serve as a basis for validating or 
amending the current recommendations. 
Important areas of research include determining 
the effectiveness of exercise restriction on the 
prevention of cardiac events in each LQTS 
subtype, as well as classifying the degree of QT 
prolongation that occurs while participating in 
different sports. This will assist in developing 
more comprehensive and genotype specific 
recommendations which may limit the negative 
iatrogenic effects of LQTS management. 
UWOMJ, Vol 78, Issue 3 
References 
I. McAlli ster M, Davies L, Payne K, Nicholls S, 
Donnai D , MacLeod R. The emotional effects of 
genetic di seases: Implications for clinical genetics. 
American Journal of Medical Genetics Part A. 
2007; 143A(22):2651-2661. 
2. Maron BJ, Chaitman BR, Ackerman MJ et a/. 
Recommendations for physical activity and 
recreational sports participation for young patients 
with genetic cardiovascu lar diseases . Circu lat ion. 
2004; I 09(22) :2807-2816. 
3. Vohra J. The long QT yndrome. Heart, Lung Circ. 
2007; 16:S5-S 12. 
4. Farnsworth MM, Fosyth D, Haglund C, Ackerman 
MJ. When l go in to wake them ... I wonder: 
Parental perception about congenital long QT 
syndrome. Journal of the American Academy of 
Nurse Pract itioners. 2006; 18(6):284-290. 
5. Hallal PC, Victora CG, Azevedo MR, Well JCK. 
Adolescent physical activity and health - A 
systemati c review. Sp011s Medicine. 
2006;36( 12): l 019-1030. 
6. Glass JM, Lyden AK, Byrne-Dugan CJ et a/. 
Increased symptoms of pain, fatigue, cognitive 
problems and negative mood after exercise 
deprivation and sleep restriction are predicted by 
baseline autonomic and HP A function . Arthriti s and 
Rheumat ism. 2006;54(9):S828. 
7. Ussher MH, Owen CG, Cook DG , Whincup PH. 
The relationship between physical act ivity, 
sedentary behaviour and psychological wellbei ng 
among adole cents. Social Psychiatry and 
Psychiatric Epidemiology. 2007;42( I 0):85 1-856. 
8. Adlard PA, Cotman CW. Voluntary exercise 
protects aga inst stress-induced decreased in brain-
derived neurotrophi c factor protein expres ion . 
Neuroscience. 2004; 124( 4 ):985-992. 
9. Duche P. Phy ical activ ity and infantile obesity: 
Tracking, prevention and treatment. Science & 
Spoi1s . 2008;23(6):278-282. 
I 0. Biddle SJH, Gorely T, Sten e l DJ. Health-
enhancing physica l acti ity and sedentary behaviour 
in children and adolescents. Journal of ports 
Sciences. 2004;22(8):679-70 I . 
11 . Me arthy PJ, Jones MY, Clark-Carter D. 
Understanding enj oyment in youth sp011: A 
deve lopmenta l perspective. Psychology of Sport 
and Exercise. 2008;9(2): 142- 156. 
12. McCai1hy PJ, Jone MY. A qualitative study of 
sport enj oyment in the sampling years. Sp011 
Psychologist. 2007;21 (4 ):400-4 16. 
13. Bailey R. Physical education and spot1 in chools: 
A review of benefi ts and outcomes. Journal of 
School Health. 2006;76(8):397-40 I . 
Page I 57 
FEATURE 
Genetic Susceptibility in Rheumatoid Arthritis 
Kimberley Colangelo (Meds 2011) a nd Caleb Zelenietz (Meds 2011) 
Faculty Reviewer: Dr. j anet Pope 
Rheumatoid arthritis is a cond ition that causes chronic inflammatory arthritis. It has been linked to multiple 
etio logies; the cause is thought to be a combinati on of the environment, infec tion, hormones and a genetic 
component. The prec ise contri buti on of geneti cs to the development and course of rheumatoid arthriti s is 
curren tl y under investigation, and numerous gene candidates have been identified . The HLA-DR gene has 
been wide ly studied and numerous a lle les have been identified that correlate to the development of 
rheumato id arthritis . The role of geneti cs in rheumato id arthriti s is expl ored in thi s article. 
Background 
Rheumatoid arthriti s (RA) is a chroni c 
auto immune d isorder which causes inflammatory 
arthrit is and occurs in approximate ly l% of the 
population.1 It freq uentl y presents as periphera l 
polyarti cul ar arthri ti s, is symmetrica l, and often 
progresses wi th j oint damage and loss of function. 
There may be periods of remiss ion, although 
vari ations on this pattern occur. In addition, the 
extra-arti cular mani festat ions vary greatly among 
pati ents . Without treatment, it leads to signifi cant 
deformiti es as cartil age and bone are destroyed, 
so ca lled erosive d isease. 
The prec ise cause is unknown, but geneti c 
predispos ition, the environment, infec tions, and 
hormones (potential prec ipitators) are thought to 
a ll pl ay a ro le . The geneti c component has been 
the subj ect of much research in recent decades, as 
RA has been fo und to c luster in fa milies and 
occurs more frequentl y in fa mili es with other 
auto immune di sorders. The heritability of RA is 
estimated to be approx imately 60%, with a 12-
15% concordance rate among tw ins.2 
Severa l key genes have been targeted as 
they are impli cated in the development of RA and 
the course of the di sease. The group of human 
leukocyte antigen (HLA) genes on chromosome 6 
has been at the fo refront of geneti c research in 
RA. Certa in a lle les have been associated with an 
increased ri k of developing the di sease and 
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predicting its severi ty, and others are invo lved in 
protecti on from RA. The HLA gene products are 
invo lved in immune fu nction, particularly coding 
fo r anti gens expressed on the surface of w hite 
blood ce lls. Many genes as ide from the HLA 
group have been li nked to RA. 
Current Research 
The HLA region in the human genome is 
one of the most heterogeneou and is frequently 
targeted fo r tudies invo lv ing di sease 
susceptibili ty . For RA, the HLA-DR fa mily has 
been studied extensive ly. Severa l theori es exist 
fo r how the HLA molecule could influence the 
immune ystem. HLA molecule bind peptides 
and present them to receptors on the CD4+ T 
lymphocyte , so the epitope assoc iated w ith RA 
could determine w hich peptides bind uccessfull y, 
the affinity w ith which they bind, the epitope 
itse lf could be antigenic, or the epitope could 
influence w hich T lymphocytes surv ive in the 
thymus (i.e. g iving a propensity fo r autoreacti ve 
lymphocytes to surv ive). 1 In the maj ority of 
genetica lly -linked cases of RA, a shared epitope 
at amino ac id pos iti ons 67-74 of HLA-DRB 1 (the 
beta l subunit of the HLA-DR molecule) has been 
found. HLA-DR4, one of the most we ll studied 
s~ems to be assoc iated w ith both higher ri sk of 
d1 sease and worse prognosi , parti cularly certain 
haplotype w ithin HLA-DR4 such as 0401 .3 
Interestingly, some HLA-DR alleles are 
associated with protection from RA, even 
counteracting the increased susceptibility when 
the sister allele was associated with an increased 
RA risk. 4 
These protective HLA-DR alleles have a 
different conserved seq uence than the so-called 
shared epitope associated with an increased risk. 
A well known example is HLA-DRB 1 with the 
conserved epitope DERAA at positions 70-74 of 
the amino acid sequence. This allele was not only 
correlated with a lesser risk of developing RA, 
but was also linked to a less severe form in people 
with RA.5 
The presence of the HLA alleles with the 
shared epitope has also been shown to have a high 
concurrence with the presence of anti-cyclic 
citrullinated peptide antibodies (anti-CCP), 
which are used in diagnosing RA. One theory is 
that the citrullinated peptide binds the HLA 
shared epitope resulting in activation of T 
lymphocytes. This may in tum lead to increased 
autoantibody production that results in the 
formation of anti-CCP antibodies.6 Anti-CCP is a 
stronger predictor of radiographic damage in early 
inflammatory arthritis than Rheumatoid Factor 
(RF) and is especially useful as a marker in those 
with negative RF who have RA. However, anti -
CCP is not sufficiently sensitive to identify all 
those who will have radiological damage in early 
inflammatory arthritis. 
Some important discoveries related to the 
HLA susceptibi lity region include7: 
• 
• 
• 
• 
• 
Having two copies of a susceptibility 
allele makes a person even more like ly to 
develop RA compared to hav ing on ly one 
copy 
Having one or two copies of a 
susceptibility allele makes a person more 
likely to have severe di sease 
The combination of alleles present alters 
the relative ri sk (i.e DR4/DR I vs. DR4/X) 
Presence of the allele may also influence 
if a person will have extra-articular 
manifestations 
The timeline of progress ion of RA is 
influenced by the alleles present 
The HLA-DR genes cannot be the only 
genetic contribution though, as not all RA 
patients have the implicated alleles and there is 
still a wide clinical heterogeneity amongst those 
that do. It has been estimated through sibship 
studies that HLA linked genes contribute about 
30-40% of the genetic component in RA.8 
Numerous other genes have been identified, and 
the more popular ones are summarized in Table 1. 
The products of these genes are proteins or 
molecules that are involved in the immune 
response; as an intracellular signalling molecule, 
in the fom1ation of antibodies, or in carrier 
molecules. A physiologic mechanism through 
which they contribute to the development of RA 
has been postulated for each one. Currently, 
screening of whole genomes of families where 
RA is preva lent is being undertaken to poss ibly 
discover other genes and better characterize the 
genes that have been discovered . 
Table 1. Summary of genes that confer susceptibility to rheumatoid arthriti 
Gene Product 
HLA-DR9 Encodes cell surface antigens that present protein to the T lymphocytes 
STAT4 10 Encodes a transcription factor for signals from ce11ain cytokines 
PAD14 11 Encodes an enzyme that catalyzes peptidyl arg inine to peptidyl ci trulline 
N22/PTPN22 II Encodes intracellular tyrosine phosphata e in T and B cells 
SLC22A4 12 Encodes for an organic cation transporter 
FCRL3 13 Encodes a B-lymphocyte specific membrane molecule 
CTLA4/CD 152 1 Encodes a protein produced by activated T ce ll s 
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The presence and implications of these 
genes vary widely by ethnic population with 
respect to rheumatoid arthritis. The prevalence of 
RA itself differs by ethnic group, for example 
Native Americans have been reported to have a 
prevalence as high as 2% whereas Asian 
populations as low as 0.3 %. 14 In addition, the 
polymorph isms of the human genome sequence in 
the alleles that are related to RA vary by ethnic 
populations, wi th higher concordance amongst 
more close ly related populations.15 
Relevance 
The key question regarding thi s research is 
whether it is limited to being an expensive 
research tool or if it will become relevant to 
patients and physic ians. Given that many of these 
alleles are common in the general population, 
gene screening will not be useful as a screening 
tool to di scover asymptomatic patients that will 
develop RA. However, since HLA alleles remain 
constant over a lifetime, typing may be useful as a 
predictor of the course of di sease in patients 
already diagnosed with RA, it can be used to 
decide which patients will have more severe 
di sease and who will progress quickly so that 
aggressive therapy can be initiated. Whether thi s 
will change outcomes needs to be studied. For 
now, its value seems limited to research where 
family members at ri sk for RA are being 
prospective ly studied, particularly those who have 
already developed anti-CCP or RF. 
Conclusions 
It cannot yet be said what interaction and 
combination of alleles is neces ary for the 
development of RA and for the specifi c 
phenotypes that are expressed. RF testing is done 
to determine who with early inflammatory 
arthritis will develop erosions, but combining RF 
and HLA may increase the sensitivity and 
specificity so that early aggressive treatment can 
be implemented. Since anti-CCP antibodies may 
have higher specificity for the development of 
RA, the combination of these two components 
could poss ibly increase the ability to predict the 
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development and course of progression of the 
disease. 
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Nuchal Translucency and Prenatal Diagnosis of Congenital Heart 
Disease: Progress and Future Directions 
Xiangning Fan (Meds 2010) 
Fa culty Reviewer: Dr. Eva Welisch 
Nuchal tran lucency thicknes is an important component of prenata l screening programs, which exist to 
he lp quanti fy the ri sk of certa in chromosomal and anatomica l abnormaliti e in a fetus in utero . Abnormally 
increased nuchal trans lucency thickness has been used as a oft marker for Down's Syndrome and other 
aneuploidies fo r more than a decade. Recently, an as oc iation has been identified between increased nuchal 
translucency thi cknes and congenita l heart di sease, rais ing the possi bili ty that nuchal trans lucency 
thickne s may he lp identi fy affec ted fe tuses as earl y as 11-1 4 weeks gestation. However, the 
pathophys iologica l mechanism which produces an abnormal nuchal tran lucency thickness in the fetus is 
not we ll understood and an abnormal measurement is not spec ifica ll y a oc iated w ith any one type of 
le ion. Therefore, nuchal trans lucency thickness cannot be used for diagno i of congenital heart di ea e in 
utero, but may be very he lpfu l in identi fy ing fe tuses at ri sk, whi ch may he lp improve diagnosti c accuracy 
and direct resource-effi c ient u e of diagnosti c method such as fetal echocardiography. 
Introduction 
Although it has long been the ho ly grail of 
prenata l care to be able to assure every woman a 
healthy infant at term, 2-3% of infa nts are born 
with at lea t one anatomical deformi ty. The 
congenital heart di sease are co llecti ve ly the most 
common congenita l defects, with a combined 
inc idence estimated at approx imate ly l/ 1 00 at 
term, and higher in the prenatal population.1 
Cardiac les ions may occur in iso lation, or 
alternate ly a part of a geneti c yndrome. Even in 
iso lated cases, there appear to be a genetic, likely 
multi fac tori a l, component to the ir e ti o logy. They 
range from inc identa l findin gs of no grea t 
fun ctional signifi cance (e.g. small atri a l septal 
defect ) to les ions w hich, if left untreated, are 
immedi ate ly life-threatening to the neonate (e.g. 
transpos ition of the great arteri es). Structural 
hea rt defects a re thought to contribute to up to 
20% of a ll neonata l deaths and up to 50% of all 
in fant dea th .2 
Recently, attention has focused on the 
utili ty of ultrasound mea urement of the free fluid 
behind the neck of the fe tus- termed the " nuchal 
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trans lucency" (NT)- in predicting congenital 
heart di ea e in the fe tu . It has been suggested 
that the ub et of fe tuse with abnormal NT 
measurement i at increased ri sk for congenital 
heart defect ; therefore the NT thickness may be 
of u e in prenata l di agno is of congenita l heart 
di ea e . 
What is Nuchal Translucency? 
The NT mea urement is a measurement of 
the thi cknes of the free fluid layer behind the 
feta l neck. Thi is measured by ultrasonography 
between I I and 14 weeks gestation. There are 
stri ct cri te ri a to establi h an ultra ound imaae a 
0 
adequate fo r the assessment of nuchal 
tran lucency and the norma l limit to the 
measurement is dependent upon gestationa l age. 
The NT measurement was first suggested as a soft 
marker for feta l aneuplo idy by Nicola ides and 
co ll eagues in 1994, and thi s assoc iation wa la ter 
confim1ed by other researchers. 3-6 It is now 
known that the nuchal trans lucency mea urement 
i 77% ensiti ve and 95% specifi c for Down' 
Syndrome/Tri omy 2 1, the most common of the 
three autosomal aneuploidies that are compatible 
with li fe. 4 
However, the NT measurement is also 
assoc iated with a host of other abnormalities in 
the fe tus. Even in chromo omally normal 
fetuses, increas ing NT is associated with adverse 
fe tal outcome . 7•8 Bilardo and co lleagues report 
that up to 20% of chromosomally normal fe tuses 
with increased NT experienced an adverse 
outcome, defined as mi carri age, intrauter1ne 
death , parental choice to terminate the pregnancy, 
or one or more structura l or geneti c di sorders in 
the fe tus. Of the 86 adverse outcomes, 14 (1 6%) 
were pregnancy terminati ons. The likelihood of 
adverse outcome appeared to correlate with 
increasing degrees of NT abnormality.8 
Nuchal Translucency and Congenital Heart 
Disease 
Recently, in both euploid9- 12 and 
aneuploid 13-16 fe tuses, an abnonna lly elevated NT 
measurement has been described in assoc iation 
with congenita l heart di sea e in the fetus. There is 
increas ing ri sk of cardiac les ions as the NT 
become progress ive ly more abnormal. 12 Ghi and 
colleague report the overa ll incidence of major 
cardiac defects to be 4.5% in fe tuses with NT 
above 2.5 mm, with 7% incidence in fetuses w ith 
nuchal translucency thickness equal to or greater 
than 3.5 mm.12 They suggest that abnormal NT 
may be more of a ri sk fac tor for major congenita l 
cardiac le ions than maternal diabetes, pos itive 
fa mily history of congenital heart di sease or 
exposure to teratogenic agents, and that therefore 
fe tal echocardiography is indica ted for a ll fe tuses 
with elevated NT mea urements. At a NT 
thickne s at or above 3.5 mm (roughly the 99111 
percentile), major cardiac anomalies appear to be 
present in 5-10% of screen-positive fe tuses. 12•17-19 
Hyett and colleagues 11 propose a cutoff of 
between the 95 111-99111 percentil e as the optimum 
point to 1mt1ate referra l fo r fe ta l 
echocardiography. Hyett suggests the nucha l 
translucency measurement could contribute to the 
detection of approximately 30% of all cases of 
congenital heart defects. 19 
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Prev iously, Hyett and co ll eagues 13 have 
suggested that the nuchal tran lucency 
measurement may be related to fai lure of the feta l 
heart ra ther than to the d irect effects of 
aneuploidy. As cardiac lesions are seen in many 
of the genetic syndromes, this is certainly a 
plausible explanation for the close assoc iation 
seen between increased nuchal translucency, 
aneuploid conditi ons and congenital heart d isease . 
However, thi s interpretation is by no means 
unanimou ly accepted, and mu ltipl e authors20•21 
report that the degree of NT abnormality is not 
specifica ll y assoc iated with any parti cular heart 
les ion. Makrydima and co lleague 21 report that 
there is considerable overlap between the average 
NT measurement fo r di ffe rent cardi ac le ions and 
the identi ty of the les ion; thus, the NT 
measurement is not helpfu l fo r the specific 
diagnos is of fe tal congenital heart di sease except 
to indicate that a cardiac lesion may be present. 
The underl ying pathophys iology remain unclear, 
and alternate explanations for the elevated NT in 
ca es of congenital heart di sease include venous 
congestion in the head and neck of the fe tus, 
abnorn1ali ties of lymphatic drainage, altered 
distr1bution of subcutaneous ti ssue, 
g lycosaminoglycan and proteoglycan 
accumul ati on, fe ta l anemi a and/or decrea ed fe ta l 
..,.., 23 c . 
movement.--· Theretore, the NT may mdeed 
identi fy fe tuse who are at increased r1 sk of 
congenital heart defects so that these can be 
referred on fo r more specia li zed diagnostic testing 
(e.g. fe ta l echocardiography) . However, in 
iso lation, it doe not appear to be sen itive or 
pecific enough to be a diagnosti c te t fo r 
. I h d. 17 congemta eart 1sease. 
Mo f24 has uggested that relying on nuchal 
translucency to identi fy fe tuses with Down' s 
Syndrome may in fact preferentially identi fy 
fe tuses in w hom there is an as oc iated cardiac 
defect. G iven the re lati ve incidence of congenital 
heart disease ( l/ 100) and Down's syndrome 
( l/800-l 000 overa ll )25.26 , the NT measurement 
may in fact pick up more babies with congenital 
heart disease w ho incidenta lly have Down's 
syndrome than babies wi th Down' s syndrome 
who have an assoc iated cardi ac defect. 
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The clinical implications of this finding 
are less clear. It could be argued that, even if 
increased NT is a marker for congenital heart 
disease in the fetus, it is not useful clinically as it 
is a standard of care to offer all pregnant women 
(regardl ess of NT measurement) a morphological 
ultrasound scan at L 8-20 weeks during which 
structural cardiac les ions can be identified. The 
current recommendation is a four-chamber view 
of the heart and imaging of the ventricular 
outflow tracts in an attempt to identify major 
anomalies. 27 However, it has been previously 
noted in population studi es of prenata l pat ients 
that morphological echocardiography JS 
dependent upon the ex perti se of the 
ultrasonographer and consequently an 
inexperienced one may mi ss a signifi cant 
proportion of major cardiac defects .28·29 In their 
tudy, Hyett and co lleagues'' report abnormal NT 
mea urement in 55% of fetuses w ith major 
congenital heart disease, compared to an 
abnorma l four chamber view on prenata l 
ultrasound in 26% of those same babies. The 
26% detection rate in that study was consistent 
w ith prior estimates.2 Wald and colleagues have 
suggested, based on a meta-ana ly is of studies of 
the utility of nuchal trans lucency measurements 
and congen ita l heart disea e, a detection rate of 
52% and a fa lse-po itive rate of 5% using a 
screening cutoff of L. 7 multipl es of the median .30 
This is greater than that achieved using a four 
chamber view alone, and, therefore, the nuchal 
trans lucency shows great promi se as a potenti al 
screen ing tool for congenita l heart di sease which 
can he lp direct appropri ate and resource-effi c ient 
use of fetal echocardi ography. 
Summary 
N uchal trans lucency is typically mea ured 
at L L -14 weeks as part of prenata l screening 
programs in order to he lp estimate materna l ri sk 
of bearing a child with aneuploidy or neura l tube 
defects. In recent years, an assoc iati on has been 
demonstrated between abnormally e levated 
nuchal translucency and a group of structura l, 
geneti c and chromosomal abnormalities in the 
developing fetus, including the congenital heart 
di seases, as well as poorer pregnancy outcomes 
for the fetus, and thi s is een even in fetu ses with 
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normal chromosomes. Routine measurement of 
the nuchal translucency shows great promise in 
helping to identify fetuses at increased risk of 
congenital heart disease, and therefore may help 
direct resource-efficient use of fetal 
echocardiography. However, by itself, i~crease_d 
nuchal translucency does not predict the d~agnos1s 
of a specific type of cardiac defect in the fetus . 
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The Legacy of a Life Lived: Trans-Generational Epigenetics and Cancer 
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Your grandfa ther smoked everyday, your mother was stressed while pregnant, your fa ther worked in the 
petrochemica l industry, should any of thi s matter to you? Evidence is emerging that the li ves we live affect 
us fa r beyond the boundaries of our own body and can reach we ll into the li ves of fu ture generations. 
These lingeri ng traces of li ves li ved mani fes t themselves in changes to the DNA of our cells, commonly 
referred to as epi geneti cs . Epigeneti cs is defined as inheritable changes in gene express ion that don ' t a lter 
the actual DNA equence itse lf, most commonly mediated by DNA methylation and/or hi stone methy lation 
or acetylation. In thi s paper, we w ill di scuss some of the epi geneti c changes that have been associated with 
the deve lopment of di sease with spec ific foc us on the deve lopment of cancer. Moreover, we w ill look at 
environmental exposures in current generations that may affect cancer development in future generations. 
We may mere ly be guardi ans of our DNA for future generations, and perhaps the impact of the way we 
treat our bodies should now be examined in thi s new light. 
My parents are children of World War ll. 
They grew up amongst the bombings, death and 
destruction. Their li ves were foreve r changed by 
these experi ences at a leve l far deeper than one 
would expect. Beyond the psychologica l, 
emotional or physica l impact of those 
experi ences, those moments would fo rever 
change their DNA. Such are the findin gs of Dr. 
Yehuda, who fo und that traumati c events can 
permanently alter the express ion of the tres 
hormone, corti so l. 1 Yehuda fo und that children of 
mothers who suffe red psycho logica l trauma from 
the events of WWll had children who had lower 
levels of corti sol production.:! T hi s change in the 
offspring re lated to materna l behav iour or 
experi ences has been linked to changes within the 
DNA of the children. These changes are refen·ed 
to as epigeneti cs, which is defin ed as inheritabl e 
changes in gene express ion that don ' t alter the 
actua l DNA sequence itse lr_3 ln thi s arti cle, we 
w ill expl ore the re lation hip between the 
environment, epigeneti cs and cancer. 
There are two maj or moda lities by which 
DNA can be altered to change the expres ion of a 
parti cul ar gene: the methy la ti on of DNA and 
Page I 66 
modifi cation of histones . The methy lation of 
DNA invo lve the addition of methy l groups to 
the cytos ine bases in the C pG domains.4·5 The 
modifi cati on of hi stones is the o ther major 
epigeneti c regulatory mechani sm . The more 
tightly the DNA is wrapped around the hi stone 
complex, the lower the express ion of the genes 
coded on that p1 ece of DNA. Hi stone 
modi fica tion invo lves the methy lation or 
acety lation of amino ac id such as lys ine, arginine 
and serine. Hi tone acety la ti on generally results 
in the loosening of the a sociation be tween the 
DNA and the hi tone, a llowing fo r increased gene 
expre sion.6;7 The effects of histone methy lation 
are more va ri able and can results in the increase 
or decrease in gene ex pre sion depending on 
whi ch res idues are modi fied and w here w ithin the 
hi stone protein the modifi cati on takes place.6•7 
Epigeneti c changes have lon o been 
assoc iated w ith cancer. T he fi rst maj orb findin g 
was that the DNA of cancerous ce lls wa g loba lly 
hypometh ylated .8 In additi on, the degree of 
hypometh ylation of the DN A seemed to corre la te 
with the aggress ivene s and prognos i of a 
particul ar cancer. 4'9 There is some debate a to the 
effects of DNA hypomethylation, but several 
theories have garnered attention. These include 
the idea that hypomethylated DNA is more 
unstable and thus leads to deletions and 
translocations, potentially creating truncated 
genes or genes that have different promoter 
elements.10 Other theories are based on the 
observation that imprinted DNA, that is selective 
DNA methylation to inactivate the expression of 
either a maternal or paternal allele, is di srupted in 
cancer cells. 3' 11 Therefore, hypomethylated DNA 
may correspond to the disruption of genomic 
imprinting. As an example, it is known that the 
loss of imprinting of the insulin-like growth factor 
. . k c. c. I I 1 2- 1 c~ gene IS a ns 1actor 10r co orecta cancer. 
The other major epigenetic mechanism 
that has been found to be prevalent in cancer cells 
is the inactivation of tumour-suppressor genes.6 
Tumour-suppressor genes prevent the progression 
of cancerous cells and some of their functions 
have been related to the inhibition of cell di vision, 
the initiation of apoptosis and the mediation of 
cell adhesion.4-6 Hypermethylation in the 
promoter regions of tumour-suppressor genes is 
one of the major steps required for the 
transformation from benign to malignant Two 
well known genes, the retionoblastoma tumour-
suppressor gene (Rb) and the breast cancer 
susceptibility gene 1 (BRCAl) are examples of 
genes that have hypermethylated promoter 
regions in cancerous cells. 15•16 The inactivation of 
tumour-suppressor genes by hypoacetylation and 
hypermethylation of hi stones have been 
associated with colon cancer, prostate cancer, 
liver and breast cancer. 6' 12' 17 
The question now concerns why these 
changes arise and how they result in cancer. We 
are all familiar with the concepts of nature and 
nuture intersecting to result in the genetic changes 
required to initiate the transformation into 
cancerous cells. For example, lung cancer 
requires a genetic predisposition on top of an 
environmental factor, commonly smoking. 
Research has shown that exposure to cigarette 
smoke can induce the hypermethylation of 
BRCA l/BRCA2 and XRCC, all tumour-
suppressor genes, as well as the hypomethylation 
. G 18, 19 O h of the pro-metastatic oncogene, SNC . t er 
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exampl es of environmental agents that induce 
changes to the epigenome resulting in increased 
inc idence of cancer include aniline dyes and 
bladder cancer, so lar UV radiation and skin 
cancer, and a lfatoxins found in the soi l and on 
plants and li ver cancer. :!0-22 We are a ll aware of 
thi s direct link between an environmental factor 
and the deve lopment of cancer. But what of the 
offspring of a person exposed to these 
environmental agents, are they ultimately at risk 
as well? 
Exposure to environmenta l toxins has 
been shown to increase the transgenerational risk 
of diseases, including cancer. One of the most 
widely studied toxins is vinc lozolin, which is an 
anti-androgenic compound used as a fungicide in 
the fruit industry.23 Transient exposure of 
gestating rats to vinclozolin leads to a variety of 
diseases in offspring up to four generations later, 
including tumour development, prostate disease, 
kidney disease, immune abnormalities and defects 
in sperm formation ? 3•24 Bispheno l A is perhaps 
the most well known endocrine di srupte r believed 
to change the epigenome. Bisphenol A is an 
organic compound that, until recently, could be 
found in many baby bottles , baby and children's 
toys, and in the epoxy resins that coat a lmost 
c. d d ?Q 1? 14 every tOO an beverage can.- ·-- ·- Neonata l 
exposure to bisphenol A has been show n to a lter 
the methylation status of a variety of genes and 
result in cellular transformations that promote the 
development of pro tate cancer. 25 Prenatal 
exposure to bisphenol A has been linked w ith an 
increased ri k of breast cancer via 
hypomethylation.26 Whil e the temporal effects of 
bisphenol A have been shown in the first 
generation, further studies are required to 
determine if changes are transmitted to 
sub equent generations. Other links have emerged 
between environmental tox ins and cancer 
including the transgenerational effects of alcohol 
leading to colon cancer and benzene leading to 
I k . 27,28 A th h . . eu em1a. s e researc mto ep1genetics 
grows, we will undoubtedly continue to see an 
expansion of the environmental agent that can 
alter the epigenome. 
The relationship between nutrition, 
epigenetics and the di sease processes warrants 
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further consideration. One of first multi-
generational epigeneti c studies was done in 
Sweden, where pari sh registri es and harvest 
records were u ed to link disease in generations 
after feasts or fa mines. 29,3 ° These studies found 
that if a paternal grandfather experienced a 
surplus of food before the onset of puberty, the 
grandchild had a four-fold increased chance of 
dying from compli cations of diabetes.29•30 
Interestingly, the children of mothers who 
experienced abundance of food before the onset 
of puberty had ch ildren who were protected from 
d i ea e re lated to d iabetes.29 · 0 In terms of 
cancer research, evidence is emerging that links 
nutrition, epigenome status and cancer 
deve lopment. xcessive maternal weight ga in 
during pregnancy leads to increased ri sks of 
breast cancer in the chil d. 31 In addition, the 
nutr itiona l content of the diet has been shown to 
be important in deve loping and maintaining the 
epigenome. pecifi ca lly, the ava ilabili ty of 
methyl donors, including fo late, cho line and 
methi onine seem to be important in preventing 
di ea e.32•33 In rat mode ls, decreased ava ilability 
of methyl donor has been shown to induce the 
development of li ver cancer, even in the absence 
of any known carcinogens.33 In the agouti mouse 
model , di etary suppl ementati on in utero with 
fo lic ac id, vitam in B 12, cho line, beta ine and zinc 
was assoc iated with a lower ri sk of cancer, 
diabetes and obes ity and an increased life 
expectancy.H 35 Low prote in di ets in utero al o 
seem to affect DNA methy lati on and disease m 
offspring, leadi ng to increased susceptibili ty to 
d. b h . d 31 36 1a etes, yperten ton an cancer. · 
S ince epigeneti c changes to the DNA are 
reversibl e, it prov ides the perfec t target for cancer 
therapies. Already, we are seeing the emergence 
of therapi es that are based on altering DN A 
methy lati on and histone acetylati on.37 ln 
parti cular, in vitro ev idence using DNA 
demethylating dmgs and the ability to re-express 
tumour suppressor genes has lead to the 
development of c linical therapies. Two DNA 
demethylating drugs, 5-azacytidine (Yidaza) and 
5-aza-2'-deoxycytidine (Decitabine), have been 
approved for the treatment of myelodyspl as ti c 
syndrome and leukemi a.38-4° The other maj or 
c lass of drugs developed on the principl es of 
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epigenetics is the histone deacetylase (HDAC) 
inhibitors. These drugs have been fou~d ~o 
induce cell-cycle arrest and apopt~s1s ~n 
vitro."·37,4l,.n Suberoylanilide hydroxam1c ac1d 
(Vorinostat) is the first HDAC inhibitor approved 
for the treatment of cancer, specifically cutaneous 
T-cell lymphoma.4 1•42 While these drugs have 
been approved, they lack specificity for _cell ~pe 
which may lead to unintended effects, mcludmg 
the express ion of previously silenced oncogenes. 
As with any cancer therapeutic, the eventual goal 
will be to develop agents that target only 
cancerous ce lls, sparing normal ti ssue and cells. 
If the las t century belonged to DNA and 
the genome, thi s century w ill surely belong to 
epigenetics and the epigenome. We are slowly 
discovering that the epi genome is an important 
pl ayer in the development of di sease. What has 
come as a urpri e is the degree to which the 
epi genome i influenced by the environment, by 
everything from drugs, toxins to vitamins and 
caloric intake. Even more astonishing is the 
emerging data indi cating that what we experience 
in our lives w ill ultimately influence the lives of 
our children and perhap even their children. In 
effect, we are the guardians of our genes and need 
to wa tch over them o that we may pass them on 
in the be t conditi on we can. 
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FEATURE 
Amish, Mennonite and Hutterite Genetic Disorder Database 
Michael Payne (Meds 201 OJ 
Faculty Reviewers: Dr. C. Anthony Rupar and Dr. Victoria Mok Siu 
Clinical Example 
A newborn baby girl presented with bowel 
obstruction. The possibility of cystic fibrosis was 
raised, particularly since there was a positive 
family history of cystic fibrosis in a deceased 
relative. CFTR mutation ana lysis was ordered 
using a panel that included .6.F508 and 28 other 
common mutations which account for 85% of al l 
CF mutations. The results were negative for all 
mutations in the screening panel. 
Since the parents were members of the 
Old Order Amish community, the Amish, 
Mennonite and Hutterite Genetic Disorder 
Database was accessed via the Internet and it was 
determined that a specific mutation (3905 ins T) 
had been described in the Old Order Amish. 
Further DNA testing confirmed that the baby was 
homozygous for the 3905 ins T mutation. 
Although the sweat ch loride test is the go ld 
standard for cystic fibrosis testing, it can be 
difficult to obtain suffic ient sweat vo lume 
collection in the newborn period. 1 
Correct diagnosis of newborns with CF 
through mutation ana lysis is important as this will 
help direct therapies and improve overall 
outcomes.2 This case illustrates the usefulness of 
the Amish, Mennonite and Hutterite Genetic 
Disorder Database as it a ll ows medical 
professionals to identify genetic disorders and 
specific mutations which otherwise may be rare in 
the North American general population. 
Introduction 
The Amish, Mennonite, and Hutterite 
Genetic Disorder Database was created in 
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response to a paucity of resources for Canadian 
medical practitioners who treat ' 'Plain People." 
The database focuses on genetic diseases which 
are found with higher prevalence in these groups 
due to their unique cultural history. The database 
can be viewed at: 
http ://www.biochemgenetics.ca/plainpeople/ 
Common Background 
The Amish, Mennonite and Hutterite 
populations share some similarities. They all 
arose in Europe during the Protestant Reformation 
in the 161h century.3 In contrast to other 
Protestants and Catholics, they are Anabaptists, 
believing that chi ldren shou ld not be baptized at 
birth, but instead at an age when they can make a 
consciou decision to join the church. They also 
believe in the separation of church and state. 
These views were seen as heretical and led to 
their persecution in Europe by the Protestant and 
Catholic majority. The Anabaptists are a lso 
pacifists who do not engage in war and believe in 
segregating themselves from the general 
population .3 "P lain People" is a term which refers 
to their plain dress and restricted use of 
technology.4 
History and Migrations 
In order to understand present day genetic 
issues surrounding the Plain People it is important 
to understand where they originated and how they 
came to Canada and the USA. They can broadly 
be divided into 4 groups: the Hutterites , Old 
Colony Mennonites, Old Order Mennonites and 
Amish. 
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The Hutterites were followers of Jakob 
Hutter in Austria, and their co lony was founded in 
1528.5 They were persecuted for most of their 
history and were forced to migrate between 
settlements in Morav ia, Romania, Hungary and, 
U kraine. From 1874 to 1879, 443 individuals 
immigrated to the United States. 5 They settled on 
the prairies and prospered until WW 1 when they 
refused to accept conscription. Canada offered 
them land and exempti on from military serv ice. 
Many Hutterites imm igrated to Canada during 
thi peri od and settl ed in Alberta, Saskatchewan 
and Mani toba. There are a lso a few coloni es in 
British Columbia. Their current population in the 
US and Canada numbers over 40,000.5 The 
Hutteri tes believe in communal ownership, with 
minimal personal posses ion . They li ve in 
communal colonies, use modem fa rming and 
manufac tu ring technique , and utili ze modem 
hea lth care.6 
Mennonites are named fo r the ir foundin g 
leader, Menno Simons. The Mennonites can be 
divided into two groups: Dutch-North German 
and Swiss-South German. The Dutch-North 
German (O ld Colony) Mennonites originated in 
the low countri es of Europe in the 16th centu ry .3 
A a result of persecution they were forced to 
move to Pruss ia and li ved there in re lati ve peace 
until the 18th century. With continued growth , 
land shortages fo rced emi gration from Pruss ia to 
Russ ia. In 1870, 7000 Mennonites immigrated to 
Manitoba, while another I 0,000 immi grated to the 
American Midwest. 3 Anothe r wave of Russian 
Mennonite came to Canada in 1920 fo llowing 
the Ru sian revo lution.3 
In the 1920s, 7000 of the Canadian O ld 
o lony Mennonites emigrated to Mex ico, Beli ze 
and South Ameri ca. Recently, many O ld Colony 
Mennonites have returned to Canada from 
Mex ico and South America, ettling mostly in 
Southwestern Ontario, Alberta and Manitoba.3 
Today, O ld Colony Mennonites in Canada 
number over 27,000. T hey speak Low German at 
home, and High German for more fon11a l 
occas ions, uch as church.3 
The Swiss-South German Mennonites 
were fo unded in the 16th centu ry in Switzerl and. 
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In 1693 followers of Jakob Amman split from the 
Swiss-S,outh Mennonites to form the Amish sect, 
a more conservati ve group.7 Both the Swiss-South 
German Mennonites and the Amish suffered 
persecution in Europe . Between 1683 and 18_80, 
approximately 8000 Sw iss-German Mennomtes 
immigrated to the United States. 7 With the onset 
of the revolutionary war in the USA, members of 
the Mennonite and Ami h communities trave lled 
to Canada, settling in the Kitchener-Waterloo and 
Aylmer-St. Thomas area . 
In 1824, A mi sh families began 
immigrating directl y to the W aterloo and Perth 
County areas of Ontari o from Europe.8 In the late 
19111 century, Old Order Mennonites (OOM) split 
from the other Swiss-Mennonite groups in the 
USA and Canada due di ffe ring opinions over 
Sunday school and higher education.7 OOM and 
the Amish are both quite con ervati ve and can be 
een dri ving buggies and wearing conservative 
c lothes. 7 
Suitability for Genetic Study 
The unique hi tory of Pla in People groups 
make them especia lly uitable for genetic 
re earch. They are ocia ll y isolated w ith little 
geneti c inflow. They k ep exten ive genealogica l 
records, mainta ined by loca l ministers. Their 
initia l founder population are we ll know n. They 
have experi enced many geneti c bottleneck events 
cau ed by succe s ive mi grations over their 
hi story. Large fa milies are common, w ith low 
rate of non-paterni ty . They have a re lati ve ly high 
tandard of medical ca r .9 
The fo under effect i quite pronounced in 
Pla in Peopl e population . For example, most of 
the over 40,000 Hutterite in North America can 
trace their ance try back to a group of 89 
founding members.5 The Amish and M ermonite 
populations of North Ameri ca are similar with 
. ma ll fo~nding popul ~ ti o7ns an~ iso lation re ulting 
m genetic homogeneity. T his can highly skew 
the preva lence of certain di eases in the i olated 
popul ati ons, part icularl y auto omal reces ive 
~onditions. For exampl e, nephropa thi c cy tino is 
1 . a rare auto~oma l rece s ive lysosomal storage 
d1 order affectmg about l in 100,000 children in 
the general population with a carrier frequency of 
about 1 in 150. 10 In the Old Order Amish 
population of Ontario, the cystinosis carrier 
frequency is 1 in 4.5 , predicting an extraordinarily 
high incidence of 1 in 78. 11 The increased 
incidence of these otherwise rare conditions allow 
for linkage analysis and identification of causative 
genes.12 
These genetic studies are not only useful 
for Plain People, but also for the general 
population. Since 10-20% of each generation of 
Old Order Amish and Mennonite children have 
chosen to leave their communities, many alleles 
have entered the general population. 13 Also, many 
of the mutations causing disease in the Plain 
People can be found in Europe, where the 
founding populations originated. 13 Genetic 
linkage studies in the Mennonites has led to the 
discovery of the genes for many conditions, such 
as hypophosphatasia and X-linked congenital 
stationary night blindness. 3 The Clinic For Special 
Children in Pennsylvania specializes in care for 
Plain People and have been successful in isolating 
over 50 different mutations causing disease in the 
Mennonite and Amish communities over the past 
5 years. 14 
The Database 
The Amish, Mennonite, and Hutterite 
Genetic Disorder Database is intended to be used 
as a resource to assist in research and diagnosis of 
genetic conditions for patients of Plain People 
ancestry. It has been compiled by researching 
published genetic conditions for Plain People. 
Literature searches were performed on PubMed. 
Some disorders and mutations were entered based 
on personal communication with other genetic 
researchers. 
For each disorder, the group affected is 
recorded along with the geographic location (e.g. 
Amish, Ontario). This is important because 
disease prevalence can vary between locations, 
even within a specific group (e.g. Hutterite), as a 
result of differences in the founding 
populations. 12 The specific gene and mutation(s) 
are also listed, if known. The journal articles 
detailing the illness with specific mutation(s) 
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found in Plain People are listed along with the 
OMIM reference number. Finally, the clinical 
symptoms of each condition are listed, assisting 
healthcare providers in recognition and diagnosis. 
In order to navigate the database, users 
search by disorder, mutation or clinical signs and 
symptoms. When searching by disorder, the user 
is able to input either the OMIM number or the 
name and is directed to the corresponding page. 
Alternatively, the user can input a specific gene 
and identify any disorders which are caused by 
mutations in that gene. Finally, the user can 
search the database by clinical manifestations of 
the genetic conditions. This is done using a drop-
down menu divided by different body systems. 
The clinical search may be limited to one specific 
Plain People group and a geographic location. 
Finally, users are provided a link in order to 
communicate with the site administrator if they 
have questions or new information to add to the 
database. 
Conclusion 
Plain People have unique healthcare needs 
as a result of small founding populations and 
cultural isolation. It is our hope that The Amish, 
Mennonite, and Hutterite Genetic Disorder 
Database will improve the healthcare delivery to 
Plain People in Canada. We view it as an ongoing 
project, with continuing updates to the database 
with future discoveries. 
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FEATURE 
Hemochromatosis - Screening for a Common Condition 
Nick Sunderland (Meds 2010) 
Faculty Reviewer: Dr. Kami/ia Rizkalla 
Hemochromatosis is a common genetic disorder in the Caucasian population. It can go unrecognized in 
many patients for years before manifesting itself as multisystem end-organ damage. There is debate as to 
whether this condition should be screened for on a routine basis; as such this article serves to explore the 
basics of the disease and to review current guidelines for screening at the primary care level. 
Case 
A 26 year old female fashion student 
getting lab work for allergy testing was 
incidentally found to have significantly increased 
serum transferrin and ferritin levels. Subsequent 
genetic testing revealed homozygous mutation for 
the gene encoding the HFE protein . 
Retrospectively , the mother reports a history of 
improvement in chronic fatigue and joint pains 
following elective phlebotomies at the local blood 
bank. Her testing revealed a compound (double) 
heterozygous mutation in the HFE gene, but no 
abnormality in her liver function tests or iron 
levels . The father and 24 year old brother have 
normal ferritin and liver enzymes; the 28 year old 
brother, however, has markedly increased iron 
stores. 
Introduction 
Hereditary hemachromatosis (HH) is an 
autosomal recessive inl1erited disorder in which 
mutations in specific genes related to iron 
transport proteins lead to increa ed iron 
absorption from the diet. This eventually leads to 
deposition of iron in the parenchyma of the liver, 
heart, pancreas and pituitary g lands if left 
untreated, and can cause significant long tenn 
morbidity. 1 
This disorder was originally described as 
"bronze diabetes" by Armand Trouseau in 1865, 
when he observed an association of skin 
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pigmentation with diabetic patients. 2 The first 
report of deposition of iron in tissue leading to 
dysfunction was by Yon Reckinghausen in 1890. 
The sequencing of the human genome has 
allowed identification of the specific mutations 
associated with the HFE protein, the commonly 
affected protein in HH. Mutations in this protein 
are the focus of this article. Note that there are 
other, less common hereditable defects in iron 
metabolism. 
Genetics 
The most common genetic defect is in the 
HFE protein, which interacts with the transferrin 
receptor and other iron regulating proteins to 
regulate absorption of iron from the GI tract. 
There are two common mutations in HFE, 
C282Y and H63D. The mutation is most 
prevalent in Caucasians of European decent, with 
a homozygote prevalence (C282Y) of about l in 
200. The prevalence is about l in 250 in the 
general population. 
In this same population, 12% are carriers 
of the C282Y and 25% the H63D mutation. Most 
HH patients are homozygous for the C282Y 
mutation. The penetrance of the H63D mutation is 
considerably lower, thus compound heterozygotes 
(C282Y/H63D) and H63D homozygotes 
constitute l 0% of HH patients .3-5 
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Pathogenesis 
The HFE prote in as mentioned is 
important in regu lating the uptake of iron from 
the diet in the GI tract. Iron can only be lost 
through sweat, skin and the GI tract, menses in 
fema les, and during times of growth such as 
pregnancy and ado lescence. Ma les lose 
approximate ly l mg/day and fe males 
proportiona lly more ( l .5-2mg/day). In HH, the 
abi lity of the body to sense overa ll iron stores is 
lost, leading to an extra absorption of l -4mg of 
iron daily, which averages over a year 
approximate ly I gram. The s low accumulation of 
iron i genera lly asymptomatic until the tota l 
body iron stores are greater than 20 grams. 
Excess ive iron is tox ic to ti ssues by free 
radical reactions, timulation of co llagen 
fo rmation, and interaction with DNA. Most of 
these changes are reversible if the iron is 
removed. Depositi on of hemosiderin , an 
intrace llul ar iron storage compl ex, in the ce lls of 
the li ver, pancreas, myoca rdium, pituitary , 
adrenal, thyro id and parathyro id g lands, jo ints and 
skin lead to di sco louration, fibrosis, and 
dysfunction. Interacti on w ith DNA has lead to 
increased ri sk fo r hepatocellular carcinoma 
(HCC) in advanced cases. 1'7 HCC and cirrhos is 
are the leading causes of morta li ty due to HH. 
Presentation and Differential 
Most cases of HH are di scovered through 
screening, as either an inc idental finding when 
bloodwork is done for another reason or becau e 
of a re lati ve with a di agnosis. The manifestation 
of HH usua lly occur after age 40 in males (50 in 
females), after iron stores are grea ter than 20 
grams. The most frequent symptoms include 
hepatomega ly, abdominal pain , skin pigmentation 
(especia lly on sun exposed areas), altered g lucose 
metabo li sm or diabetes, cardiac arrythmias, and 
an atypi cal arthriti s. Hypogonadism resulting m 
amenorrhea in fema les and a drop in libido m 
males is also a common initi a l presentation. 
Each of the symptoms is due to 
hemos iderin depositi on in organ parenchyma and 
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the ensuing fibrotic reaction from chronic 
damage. Cirrhosis, pancreatic . insufficien~y 
secondary to islet cell destructw.n and skm 
pigmentation are all fairly late findmgs , b.ut a~e 
considered the class ic " triad" . Hypogonadism IS 
related to alteration of the hypothalamic-pituitary 
. I 
ax is. 
The differentia l for HH includes other 
causes for elevated iron stores. Most alternative 
diagnoses are secondary causes of iron overload, 
most commonly chronic transfusions, either alone 
or in association with ineffective erythropoiesis . 
The latter conditi on results from RBC being 
destroyed before they can leave the bone 
marrow.
6 
Screening 
The understanding of the underlying 
pathophysiology of thi s di sorder has come a long 
way. At a population level, it has been debated 
whether routine screening (via a fasting serum 
transferrin saturati on) should be implemented, 
due to the high prevalance of the mutation, ability 
for early diagnos i and treatment, and ease of 
geneti c testing. However, a t thi s time widespread 
screening has not been recommended, due to lack 
of predictabili ty about the express ion of the 
mutati ons and lack of information on ri k-
strati fy ing pati ents. 3· 6- Labelling of individuals 
who test pos iti ve through geneti c testing but are 
a ymptomatic is a l o another concern and could 
lead to diffi culti es w ith obta ining in urance, for 
exampl e.7 
The va ri able express iOn m thi s condition 
has been a focus of some re latively large 
creening studi es, inc luding a study by Beutler el 
a/. (2002) whi ch involved 4 1,000 US individuals 
tested for the C282 Y and H63 D mutations. They 
found no difference in the age di stribution or 
frequency of signs and symptoms of HH between 
the cases and contro ls. However, a more recent 
study of 3 1,000 Austra lian pati ents of northern 
~uropean decent (fo llowed for 12 year ), bowed 
Iron-overload re lated di sease in 28% of mal e and 
1.2% of fema le homozygotes. 5 Other 
observational studi es have identified a substantial 
percentage of first degree re la ti ve of 
homozygotes with subclinical conditions related 
to HH.10 
Following from this, a reasonabl e strategy 
for screening would include targeting high ri sk 
individua ls, such as adult men > 25 years o ld of 
northern European decent and first degree 
relatives of patients w ith known hered itary 
hemochromatosis . The screening test of choice 
would be a fasting serum transferrin saturation 
(men >52% and women > 50%) or a fasting serum 
unsaturated iron binding capacity. Follow-up to 
thi would be genetic testing.3•4• •10 
Diagnosis 
The diagnosis of HH rests on a 
combination of the clinical features mentioned 
above, and an e levated serum ferritin and fasting 
transferrin saturation. In the past, a li ver biopsy 
was used in confirmation of the di sease; however, 
genetic testing has largely replaced thi s invas ive 
test except in the case of documented li ver 
impairment and need to determine extent of 
cirrhosis. The serum ferritin value needs to be 
analyzed with caution as it is an acute phase 
reactant. Excluding the secondary causes of iron 
overload is important (Table 1 ). 
Treatment 
The definiti ve treatment of HH and the 
associated iron-overload is phlebotomy, 500ccs 
weekly. This is continued until iron-deficiency 
erythropoiesis is induced as ev idenced by a 
reduced MCV and decreased Hb value, and/or 
Table 1: Cause of iron overload6 (*focus of arti cle) 
Hereditary hemochromatosis 
Related to HFE gene* 
African (Bantu) hemochromatos is 
Juvenile hemochromatos is 
Neonatal hemochromatosi 
Chronic anemias 
Thalassemia major 
Sideroblastic anemia 
Congenital dyserythropoietic anemia 
Conoenital atransferrinemia b 
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serum ferritin leve ls and transferrin saturation 
markers are within the target range , w hi ch are 
below 50% and 50ng/mL, respectively. Patients 
w ill usually require a phlebotomy every 2-3 
months as maintenance therapy, which in many 
cases can be accomp lished by regular donations 
to the local bl ood bank. Patients testing pos iti ve 
for HF E mutation but without laboratory ev idence 
of iron overload can be followed annually for 
evidence of disease, but do not require active 
treatment. 
There is no need for pat ients to avo id red 
meats and other di etary sources rich in iron ; a 
well ba lanced di et is acceptabl e. Pati ents can be at 
higher ri sk for certa in infections such as Vibrio 
vulnificus, and as such eating raw seafood is 
discouraged. 
Case Discussion 
The case represents a common scenario, in 
thi s case a Caucas ian fam ily with a compound 
heterozygote mother (C282Y/H63D) and the 
daughter homozygous for the C282Y mutat ion. 
This ca e illustrates the need for awareness on the 
part of family doctors of at-ri sk population to 
determine the need for geneti c testing. Had the 
fashion tudent (homozygote) not bad her blood 
tested she may have gone years w ithout any 
knowledge of her condition, until pre entation 
w ith signs of end organ damage. While a number 
of incidental cases of iron-overload are inevitable 
until better ev idence is ava ilabl e for specifica ll y 
identifying those at ri sk, targeting the at-ri sk sub-
groups should minimize thi occurrence. 
Exogenous iron overload 
Chronic iron supplementation 
(in ab ence of blood loss) 
Transfusion 
Iron dextran inj ection 
Chronic liver diseases 
Viral hepat iti s 
Alcoholic li ver di sease 
Nonalcoholic steatohepatitis 
P01phyria cutanea tarda 
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FEATURE 
Amniocentesis: Safety, Reliability and Alternatives 
Caleb Zelenietz (Meds 2011), Kimberley Colangelo (Meds 2011), and lshvinder Chattha (Meds 2011) 
Faculty Reviewer: Dr. Robert Gratton 
Amniocentesis is the most commonly used technique for prenatal genetic diagnosis. It is an effective 
procedure with a high diagnostic success rate, but carries the risk of severe complications including 
miscarriage. Despite the risks , amniocentesis performed in the second trimester remains the safest means of 
prenatal genetic diagnosis. With the introduction of biochemical and first trimester ultrasound screening for 
fetal aneuploidy, amniocentesis usage rates have declined. 
Background of Prenatal Genetic Screening 
Pregnancy can be a time of worry, when 
concerns over fetal health and well-being are at 
the forefront of many women's minds. Modem 
clinicians have a wide array of tools at their 
disposal to allay parents ' fears. Prenatal screening 
for genetic anomalies has become a cornerstone 
of care for expectant mothers . 
In Ontario, Integrated Prenatal Screening 
(IPS) , Serum Integrated Prenatal Screening 
(SIPS), and First Trimeter Screen (FTS) are 
offered to all women presenting before 14 weeks 
gestation .1 The testing uses serum markers and 
nuchal translucency (in the case of IPS and FTS) 
to assess the risk of trisomies 18 and 21 along 
with open neural tube defects. Testing is 
undertaken in both the first and second trimester, 
with results becoming available after the second 
set of testing. Many screening options are 
possible but IPS and SIPS (if nuchal translucency 
is not available) prove most accurate and safe. 2'3 
These tests give the mother the risk of her fetus 
having one of these conditions, but are not 
diagnostic. 
The costs to the health care system of 
screening have been estimated to be around 
$15,000 US per quality adjusted life year gained.4 
The screening tests are non-invasive and do not 
pose a risk to the fetus in and of themselves , but 
are associated with an increased risk of pregnancy 
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loss due to follow-up diagnostic tests. After a 
woman has screened positive as having increased 
risk of one of the fetal anomalies , she must be 
offered further testing; screening should therefore 
only be performed when follow-up diagnostic 
testing is available. When used in the absence of 
screening, based on matemal age , amniocentesis 
and chorionic villus sampling cost about 
$100,000 US per abnormal birth averted, giving 
substantial weight to the use of screening 
programs as a first step in assessing the risk of 
genetic abnormalities in a fetus. 5 From a safety 
perspective, however, the use of amniocentesis 
with the sole risk factor of advanced maternal age 
is justified as the risk of aneuploidy is comparable 
to the risk of miscarriage .6 
Positive Screen: What Comes Next? 
Several options are available after a woman 
has screened positive: she can choose to continue 
the pregnancy without further testing, she can 
have chorionic villus sampling (CVS) in the case 
of FTS, or she can have amniocentesis . Both CYS 
and amniocentesis are invasive procedures that 
pose ri sks to the fetus, but are also highly 
effective diagnostic tools with close to l 00% 
d. . 78 mgnosttc success rates . ' 
Amniocentesis involves the withdrawal of 
amniotic fluid from the uterine cavity. Typically, 
a 20 or 22 gauge needle is inserted into the 
amniotic sac transabdominally under ultrasound 
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guidance. It can be done both fo r obtaining cells 
to culture for geneti c testing, fe tal blood typing, 
and diagnosing fe ta l infec tion. 9 When used for 
geneti c diagnosis, amniocentes is is typically 
performed in the second trimester. It is most 
effecti ve at obtaining a useful sample after 15 
weeks gestation and before 24 weeks. 1° Cell 
cultures typica lly take 7 days to grow before they 
can be tested. For more rapid results, interphase 
flu orescence in situ hybridization (FISH) can 
detect aneuploidy of chromosomes 13, 18, 2 1, X, 
Y in one to two days . An a lternate procedure fo r 
obtaining genetic materia l fro m the fe tus is 
chorionic v illus sampling (CVS). CYS invo lves 
sampling the placenta either transabdomina lly or 
transcervically. It is usua lly performed in the firs t 
trimester, after 10 weeks gestati on. The rate of 
both amniocentes is and CVS use has decreased 
w ith the introducti on of IPS, FTS, and SIPS. 11 •12 
Safety of Early Versus Late Amniocentesis and 
cvs 
The safety of earl y versus late (first rather 
than second trimes ter) amniocentes is and CVS 
has been studied ex tensive ly in the literature. 
Earli er tes ting provides a definiti ve di agnos is 
much qui cker after a pos iti ve test, but is not 
w ithout added ri sk of complication. A Cochrane 
review of 16 randomi zed contro lled tri a ls fo und 
second trimester amniocentes is to be the safest 
method of prenatal geneti c diagnosis.8 
Amni ocentes is performed before the second 
trimes ter is assoc iated w ith a higher rate of 
pregnancy loss (7.6% versus 5.9% relati ve risk of 
1.29 95% cr 1.09 to 1.8 1) than second trimes ter 
testing, thus it is not as safe an a lternati ve as later 
amni ocentes is. CVS is the safest method of first 
trimester sampl ing, but has a hi gher loss rate than 
second trimester amni ocentesis with a higher tota l 
pregnancy loss (re lative ri sk of 1.40; 95% Cl 1.09 
to 1.8 1) and spontaneous mi scarri age (9.4%; RR 
1.50; 95% CT 1.07 to 2.11 ). 8 
Risks of Amniocentesis 
The materna l ri sks of amni ocentes is are 
low; of much greater concern are potentia l feta l 
complicati ons. The only randomized controlled 
tri a l comparing second trimester amni ocentes is to 
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placebo, a study of 4606 low risk women aged 
25-34 years, found the rate of spontaneous 
abortion to be 1. 7% in the second trimester 
amniocentes is group versus 0. 7% in the control 
ultrasound group (relative ri sk of 2.3). 13 Current 
consensus from various trials estimates the loss 
rate from second trimester amniocentesis to be 
between 0.6% to 1.0%. 14 Fluid leakage is more 
common after amniocentes is than in controls, but 
is not associated with negative pregnancy 
13 
outcomes. 
With ultrasound guidance, direct fetal injury 
is extremely rare 13 , although it has been 
reported.15•16 Indirect feta l 111Jury is more 
common, with respiratory di stress syndrome and 
pneumonia being more common in newborns 
..,., d · . . 13 11 A l a tter secon tnmester amniOcentesis. ' arge 
cohort study of women 35-49 years old (with 
71,586 parti cipants) found an increased incidence 
of muscul oskeletal deformities and respiratory 
di stress in newborns whose mothers underwent 
2nd trimester amniocentes is. There was no 
increase in limb reduction defects, infant and fetal 
morta lity, prematurity, low birth weight, or fetal 
di stress with amniocentes is.18 There is no long 
tern1 increased ri sk fo r di sabilities in children 
after amniocentesis. 19 
Verti ca l transmi ss ion of infections such as 
cy tomega lov irus, hepatiti s C Virus, and human 
immuno defi c iency virus has been linked to 
amniocentesis perfonned in infected women. 20•21 
Like a ll invas ive procedures in chronically 
infec ted women, amniocentes is should be used 
only when abso lute ly necessary. 
Advantages of Early Versus Late Diagnosis 
Although second trimester amniocentes is 
has been conclusive ly shown to be the safest 
method of prenata l geneti c diagnosis, it is not 
without d isadvantages . Because it is performed in 
the second trimester, there is a long lag time 
between a screen pos itive test from IPS or SIPS 
and definiti ve di agnosis. CVS is ava il able in the 
first trimester, thus cutting the lag time 
considerably. Several studi es of women's 
subj ecti ve we ll being have shown shorter time to 
maternal feta l bonding, earli er anxiety reduction , 
and improved health related quality of life in 
women having a positive screening test followed 
by a negative CVS as compared to a negative 
second trimester amniocentesis?2-24 The 
magnitude of the reduction of anxiety post test is 
the same for the CVS and amniocentesis groups, 
but occurs sooner because the CVS is done 
earlier.23 This benefit in anxiety reduction exists 
despite the increased risk for miscarriage with 
CVS.23 The same is true for the maternal-fetal 
bonding improvements, the bonding improves 
markedly after a negative test result, equally for 
CVS and amniocentesis, but the CVS is 
performed earlier. 22 Whether these subjective 
improvements outweigh the very real increased 
risk of miscarriage should be discussed with each 
patient. 
Aftermath of a Positive Test 
After a positive diagnosis of a chromosomal 
abnormality, the patient faces the difficult 
decision of whether or not to terminate the 
pregnancy. The attitudes and knowledge of the 
health care provider providing the diagnosis 
affects the patient 's choice. 25•26 The patient's level 
of education and socio-economic status also plays 
a role in her decision making.25 Detection rates do 
not correlate with termination rates ; older women 
l .k I . h n 28 are more 1 e y to contmue t e pregnancy.- · 
Pregnancies with sex chromosome abnormalities 
(SCA) causing infertility and abnormal sexual 
development were more likely to be terminated 
than SCA's that did not affect fertility and sexual 
development.28-3 1 The lowest termination rates for 
SCA are for the 4 7 XYY and 4 7 XXX 
karyotypes.28•30•31 Abnormalities visible on 
ultrasound make the pregnancy less likely to be 
continued?8•30-32 Overall detection rates are 
increasing for SCA while termination rates have 
steadily declined. 29'33'34 
Conclusions 
Second trimester amniocentesis is an 
effective tool for prenatal genetic diagnosis. 
Although it is not without risks of serious 
complications such as miscarriage, it remains the 
safest technique for prenatal genetic diagnosis. 
The greatest limitation of second trimester 
UWOMJ, Vol 78, Issue 3 
amniocentesis remains the late availability of 
results , which gives parents little time to make 
deci ions based on the results of the testing. As 
detection rates of genetic disorders by 
anmiocentesis have increased, termination rates 
have decreased. Amniocentesis remains a 
valuable tool for prenatal genetic diagnosis. 
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CASE REPORT 
Ductal Carcinoma in situ in a 25-Year-Oid Male with Unilateral 
Gynecomastia 
Christopher}. Coroneos (Meds 2010) 
Faculty Reviewer: Dr. Caroline Hamm 
DCIS in a young ma le is rarely reported. Our pati ent is a 25 year o ld male who presented with symptomatic 
unilateral gynecomastia. He presented w ith a trong fa mily history of cancer on both matem al and paternal 
sides of his fa mily including breast, lung (maternal) and melanoma, colon and pancreatic (paterna l). His 
mother te ted negative fo r BRCA 1 and BRCA2. There is no info rmation on the patemal geneti c testing . He 
was treated w ith left subcutaneous mastectomy. Upon histologic review of the sample, concurrent 
gyecomastia and ducta l carcinoma in situ was di scovered. To date, only fo ur ca es of gynecomasti a and 
DC IS have been described in younger male pa ti ents. Since onl y 30 - 50% of pati ents with DCIS eventua lly 
develop invas ive cancer in the subsequent 10 - 20 years, thi s fi gure in the general populati on may be 
higher. This case underscores the importance of fa mily history in any pati ent presen ting with a breas t mass. 
Patients must be made aware of the risk, however small it may be, and phys icians must remain cautious of 
malignancy in young ma les with gynecomasti a. 
Introduction 
By definiti on, gynecomasti a is a benign 
condition affecting males characteri zed on 
histology by g landular ti ssue proliferation.1 It 
must be di stingui shed first from 
pseudogynecomastia, the depositi on of fat with 
absence of g landular ti ssue proliferation seen in 
obese ma les and second, from breast carcinoma. 
The increas ing size of the breast is due to 
parenchyma and/or fatty ti ssue. Gynecomasti a is 
common and most prevalent in the neonata l, 
pubertal and elderl y periods. 2 However, it is a lso 
present in 33-4 1% of adult males aged 25 -45 .2 
Long-standing cases that are res istant to medi ca l 
management or aesthe ti ca lly displeas ing are 
treated w ith surgical excision with or w ithout 
liposuction . 3 
In contrast, cases of ma le breast cancer 
(MBC) are uncommon, occurring in 
approximate ly 1 in 100 000 men4 and leading to 
under 0.5% of male cancer deaths annually.5 The 
age of incidence is typically 65-67 years.6-9 Ri sk 
factors inc lude testicular abnorma lity, 
estrogenic/androgenic imba lance, Klinefe lter 
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syndrome, BRCA mutation, pos itive fa mily 
history, obes ity , radiati on exposure and liver 
di sease.8 While gynecomasti a ha been 
hypothes ized to be associated with MBC, 
research indi cates its incidence is not higher 
among MBC patients w hen compared to the 
I I . 4 10 II Th . f genera popu at10n. · ' e rare coex i tence o 
the two conditions has been identified in the 
literature.12• 13 Still more rare are cases of ductal 
carcinoma in s itu (DCIS) with gynecomasti a, 
espec ia lly in the young adult popul ation. To date, 
only fo ur cases of DC IS in the setting of 
gynecomasti a have been described in pati ents that 
are 25 yea r o ld or less 14- 17 and only one of these 
describes unilateral gynecomastia as our pati ent 
does. 16 
Case Report 
A 25 year o ld ma le presented in 2007 for 
cosmetic mastectomy. He reported a hi story of 
new onset localized discomfort in the peri areolar 
region of the left breast and a growth in the left 
breast for one year, increas ing in s ize. On 
presentation, both the size of the mass and the 
associated pain had decreased in magnitude. 
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Phys ical exam noted slight swelling deep to the 
left nipple areo lar complex with no ax illary 
lymphadenopathy. The right breast had no 
di scernable changes. Family hi story was 
significant fo r malignancy including the maternal 
grandmother (metastati c lung cancer to bone and 
bilatera l breast cancer at ages 45 and 46 
respecti vely, death at 49) , maternal great-aunt 
(breast cancer, death at 65), second maternal aunt 
(breast carc inoma at age 60, relapse and bone 
metastases, currently undergoing treatment), 
maternal grandfa ther (pancreatic cancer), paternal 
grandfa ther (co lon cancer), paternal great-uncle 
and two paterna l uncles (melanoma) . He reported 
no other hea lth concerns, and history was notable 
only for surgica l hernia repa ir at age three. The 
remainder of the phys ical exam was 
unremarkab le. 
Ultrasound reported a small amount 
( 1.5cm) of mixed echogenic tissue in the 
retroareolar region, consistent with benign 
changes and gynecomasti a. Left subcutaneous 
mastectomy was performed. The suspected 
gynecomasti a was completely excised, measuring 
approx imately 6.5x6 .0x2 .5cm, weighing 48 
grams. On microscopi c examination, patho logy 
reported gynecoma tia hav ing abundant fib rous 
stroma separating ducts hav ing columnar ce lls 
w ith inbudding. ln additi on, a cribiform pattern 
of cellular change was present. Pathology was 
consistent with nuclear grade I/ lii DCIS, largest 
focus 7mm. The patho logy report mentioned the 
re lat ive rarity of intraducta l ca rc inoma in the 
demographi c group of our patient. 
-Further investigation included MR 
mammogram at three months post-operati ve, 
reporting increased signal intensity in the left 
retroareolar region consistent with post-surgical 
changes and no abnormal enhancement. CA 19-9 
was normal at 13 kU/L. Ultrasound of the 
abdomen and bone scan demonstrated no 
abnormali ties . Ultrasound of the right 
(unaffected) breast was unremarkable. The 
pati ent's mother has te ted BRCA I /2 negati ve. 
The patient underwent fo llow-up with medica l 
and radiati on oncologi sts and received genetic 
counselling. G iven the nega ti ve surg ical marg ins 
described on pathology, low grade malignancy, 
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absence of ax illary findings and potential 
toxiciti es of adjuvant treatment in this young age 
group, no further intervention was recommended. 
Discussion 
Breast cancer in males is far less common 
than in females . On average, the typical age of 
onset is up to ten years older than in females.6 
Similar to fe male cases, incidence of MBC has 
increased fro m 0.86 per 100 000 in 1973 to 1.08 
in 1998 .18 HER2 overexpression, a negative 
prognosti c fac tor in women, is found less often in 
males. 19 Male cases are more frequently ER and 
PR positive ,8 perhaps indicating increased 
pro li fe rat ive acti vity .20 
DCIS accounts fo r approximately 7% 2 1 of 
MBC and is fa r less common than invasive ductal 
(90% of case ), though lobular malignancy is still 
more rare with only 1.5% of cases. 18 Median age 
of incidence is 65 years >~2 On histology, the 
papillary form is most common though all 
subtypes present in fe males can potentia lly occur 
in males. 22 Pure DCIS occurs only in 5% of cases 
as the pathology i often present in association 
with infi ltra ting ma lignancy e lsewhere.22 DCIS is 
more common in fe males , representing 20% of 
J I 
case - . Only 30 - 50% of a ll male and fema le 
patient wi th DCIS eventua lly deve lop invasive 
cancer in the ubsequent 10 - 20 years, so actual 
prevalence in the genera l population may be 
hi gher. 23 -25 Compared to males, fewer intraducta l 
papillary ca e with higher grade and younger age 
are een in fe ma les .22· 26 The etio logy of DC IS is 
unknown fo r male s ince they lack the terminal 
duct lobul ar unit (TD LU) where the malignancy 
has frequently been found to originate in 
fe male .13 However, not all cases are associated 
with the T DLU and it is hypothes ized cases in 
males originate from epithelium of ducts. 22 Only 
a limited number of large studies perta ining to 
ma le DC lS are avail able.22• 27• 28 
Breast cancer of any form in young men is 
excepti onally rare. At the time of our patient 's 
presentation, only s ix cases had been described in 
I d 25 14, I 5, 29-32 rna es un er age , and only four cases 
of males of any age with breast cancer revealed 
on pathologica l examination fo llowing urg ical 
. t . . 14 15 29 33 
m erventJOn for gynecomastia. ' ' ' To our 
knowledge, among males 25 years of age or 
younger, a case of unilateral gynecomastia and 
DCIS has only been described once in the 
literature with Chang's account of a 16 year old 
male. 16 
Our patient originally presented with 
unilateral gynecomastia, though bilateral cases are 
more common.
34 There is no evidence that either 
unilateral or bilateral gynecomastia increase risk 
for MBC. 35 Obesity is an independent risk factor, 
and may confound the associatiOn with 
gynecomastia. 15 Gynecomastia in adults is most 
often due to persistence from puberty, drugs, 
cirrhosis, hypogonadism, testicular tumor, 
hyperthyroidism and idiopathic. 36 Beyond his 
breast, our patient had an otherwise normal 
physical exam and investigations. Of note 
however, is the comment in the surgical 
pathology report of putative anabolic steroid use. 
Use of anabolic steroids is not mentioned 
anywhere else in the patient ' s medical record. 
Some state that cases of gynecomastia should be 
biopsied if presentation includes query 
Klinefelter ' s syndrome, bloody discharge, firm, 
irregular or unilateral mass.37 '38 Others endorse 
mammography to recognize mass since it 
distinguishes between glandular tissue and fat,39A0 
though it is not universally supported since male 
breasts are small and dense. 41 ' .. n Mammography 
for MBC has been reported as successful as 92% 
sensitive, 91% specific.43 Our patient received an 
ultrasound which demonstrated findings 
consistent with gynecomastia but made no 
mention of possible malignancy. (t did not report 
microcalcifications typical of DCIS.17 The 
patient was seen again in follow-up with no 
improvement and surgical intervention of 
gynecomastia for comesis was planned. The 
possible increased risk of squamous cell 
carcinoma and testicular cancer later in life44 is 
considered prior to surgery in a younger patient 
and annual screening is suggested for cases of 
. 16 gynecomastia. 
DCIS will most often present with bloody 
nipple discharge and a mass21, though mild 
symptoms, concurrent gynecomastia and the 
scarcity of its incidence result in frequent mis-
UWOMJ, Vol 78, Issue 3 
diagnoses.14 Our patient had malignancy 
diagnosed on routine post-operative pathological 
investigation . Thus he did not benefit from pre-
operati ve diagnostic evaluati on and taging. Fine 
needle aspiration cytology is accurate in men 
when suffici ent ti ssue is obtained, though up to a 
quarter of cases have insufficient samples.45 ER, 
PR and HER2 profiles are obtained. The 
remainder of diagnostic routine mirrors cancer in 
women and investigation includes lab work, bone 
scan, CT pelvi s/abdomen and plain films as 
clinically relevant.46 
Research pertaining to the prognosi s of 
DCIS is conflicting. Studies in the past concluded 
a poorer prognosis in MBC when compared to 
females , though the older age and delay in 
diagnosis are thought to have been factors . 1 (t is 
currently believed that prognosis MBC is equal to 
that in females,6 though specific outcomes for 
DCIS unavailable. Breast cancer specific survival 
for treated DCIS is as high as 99% in females and 
85% in cases of invasive recurrence.47 Cutuli el 
a/. observed four recurrences among their 27 
DCIS patients in follow-up following 
lumpectomy who were then treated with radical 
I ~7 savage surgery.-
Treatment for DCIS in males does not 
have an established benchmark and no definitive 
trial has been published. Current treatment has 
been guided by experiences reported in the 
literature. 14 For any MBC, surgeons have the 
option of mastectomy, local exciSion or 
lumpectomy and adding adjuvant therapy as well 
as axillary dissection. Total mastectomy is 
suggested21 and a recurrence following this 
procedure has yet to be described.42' 49 Research 
pertaining to lumpectomy and adjuvant radiation 
therapy are sparse and it is not endorsed.21 
Though it bears the potential to improve 
cosmesis,50 the potential long-tem1 toxicites of 
radiation treatment in our patient 's young age 
group outweighs benefit. Nipple excision is often 
necessitated42 since the male breast most often 
leads malignancy to a subarelor presentation. 14 
There is no evidence for axillary lymph node 
dissection, tamoxifen and adjuvant radiation or 
chemotherapy.21 Since our patient received 
treatment for what was thought to be 
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gynecomastia, subcutaneous mastectomy was 
performed. The patient was well and no 
recurrence was detected on follow-up at three 
months . 
There is no indication in the literature that 
samples from gynecomastia procedures should be 
routinely sent for pathological examination. 
Given the unilateral nature in our patient, samples 
were sent for examination to rule out the rare 
occurrence of malignancy. Liao et a/. recognize 
the routine hi stologica l examination of samples in 
female cases of reduction mammaplasty. 15 It is 
further suggested that the same procedure be 
following for gynecomastia samples when 
poss ible, noting suction lipectomy may make it 
difficult because of large volume and destruction 
of cells . 15 Perhaps surgical mastectomy should be 
applied to more cases, allowing for better review 
of not only the sample itself, but also the surgical 
margms. 
Our patient had a ignificant family 
history of breast cancer, though his mother had 
tested negative for BRCA 1 and 2. Fifteen to 
twenty percent of all MBC patients have a family 
hi story of breast cancer. Just as our patient was, 
all MBC cases are routinely offered genetic 
counselling. Beyond BRCA, MBC has been 
associated with PTEN mutation in Cowden's 
syndrome51 as well as MLH l , a mismatch repair 
gene re lated to hereditary nonpolyposis colorectal 
cancer syndrome. 52 Our patient did not undergo 
genetic testing s ince hi s mother had tested 
negative . 
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